OA17450A - Combination formulation of two antiviral compounds. - Google Patents
Combination formulation of two antiviral compounds. Download PDFInfo
- Publication number
- OA17450A OA17450A OA1201500300 OA17450A OA 17450 A OA17450 A OA 17450A OA 1201500300 OA1201500300 OA 1201500300 OA 17450 A OA17450 A OA 17450A
- Authority
- OA
- OAPI
- Prior art keywords
- ledipasvir
- sofosbuvir
- weeks
- pharmaceutical composition
- génotype
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims description 173
- 150000001875 compounds Chemical class 0.000 title description 75
- 238000009472 formulation Methods 0.000 title description 34
- 230000000840 anti-viral Effects 0.000 title description 5
- VRTWBAAJJOHBQU-KMWAZVGDSA-N Ledipasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N([C@@H](C1)C=2NC(=CN=2)C=2C=C3C(F)(F)C4=CC(=CC=C4C3=CC=2)C=2C=C3NC(=NC3=CC=2)[C@H]2N([C@@H]3CC[C@H]2C3)C(=O)[C@@H](NC(=O)OC)C(C)C)CC21CC2 VRTWBAAJJOHBQU-KMWAZVGDSA-N 0.000 claims abstract description 351
- 229960002461 ledipasvir Drugs 0.000 claims abstract description 344
- TTZHDVOVKQGIBA-IQWMDFIBSA-N sofosbuvir Chemical compound N1([C@@H]2O[C@@H]([C@H]([C@]2(F)C)O)CO[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC=2C=CC=CC=2)C=CC(=O)NC1=O TTZHDVOVKQGIBA-IQWMDFIBSA-N 0.000 claims abstract description 255
- 229960002063 sofosbuvir Drugs 0.000 claims abstract description 253
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 85
- 241000711549 Hepacivirus C Species 0.000 claims description 110
- 239000007962 solid dispersion Substances 0.000 claims description 109
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 68
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims description 61
- 229920001531 copovidone Polymers 0.000 claims description 56
- 229960000329 Ribavirin Drugs 0.000 claims description 49
- 229920000642 polymer Polymers 0.000 claims description 48
- 239000002552 dosage form Substances 0.000 claims description 41
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 38
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 25
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 25
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims description 25
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 23
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 23
- 229920002785 Croscarmellose sodium Polymers 0.000 claims description 22
- 229960001681 Croscarmellose Sodium Drugs 0.000 claims description 20
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 20
- 230000002354 daily Effects 0.000 claims description 20
- WSVLPVUVIUVCRA-RJMJUYIDSA-N (2R,3R,4S,5R,6S)-2-(hydroxymethyl)-6-[(2R,3S,4R,5R)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol;hydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-RJMJUYIDSA-N 0.000 claims description 18
- 229960001021 Lactose Monohydrate Drugs 0.000 claims description 18
- 239000000377 silicon dioxide Substances 0.000 claims description 18
- 235000012239 silicon dioxide Nutrition 0.000 claims description 17
- 108010050904 Interferons Proteins 0.000 claims description 15
- 102000014150 Interferons Human genes 0.000 claims description 15
- 239000007888 film coating Substances 0.000 claims description 12
- 208000005176 Hepatitis C Diseases 0.000 claims description 10
- 229940079322 interferon Drugs 0.000 claims description 9
- 238000009501 film coating Methods 0.000 claims description 8
- 239000011159 matrix material Substances 0.000 claims description 7
- 241000700605 Viruses Species 0.000 claims description 5
- JTZZSQYMACOLNN-VDWJNHBNSA-N Simeprevir Chemical compound O=C([C@@]12C[C@H]1\C=C/CCCCN(C)C(=O)[C@H]1[C@H](C(N2)=O)C[C@H](C1)OC=1C2=CC=C(C(=C2N=C(C=1)C=1SC=C(N=1)C(C)C)C)OC)NS(=O)(=O)C1CC1 JTZZSQYMACOLNN-VDWJNHBNSA-N 0.000 claims description 4
- 229960002091 simeprevir Drugs 0.000 claims description 4
- MJNIWUJSIGSWKK-UHFFFAOYSA-N Riboflavine 2',3',4',5'-tetrabutanoate Chemical compound CCCC(=O)OCC(OC(=O)CCC)C(OC(=O)CCC)C(OC(=O)CCC)CN1C2=CC(C)=C(C)C=C2N=C2C1=NC(=O)NC2=O MJNIWUJSIGSWKK-UHFFFAOYSA-N 0.000 claims 4
- 239000003826 tablet Substances 0.000 description 179
- 230000002401 inhibitory effect Effects 0.000 description 71
- 239000003112 inhibitor Substances 0.000 description 69
- 239000003814 drug Substances 0.000 description 66
- 229940000425 combination drugs Drugs 0.000 description 64
- 239000012458 free base Substances 0.000 description 56
- -1 excipient Substances 0.000 description 39
- 238000004090 dissolution Methods 0.000 description 35
- 229940079593 drugs Drugs 0.000 description 35
- YWRYBUCQWKGONV-CABNZSRHSA-N methyl N-[(2S)-1-[(6S)-6-[5-[9,9-difluoro-7-[2-[(1S,2S,4R)-3-[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]-3-azabicyclo[2.2.1]heptan-2-yl]-3H-benzimidazol-5-yl]fluoren-2-yl]-1H-imidazol-2-yl]-5-azaspiro[2.4]heptan-5-yl]-3-methyl-1-oxobutan-2-yl]carbama Chemical compound N1([C@@H]2O[C@@H]([C@H]([C@]2(F)C)O)CO[P@](=O)(N[C@@H](C)C(=O)OC(C)C)OC=2C=CC=CC=2)C=CC(=O)NC1=O.COC(=O)N[C@@H](C(C)C)C(=O)N([C@@H](C1)C=2NC(=CN=2)C=2C=C3C(F)(F)C4=CC(=CC=C4C3=CC=2)C=2C=C3NC(=NC3=CC=2)[C@H]2N([C@@H]3CC[C@H]2C3)C(=O)[C@@H](NC(=O)OC)C(C)C)CC21CC2 YWRYBUCQWKGONV-CABNZSRHSA-N 0.000 description 33
- 239000003795 chemical substances by application Substances 0.000 description 31
- 230000037242 Cmax Effects 0.000 description 28
- 230000000275 pharmacokinetic Effects 0.000 description 28
- 239000000126 substance Substances 0.000 description 28
- 239000007921 spray Substances 0.000 description 26
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 25
- 239000000463 material Substances 0.000 description 25
- 239000002904 solvent Substances 0.000 description 25
- FEWJPZIEWOKRBE-LWMBPPNESA-N (-)-tartaric acid Chemical compound OC(=O)[C@@H](O)[C@H](O)C(O)=O FEWJPZIEWOKRBE-LWMBPPNESA-N 0.000 description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 23
- 230000036912 Bioavailability Effects 0.000 description 22
- 230000035514 bioavailability Effects 0.000 description 22
- 230000000694 effects Effects 0.000 description 21
- 239000007787 solid Substances 0.000 description 21
- 235000013305 food Nutrition 0.000 description 20
- 230000036364 AUCinf Effects 0.000 description 19
- 238000000034 method Methods 0.000 description 19
- 239000002274 desiccant Substances 0.000 description 18
- XUFQPHANEAPEMJ-UHFFFAOYSA-N Famotidine Chemical compound NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1 XUFQPHANEAPEMJ-UHFFFAOYSA-N 0.000 description 17
- 229960001596 Famotidine Drugs 0.000 description 17
- 239000003925 fat Substances 0.000 description 17
- 229940118849 sofosbuvir and ledipasvir Drugs 0.000 description 17
- 238000001694 spray drying Methods 0.000 description 17
- 229920000160 (ribonucleotides)n+m Polymers 0.000 description 16
- 239000002777 nucleoside Substances 0.000 description 16
- 150000003833 nucleoside derivatives Chemical class 0.000 description 16
- 229960001866 silicon dioxide Drugs 0.000 description 16
- 230000004044 response Effects 0.000 description 15
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 14
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 14
- 230000001965 increased Effects 0.000 description 14
- 229940029186 ledipasvir 90 MG Drugs 0.000 description 14
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 14
- YMWUJEATGCHHMB-UHFFFAOYSA-N methylene dichloride Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 14
- 101710043783 55 Proteins 0.000 description 13
- 239000000843 powder Substances 0.000 description 13
- 238000000634 powder X-ray diffraction Methods 0.000 description 13
- 230000002459 sustained Effects 0.000 description 13
- 101710027257 5a Proteins 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 12
- 239000002609 media Substances 0.000 description 12
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 12
- 238000005079 FT-Raman Methods 0.000 description 11
- 239000012530 fluid Substances 0.000 description 11
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 11
- 239000012535 impurity Substances 0.000 description 11
- 235000012054 meals Nutrition 0.000 description 11
- 230000035533 AUC Effects 0.000 description 10
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinylpyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 230000003179 granulation Effects 0.000 description 10
- 229960003943 hypromellose Drugs 0.000 description 10
- 230000003993 interaction Effects 0.000 description 10
- 230000000968 intestinal Effects 0.000 description 10
- 239000000314 lubricant Substances 0.000 description 10
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 9
- 229940067606 Lecithin Drugs 0.000 description 9
- 210000004185 Liver Anatomy 0.000 description 9
- SBQLYHNEIUGQKH-UHFFFAOYSA-N Omeprazole Chemical compound N1=C2[CH]C(OC)=CC=C2N=C1S(=O)CC1=NC=C(C)C(OC)=C1C SBQLYHNEIUGQKH-UHFFFAOYSA-N 0.000 description 9
- 108010079943 Pentagastrin Proteins 0.000 description 9
- ANRIQLNBZQLTFV-DZUOILHNSA-N Pentagastrin Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1[C]2C=CC=CC2=NC=1)NC(=O)CCNC(=O)OC(C)(C)C)CCSC)C(N)=O)C1=CC=CC=C1 ANRIQLNBZQLTFV-DZUOILHNSA-N 0.000 description 9
- 239000008186 active pharmaceutical agent Substances 0.000 description 9
- 231100000494 adverse effect Toxicity 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- 229960000517 boceprevir Drugs 0.000 description 9
- LHHCSNFAOIFYRV-DOVBMPENSA-N boceprevir Chemical compound O=C([C@@H]1[C@@H]2[C@@H](C2(C)C)CN1C(=O)[C@@H](NC(=O)NC(C)(C)C)C(C)(C)C)NC(C(=O)C(N)=O)CC1CCC1 LHHCSNFAOIFYRV-DOVBMPENSA-N 0.000 description 9
- 239000003085 diluting agent Substances 0.000 description 9
- 238000001035 drying Methods 0.000 description 9
- 235000010445 lecithin Nutrition 0.000 description 9
- 239000000787 lecithin Substances 0.000 description 9
- 229960000381 omeprazole Drugs 0.000 description 9
- 229960000444 pentagastrin Drugs 0.000 description 9
- 239000007916 tablet composition Substances 0.000 description 9
- 241000282472 Canis lupus familiaris Species 0.000 description 8
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 8
- 229940090438 Infergen Drugs 0.000 description 8
- XAPRFLSJBSXESP-UHFFFAOYSA-N Oxycinchophen Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=C(O)C=1C1=CC=CC=C1 XAPRFLSJBSXESP-UHFFFAOYSA-N 0.000 description 8
- 229940069328 Povidone Drugs 0.000 description 8
- 229920002472 Starch Polymers 0.000 description 8
- 229940032147 Starch Drugs 0.000 description 8
- 229940042399 direct acting antivirals Protease inhibitors Drugs 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 239000006185 dispersion Substances 0.000 description 8
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 8
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 8
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 8
- 201000004044 liver cirrhosis Diseases 0.000 description 8
- 239000002245 particle Substances 0.000 description 8
- 238000011160 research Methods 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 239000008107 starch Substances 0.000 description 8
- 235000019698 starch Nutrition 0.000 description 8
- 230000003612 virological Effects 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
- 241000580858 Simian-Human immunodeficiency virus Species 0.000 description 7
- NHKZSTHOYNWEEZ-AFCXAGJDSA-N Taribavirin Chemical compound N1=C(C(=N)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NHKZSTHOYNWEEZ-AFCXAGJDSA-N 0.000 description 7
- 238000001574 biopsy Methods 0.000 description 7
- 239000000969 carrier Substances 0.000 description 7
- 239000011248 coating agent Substances 0.000 description 7
- 238000000576 coating method Methods 0.000 description 7
- 239000012527 feed solution Substances 0.000 description 7
- 238000005755 formation reaction Methods 0.000 description 7
- 238000005469 granulation Methods 0.000 description 7
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- 229950006081 taribavirin Drugs 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 7
- 101700014732 GCS1 Proteins 0.000 description 6
- 102000015084 HIV Reverse Transcriptase Human genes 0.000 description 6
- 108010078851 HIV Reverse Transcriptase Proteins 0.000 description 6
- 229940047124 Interferons Drugs 0.000 description 6
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N Oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 6
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 6
- 235000019441 ethanol Nutrition 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 239000007789 gas Substances 0.000 description 6
- 239000011521 glass Substances 0.000 description 6
- FJPWYOHJVGOKNZ-NDANSHMASA-N methyl N-[(2S)-1-[(6S)-6-[5-[9,9-difluoro-7-[2-[(1S,2S,4R)-3-[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]-3-azabicyclo[2.2.1]heptan-2-yl]-3H-benzimidazol-5-yl]fluoren-2-yl]-1H-imidazol-2-yl]-5-azaspiro[2.4]heptan-5-yl]-3-methyl-1-oxobutan-2-yl]carbama Chemical compound CC(C)=O.COC(=O)N[C@@H](C(C)C)C(=O)N([C@@H](C1)C=2NC(=CN=2)C=2C=C3C(F)(F)C4=CC(=CC=C4C3=CC=2)C=2C=C3NC(=NC3=CC=2)[C@H]2N([C@@H]3CC[C@H]2C3)C(=O)[C@@H](NC(=O)OC)C(C)C)CC21CC2 FJPWYOHJVGOKNZ-NDANSHMASA-N 0.000 description 6
- 239000003960 organic solvent Substances 0.000 description 6
- 229920001223 polyethylene glycol Polymers 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 6
- BBAWEDCPNXPBQM-GDEBMMAJSA-N telaprevir Chemical compound N([C@H](C(=O)N[C@H](C(=O)N1C[C@@H]2CCC[C@@H]2[C@H]1C(=O)N[C@@H](CCC)C(=O)C(=O)NC1CC1)C(C)(C)C)C1CCCCC1)C(=O)C1=CN=CC=N1 BBAWEDCPNXPBQM-GDEBMMAJSA-N 0.000 description 6
- XQSPYNMVSIKCOC-NTSWFWBYSA-N (2R-cis)-4-amino-5-fluoro-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-2(1H)-Pyrimidinone Chemical compound C1=C(F)C(N)=NC(=O)N1[C@H]1O[C@@H](CO)SC1 XQSPYNMVSIKCOC-NTSWFWBYSA-N 0.000 description 5
- WTDWVLJJJOTABN-UHFFFAOYSA-N 5-cyclopropyl-2-(4-fluorophenyl)-6-[(2-hydroxyethyl)(methylsulfonyl)amino]-N-methyl-1-benzofuran-3-carboxamide Chemical compound C1=C2C(C(=O)NC)=C(C=3C=CC(F)=CC=3)OC2=CC(N(CCO)S(C)(=O)=O)=C1C1CC1 WTDWVLJJJOTABN-UHFFFAOYSA-N 0.000 description 5
- 210000004211 Gastric Acid Anatomy 0.000 description 5
- 108010047761 Interferon-alpha Proteins 0.000 description 5
- 102000006992 Interferon-alpha Human genes 0.000 description 5
- VKHAHZOOUSRJNA-GCNJZUOMSA-N Mifepristone Chemical compound C1([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@@]([C@]3(C2)C)(O)C#CC)=CC=C(N(C)C)C=C1 VKHAHZOOUSRJNA-GCNJZUOMSA-N 0.000 description 5
- 210000002381 Plasma Anatomy 0.000 description 5
- 239000002202 Polyethylene glycol Substances 0.000 description 5
- 239000004372 Polyvinyl alcohol Substances 0.000 description 5
- NZVYCXVTEHPMHE-ZSUJOUNUSA-N Thymalfasin Chemical compound CC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O NZVYCXVTEHPMHE-ZSUJOUNUSA-N 0.000 description 5
- 238000004166 bioassay Methods 0.000 description 5
- 201000009910 diseases by infectious agent Diseases 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 239000008012 organic excipient Substances 0.000 description 5
- 239000006187 pill Substances 0.000 description 5
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 5
- 229920000053 polysorbate 80 Polymers 0.000 description 5
- 229920002451 polyvinyl alcohol Polymers 0.000 description 5
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 5
- XBDQKXXYIPTUBI-UHFFFAOYSA-M propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 5
- 238000001228 spectrum Methods 0.000 description 5
- 238000003860 storage Methods 0.000 description 5
- 239000004094 surface-active agent Substances 0.000 description 5
- 230000001225 therapeutic Effects 0.000 description 5
- 229960004231 thymalfasin Drugs 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- IRZRJANZDIOOIF-GAJNKVMBSA-N (2R,3R,4R,5R)-2-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-5-(hydroxymethyl)-3-methyloxolane-3,4-diol Chemical compound C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(N)=C2C=C1 IRZRJANZDIOOIF-GAJNKVMBSA-N 0.000 description 4
- HLQXYDHLDZTWDW-KAWPREARSA-N (2R,4S,5R)-1-(4-tert-butyl-3-methoxybenzoyl)-4-(methoxymethyl)-2-(pyrazol-1-ylmethyl)-5-(1,3-thiazol-2-yl)pyrrolidine-2-carboxylic acid Chemical compound C([C@]1(C[C@@H]([C@@H](N1C(=O)C=1C=C(OC)C(=CC=1)C(C)(C)C)C=1SC=CN=1)COC)C(O)=O)N1C=CC=N1 HLQXYDHLDZTWDW-KAWPREARSA-N 0.000 description 4
- JBSNALXXNTWUEC-SFQUDFHCSA-N (E)-3-[4-[[1-[(3-cyclopentyl-1-methyl-2-pyridin-2-ylindole-6-carbonyl)amino]cyclobutanecarbonyl]amino]phenyl]prop-2-enoic acid Chemical compound C12=CC=C(C(=O)NC3(CCC3)C(=O)NC=3C=CC(\C=C\C(O)=O)=CC=3)C=C2N(C)C(C=2N=CC=CC=2)=C1C1CCCC1 JBSNALXXNTWUEC-SFQUDFHCSA-N 0.000 description 4
- VQFKFAKEUMHBLV-BYSUZVQFSA-N 1-O-(α-D-galactosyl)-N-hexacosanoylphytosphingosine Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@H]([C@H](O)[C@H](O)CCCCCCCCCCCCCC)CO[C@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQFKFAKEUMHBLV-BYSUZVQFSA-N 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 4
- JTEGQNOMFQHVDC-NKWVEPMBSA-N 4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-1,2-dihydropyrimidin-2-one Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 description 4
- 241000351238 Alinea Species 0.000 description 4
- OLROWHGDTNFZBH-XEMWPYQTSA-N Alisporivir Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)N(CC)C(=O)[C@@H](C)N(C)C1=O OLROWHGDTNFZBH-XEMWPYQTSA-N 0.000 description 4
- 229950007843 Bavituximab Drugs 0.000 description 4
- WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Chemical class CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 4
- 229940055354 Copegus Drugs 0.000 description 4
- ZIUSSTSXXLLKKK-HWUZOJPISA-N Curcumin Natural products C1=C(O)C(OC)=CC(\C=C\C(\O)=C/C(=O)/C=C/C=2C=C(OC)C(O)=CC=2)=C1 ZIUSSTSXXLLKKK-HWUZOJPISA-N 0.000 description 4
- ZVTDLPBHTSMEJZ-UPZRXNBOSA-N DANOPREVIR Chemical compound O=C([C@@]12C[C@H]1\C=C/CCCCC[C@H](C(N1C[C@@H](C[C@H]1C(=O)N2)OC(=O)N1CC2=C(F)C=CC=C2C1)=O)NC(=O)OC(C)(C)C)NS(=O)(=O)C1CC1 ZVTDLPBHTSMEJZ-UPZRXNBOSA-N 0.000 description 4
- 229910005429 FeSSIF Inorganic materials 0.000 description 4
- LLEUXCDZPQOJMY-AAEUAGOBSA-N Glu-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](CCC(O)=O)N)C(O)=O)=CNC2=C1 LLEUXCDZPQOJMY-AAEUAGOBSA-N 0.000 description 4
- 241000710789 Lactate dehydrogenase-elevating virus Species 0.000 description 4
- 229960001375 Lactose Drugs 0.000 description 4
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 4
- 229960001627 Lamivudine Drugs 0.000 description 4
- GVZFUVXPTPGOQT-UHFFFAOYSA-M MitoQ Chemical compound CS([O-])(=O)=O.O=C1C(OC)=C(OC)C(=O)C(CCCCCCCCCC[P+](C=2C=CC=CC=2)(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1C GVZFUVXPTPGOQT-UHFFFAOYSA-M 0.000 description 4
- YQNQNVDNTFHQSW-UHFFFAOYSA-N Nitazoxanide Chemical compound CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C([N+]([O-])=O)S1 YQNQNVDNTFHQSW-UHFFFAOYSA-N 0.000 description 4
- 229950001189 Oglufanide Drugs 0.000 description 4
- 229940068968 Polysorbate 80 Drugs 0.000 description 4
- 241000048284 Potato virus P Species 0.000 description 4
- 229940053146 Rebetol Drugs 0.000 description 4
- QIQXTHQIDYTFRH-UHFFFAOYSA-N Stearic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 4
- 229940033134 Talc Drugs 0.000 description 4
- 230000035852 Tmax Effects 0.000 description 4
- 229950002810 Valopicitabine Drugs 0.000 description 4
- HTJGLYIJVSDQAE-VWNXEWBOSA-N [(1S,6S,7S,8R,8aR)-1,7,8-trihydroxy-1,2,3,5,6,7,8,8a-octahydroindolizin-6-yl] butanoate Chemical compound O[C@H]1[C@H](O)[C@@H](OC(=O)CCC)CN2CC[C@H](O)[C@@H]21 HTJGLYIJVSDQAE-VWNXEWBOSA-N 0.000 description 4
- ZWELIJXAKMASLK-UGKPPGOTSA-N [(2R,3R,4R,5R)-4-acetyloxy-5-(5-amino-2-oxo-[1,3]thiazolo[4,5-d]pyrimidin-3-yl)-2-(hydroxymethyl)oxolan-3-yl] acetate Chemical compound CC(=O)O[C@@H]1[C@H](OC(=O)C)[C@@H](CO)O[C@H]1N1C(=O)SC2=CN=C(N)N=C21 ZWELIJXAKMASLK-UGKPPGOTSA-N 0.000 description 4
- TVRCRTJYMVTEFS-ICGCPXGVSA-N [(2R,3R,4R,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-4-hydroxy-2-(hydroxymethyl)-4-methyloxolan-3-yl] (2S)-2-amino-3-methylbutanoate Chemical compound C[C@@]1(O)[C@H](OC(=O)[C@@H](N)C(C)C)[C@@H](CO)O[C@H]1N1C(=O)N=C(N)C=C1 TVRCRTJYMVTEFS-ICGCPXGVSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 108010080374 albuferon Proteins 0.000 description 4
- 108010001114 bavituximab Proteins 0.000 description 4
- QAIPRVGONGVQAS-DUXPYHPUSA-N caffeic acid Natural products OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 235000010980 cellulose Nutrition 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 230000003247 decreasing Effects 0.000 description 4
- 239000007884 disintegrant Substances 0.000 description 4
- 238000007908 dry granulation Methods 0.000 description 4
- 229960000366 emtricitabine Drugs 0.000 description 4
- 239000003623 enhancer Substances 0.000 description 4
- 230000002708 enhancing Effects 0.000 description 4
- 108010010648 interferon alfacon-1 Proteins 0.000 description 4
- 229920000831 ionic polymer Polymers 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 4
- 229940029174 ledipasvir / sofosbuvir Drugs 0.000 description 4
- 201000009673 liver disease Diseases 0.000 description 4
- 108010046177 locteron Proteins 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 229960002480 nitazoxanide Drugs 0.000 description 4
- 239000000546 pharmaceutic aid Substances 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 239000008363 phosphate buffer Substances 0.000 description 4
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 4
- 238000009597 pregnancy test Methods 0.000 description 4
- SSERCMQZZYTNBY-UHFFFAOYSA-M sodium;3-[(4-hydroxycyclohexyl)-(4-methylcyclohexanecarbonyl)amino]-5-phenylthiophene-2-carboxylate Chemical compound [Na+].C1CC(C)CCC1C(=O)N(C1=C(SC(=C1)C=1C=CC=CC=1)C([O-])=O)C1CCC(O)CC1 SSERCMQZZYTNBY-UHFFFAOYSA-M 0.000 description 4
- 239000000454 talc Substances 0.000 description 4
- 229910052623 talc Inorganic materials 0.000 description 4
- 235000012222 talc Nutrition 0.000 description 4
- 101700042113 tap Proteins 0.000 description 4
- 229960002935 telaprevir Drugs 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 4
- DZRQMHSNVNTFAQ-IVGJVWKCSA-N (2R,3R)-2,3-dihydroxybutanedioic acid;(2R,3S,4R,5S)-1-(6-ethoxyhexyl)-2-methylpiperidine-3,4,5-triol Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.CCOCCCCCCN1C[C@H](O)[C@@H](O)[C@@H](O)[C@H]1C DZRQMHSNVNTFAQ-IVGJVWKCSA-N 0.000 description 3
- PUSNGFYSTWMJSK-GSZQVNRLSA-N (2R,3R,4S,5R,6R)-2,3,4-trimethoxy-6-(methoxymethyl)-5-[(2S,3R,4S,5R,6R)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxyoxane;1-[[(2R,3R,4S,5R,6S)-3,4,5-tris(2-hydroxypropoxy)-6-[(2R,3R,4S,5R,6R)-4,5,6-tris(2-hydroxypropoxy)-2-(2-hydroxypropoxymethyl)oxan- Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](OC)O[C@@H]1COC.CC(O)CO[C@@H]1[C@@H](OCC(C)O)[C@H](OCC(C)O)[C@@H](COCC(O)C)O[C@H]1O[C@H]1[C@H](OCC(C)O)[C@@H](OCC(C)O)[C@H](OCC(C)O)O[C@@H]1COCC(C)O PUSNGFYSTWMJSK-GSZQVNRLSA-N 0.000 description 3
- SCVHJVCATBPIHN-SJCJKPOMSA-N (3S)-3-[[(2S)-2-[[2-(2-tert-butylanilino)-2-oxoacetyl]amino]propanoyl]amino]-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid Chemical compound N([C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)COC=1C(=C(F)C=C(F)C=1F)F)C(=O)C(=O)NC1=CC=CC=C1C(C)(C)C SCVHJVCATBPIHN-SJCJKPOMSA-N 0.000 description 3
- CWSZBVAUYPTXTG-UHFFFAOYSA-N 5-[6-[[3,4-dihydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxymethyl]-3,4-dihydroxy-5-[4-hydroxy-3-(2-hydroxyethoxy)-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxyoxan-2-yl]oxy-6-(hydroxymethyl)-2-methyloxane-3,4-diol Chemical compound O1C(CO)C(OC)C(O)C(O)C1OCC1C(OC2C(C(O)C(OC)C(CO)O2)OCCO)C(O)C(O)C(OC2C(OC(C)C(O)C2O)CO)O1 CWSZBVAUYPTXTG-UHFFFAOYSA-N 0.000 description 3
- 230000035715 AUC last Effects 0.000 description 3
- 230000037082 AUClast Effects 0.000 description 3
- XRWSZZJLZRKHHD-WVWIJVSJSA-N Asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 3
- 210000000941 Bile Anatomy 0.000 description 3
- 102100012080 CCR5 Human genes 0.000 description 3
- 101700043583 CCR5 Proteins 0.000 description 3
- 102100002212 CXCR4 Human genes 0.000 description 3
- 101710003734 CXCR4 Proteins 0.000 description 3
- 229950003414 Celgosivir Drugs 0.000 description 3
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 3
- 108010092799 EC 2.7.7.49 Proteins 0.000 description 3
- 102000033147 ERVK-25 Human genes 0.000 description 3
- XPOQHMRABVBWPR-ZDUSSCGKSA-N Efavirenz Chemical compound C([C@]1(C2=CC(Cl)=CC=C2NC(=O)O1)C(F)(F)F)#CC1CC1 XPOQHMRABVBWPR-ZDUSSCGKSA-N 0.000 description 3
- 239000001856 Ethyl cellulose Substances 0.000 description 3
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 3
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 3
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 3
- XMZSTQYSBYEENY-RMKNXTFCSA-N N-[4-[(E)-2-[3-tert-butyl-5-(2,4-dioxopyrimidin-1-yl)-2-methoxyphenyl]ethenyl]phenyl]methanesulfonamide Chemical compound C1=C(N2C(NC(=O)C=C2)=O)C=C(C(C)(C)C)C(OC)=C1\C=C\C1=CC=C(NS(C)(=O)=O)C=C1 XMZSTQYSBYEENY-RMKNXTFCSA-N 0.000 description 3
- RPJPZDVUUKWPGT-FOIHOXPVSA-N NIM811 Chemical compound CC[C@H](C)[C@@H]1N(C)C(=O)CN(C)C(=O)[C@H](CC)NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC1=O RPJPZDVUUKWPGT-FOIHOXPVSA-N 0.000 description 3
- 229960002754 Paritaprevir Drugs 0.000 description 3
- 229960005190 Phenylalanine Drugs 0.000 description 3
- 229940023488 Pill Drugs 0.000 description 3
- 229920002685 Polyoxyl 35CastorOil Polymers 0.000 description 3
- 229940038850 Rebif Drugs 0.000 description 3
- VPHXUNBMNWOYNQ-XLBCSPGISA-N SETROBUVIR Chemical compound N1([C@H]2[C@@H]3CC[C@@H](C3)[C@H]2C(=O)/C(C1=O)=C1/NC2=CC=C(C=C2S(=O)(=O)N1)NS(=O)(=O)C)CC1=CC=C(F)C=C1 VPHXUNBMNWOYNQ-XLBCSPGISA-N 0.000 description 3
- 229940083542 Sodium Drugs 0.000 description 3
- 229940091252 Sodium supplements Drugs 0.000 description 3
- 229950000843 Vaniprevir Drugs 0.000 description 3
- 229960002555 Zidovudine Drugs 0.000 description 3
- HBOMLICNUCNMMY-XLPZGREQSA-N Zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N acetic acid ethyl ester Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 230000002378 acidificating Effects 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 229960002118 asunaprevir Drugs 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 230000005712 crystallization Effects 0.000 description 3
- CJBJHOAVZSMMDJ-HEXNFIEUSA-N darunavir Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1[C@@H]2CCO[C@@H]2OC1)C1=CC=CC=C1 CJBJHOAVZSMMDJ-HEXNFIEUSA-N 0.000 description 3
- 229960001418 dasabuvir Drugs 0.000 description 3
- NBRBXGKOEOGLOI-UHFFFAOYSA-N dasabuvir Chemical compound C1=C(C(C)(C)C)C(OC)=C(C=2C=C3C=CC(NS(C)(=O)=O)=CC3=CC=2)C=C1N1C=CC(=O)NC1=O NBRBXGKOEOGLOI-UHFFFAOYSA-N 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 238000000113 differential scanning calorimetry Methods 0.000 description 3
- 229960003804 efavirenz Drugs 0.000 description 3
- 229920001249 ethyl cellulose Polymers 0.000 description 3
- 235000019325 ethyl cellulose Nutrition 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 239000004700 high-density polyethylene Substances 0.000 description 3
- 239000003084 hiv integrase inhibitor Substances 0.000 description 3
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 3
- 229940071826 hydroxyethyl cellulose Drugs 0.000 description 3
- 230000000670 limiting Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- PIDFDZJZLOTZTM-KHVQSSSXSA-N ombitasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C([C@H]2N([C@@H](CC2)C=2C=CC(NC(=O)[C@H]3N(CCC3)C(=O)[C@@H](NC(=O)OC)C(C)C)=CC=2)C=2C=CC(=CC=2)C(C)(C)C)C=C1 PIDFDZJZLOTZTM-KHVQSSSXSA-N 0.000 description 3
- 229960000518 ombitasvir Drugs 0.000 description 3
- UAUIUKWPKRJZJV-MDJGTQRPSA-N paritaprevir Chemical compound C1=NC(C)=CN=C1C(=O)N[C@@H]1C(=O)N2C[C@H](OC=3C4=CC=CC=C4C4=CC=CC=C4N=3)C[C@H]2C(=O)N[C@]2(C(=O)NS(=O)(=O)C3CC3)C[C@@H]2\C=C/CCCCC1 UAUIUKWPKRJZJV-MDJGTQRPSA-N 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000002829 reduced Effects 0.000 description 3
- 239000004627 regenerated cellulose Substances 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 231100000486 side effect Toxicity 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- JAJWGJBVLPIOOH-IZYKLYLVSA-M sodium taurocholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 JAJWGJBVLPIOOH-IZYKLYLVSA-M 0.000 description 3
- 238000004611 spectroscopical analysis Methods 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- ZQVLPYMRXLPMDX-KEAIDYLOSA-N (2S,3S)-2,3-dihydroxybutanedioic acid;methyl N-[(2S)-1-[(6S)-6-[5-[9,9-difluoro-7-[2-[(1S,2S,4R)-3-[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]-3-azabicyclo[2.2.1]heptan-2-yl]-3H-benzimidazol-5-yl]fluoren-2-yl]-1H-imidazol-2-yl]-5-azaspiro[2.4]heptan- Chemical compound OC(=O)[C@@H](O)[C@H](O)C(O)=O.COC(=O)N[C@@H](C(C)C)C(=O)N([C@@H](C1)C=2NC(=CN=2)C=2C=C3C(F)(F)C4=CC(=CC=C4C3=CC=2)C=2C=C3NC(=NC3=CC=2)[C@H]2N([C@@H]3CC[C@H]2C3)C(=O)[C@@H](NC(=O)OC)C(C)C)CC21CC2 ZQVLPYMRXLPMDX-KEAIDYLOSA-N 0.000 description 2
- MHFMTUBUVQZIRE-WINRQGAFSA-N (2S,4R)-N-[(1R,2S)-1-(cyclopropylsulfonylcarbamoyl)-2-ethenylcyclopropyl]-1-[(2S)-3,3-dimethyl-2-(2-oxo-2-piperidin-1-ylethyl)butanoyl]-4-(7-methoxy-2-phenylquinolin-4-yl)oxypyrrolidine-2-carboxamide Chemical compound C([C@H](C(=O)N1[C@@H](C[C@H](C1)OC=1C2=CC=C(C=C2N=C(C=1)C=1C=CC=CC=1)OC)C(=O)N[C@]1([C@@H](C1)C=C)C(=O)NS(=O)(=O)C1CC1)C(C)(C)C)C(=O)N1CCCCC1 MHFMTUBUVQZIRE-WINRQGAFSA-N 0.000 description 2
- IWUCXVSUMQZMFG-RGDLXGNYSA-N 1-[(2S,3S,4R,5S)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2,4-triazole-3-carboxamide Chemical compound N1=C(C(=O)N)N=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 IWUCXVSUMQZMFG-RGDLXGNYSA-N 0.000 description 2
- AMOYMEBHYUTMKJ-UHFFFAOYSA-N 2-(2-phenylethoxy)ethylbenzene Chemical compound C=1C=CC=CC=1CCOCCC1=CC=CC=C1 AMOYMEBHYUTMKJ-UHFFFAOYSA-N 0.000 description 2
- XLMXUUQMSMKFMH-UZRURVBFSA-N 2-hydroxyethyl (Z,12R)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCC[C@@H](O)C\C=C/CCCCCCCC(=O)OCCO XLMXUUQMSMKFMH-UZRURVBFSA-N 0.000 description 2
- JVKUCNQGESRUCL-UHFFFAOYSA-N 2-hydroxyethyl 12-hydroxyoctadecanoate Chemical compound CCCCCCC(O)CCCCCCCCCCC(=O)OCCO JVKUCNQGESRUCL-UHFFFAOYSA-N 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K 2qpq Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- BHQCQFFYRZLCQQ-UMZBRFQRSA-N 4-[(3R,5S,7R,12S)-3,7,12-trihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid Chemical class C([C@H]1C[C@H]2O)[C@H](O)CCC1(C)C1C2C2CCC(C(CCC(O)=O)C)C2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-UMZBRFQRSA-N 0.000 description 2
- MAQDQJWCSSCURR-UHFFFAOYSA-N 4-[5-(cyclopropanecarbonylamino)-2-(trifluoromethoxy)phenyl]-N-[4-[(4-propylsulfonylpiperazin-1-yl)methyl]phenyl]benzamide Chemical compound C1CN(S(=O)(=O)CCC)CCN1CC(C=C1)=CC=C1NC(=O)C1=CC=C(C=2C(=CC=C(NC(=O)C3CC3)C=2)OC(F)(F)F)C=C1 MAQDQJWCSSCURR-UHFFFAOYSA-N 0.000 description 2
- NYNKCGWJPNZJMI-UHFFFAOYSA-N 4-amino-N-(1-benzylpiperidin-4-yl)-5-chloro-2-methoxybenzamide;2-hydroxybutanedioic acid Chemical compound [O-]C(=O)C(O)CC(O)=O.COC1=CC(N)=C(Cl)C=C1C(=O)NC1CC[NH+](CC=2C=CC=CC=2)CC1 NYNKCGWJPNZJMI-UHFFFAOYSA-N 0.000 description 2
- XBEQSQDCBSKCHJ-UHFFFAOYSA-N 5-[[6-[2,4-bis(trifluoromethyl)phenyl]pyridazin-3-yl]methyl]-2-(2-fluorophenyl)imidazo[4,5-c]pyridine Chemical compound FC1=CC=CC=C1C1=NC2=CN(CC=3N=NC(=CC=3)C=3C(=CC(=CC=3)C(F)(F)F)C(F)(F)F)C=CC2=N1 XBEQSQDCBSKCHJ-UHFFFAOYSA-N 0.000 description 2
- TZYVRXZQAWPIAB-FCLHUMLKSA-N 5-amino-3-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-4H-[1,3]thiazolo[4,5-d]pyrimidine-2,7-dione Chemical compound O=C1SC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O TZYVRXZQAWPIAB-FCLHUMLKSA-N 0.000 description 2
- 230000036153 AUC TAU Effects 0.000 description 2
- 229940099550 Actimmune Drugs 0.000 description 2
- 229950005846 Amdoxovir Drugs 0.000 description 2
- GIXWDMTZECRIJT-UHFFFAOYSA-N Aurintricarboxylic acid Chemical compound C1=CC(=O)C(C(=O)O)=CC1=C(C=1C=C(C(O)=CC=1)C(O)=O)C1=CC=C(O)C(C(O)=O)=C1 GIXWDMTZECRIJT-UHFFFAOYSA-N 0.000 description 2
- 229940003504 Avonex Drugs 0.000 description 2
- 229950010541 Beclabuvir Drugs 0.000 description 2
- ZTTKEBYSXUCBSE-QDFUAKMASA-N Beclabuvir Chemical compound C1([C@@H]2C[C@@]2(CN2C3=CC(=CC=C33)C(=O)NS(=O)(=O)N(C)C)C(=O)N4[C@@H]5CC[C@H]4CN(C)C5)=CC(OC)=CC=C1C2=C3C1CCCCC1 ZTTKEBYSXUCBSE-QDFUAKMASA-N 0.000 description 2
- JYZIHLWOWKMNNX-UHFFFAOYSA-N Benzimidazole Chemical compound C1=C[CH]C2=NC=NC2=C1 JYZIHLWOWKMNNX-UHFFFAOYSA-N 0.000 description 2
- 229940093761 Bile Salts Drugs 0.000 description 2
- 210000004369 Blood Anatomy 0.000 description 2
- 210000001772 Blood Platelets Anatomy 0.000 description 2
- 229960005069 Calcium Drugs 0.000 description 2
- YDDGKXBLOXEEMN-IABMMNSOSA-N Chicoric acid Chemical compound O([C@@H](C(=O)O)[C@@H](OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)C(O)=O)C(=O)\C=C\C1=CC=C(O)C(O)=C1 YDDGKXBLOXEEMN-IABMMNSOSA-N 0.000 description 2
- YDDGKXBLOXEEMN-IABMMNSOSA-L Chicoric acid Natural products C1=C(O)C(O)=CC=C1\C=C\C(=O)O[C@@H](C([O-])=O)[C@H](C([O-])=O)OC(=O)\C=C\C1=CC=C(O)C(O)=C1 YDDGKXBLOXEEMN-IABMMNSOSA-L 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 229960005168 Croscarmellose Drugs 0.000 description 2
- 229960000913 Crospovidone Drugs 0.000 description 2
- 229940109262 Curcumin Drugs 0.000 description 2
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 description 2
- SWXVUIWOUIDPGS-UHFFFAOYSA-N Diacetone alcohol Chemical compound CC(=O)CC(C)(C)O SWXVUIWOUIDPGS-UHFFFAOYSA-N 0.000 description 2
- NEFBYIFKOOEVPA-UHFFFAOYSA-K Dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 2
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 2
- UYXTWWCETRIEDR-UHFFFAOYSA-N Glyceryl tributyrate Chemical compound CCCC(=O)OCC(OC(=O)CCC)COC(=O)CCC UYXTWWCETRIEDR-UHFFFAOYSA-N 0.000 description 2
- 208000005721 HIV Infections Diseases 0.000 description 2
- 108010010369 HIV Protease Proteins 0.000 description 2
- 102000015787 HIV Protease Human genes 0.000 description 2
- 229940031574 HYDROXYMETHYL CELLULOSE Drugs 0.000 description 2
- 230000036499 Half live Effects 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- 102100008763 IFNA2 Human genes 0.000 description 2
- 102100015720 IFNB1 Human genes 0.000 description 2
- 101700011451 IFNB1 Proteins 0.000 description 2
- 102100005075 IFNL1 Human genes 0.000 description 2
- 101700020151 IFNL1 Proteins 0.000 description 2
- 102000003996 Interferon beta Human genes 0.000 description 2
- 108090000467 Interferon beta Proteins 0.000 description 2
- 108010079944 Interferon-alpha2b Proteins 0.000 description 2
- 229960001388 Interferon-beta Drugs 0.000 description 2
- 229940065638 Intron A Drugs 0.000 description 2
- 229950003954 Isatoribine Drugs 0.000 description 2
- KJHKTHWMRKYKJE-SUGCFTRWSA-N Kaletra Chemical compound N1([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)COC=2C(=CC=CC=2C)C)CC=2C=CC=CC=2)CCCNC1=O KJHKTHWMRKYKJE-SUGCFTRWSA-N 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N Lauric acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 101700019915 MYB26 Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- KXKVLQRXCPHEJC-UHFFFAOYSA-N Methyl acetate Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 2
- 229960002900 Methylcellulose Drugs 0.000 description 2
- IBAQFPQHRJAVAV-ULAWRXDQSA-N Miglitol Chemical compound OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO IBAQFPQHRJAVAV-ULAWRXDQSA-N 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- 229950002536 Nesbuvir Drugs 0.000 description 2
- 229940079938 Nitrocellulose Drugs 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- 229940002988 Pegasys Drugs 0.000 description 2
- 229940106366 Pegintron Drugs 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 2
- 229940077718 Proton pump inhibitors for peptic ulcer and GORD Drugs 0.000 description 2
- 229950006485 Pyroxylin Drugs 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- 229960001285 Quercetin Drugs 0.000 description 2
- 229960004742 Raltegravir Drugs 0.000 description 2
- CZFFBEXEKNGXKS-UHFFFAOYSA-N Raltegravir Chemical compound O1C(C)=NN=C1C(=O)NC(C)(C)C1=NC(C(=O)NCC=2C=CC(F)=CC=2)=C(O)C(=O)N1C CZFFBEXEKNGXKS-UHFFFAOYSA-N 0.000 description 2
- NCDNCNXCDXHOMX-XGKFQTDJSA-N Ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 description 2
- 229920001304 Solutol HS 15 Polymers 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 210000002784 Stomach Anatomy 0.000 description 2
- 229960004693 Tenofovir disoproxil fumarate Drugs 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H Tricalcium phosphate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- HPAPGONEMPZXMM-CMWVUSIZSA-N Vaniprevir Chemical compound O=C([C@H]1C[C@@H]2OC(=O)N3CC=4C=CC=C(C=4C3)CCCCC(C)(C)COC(=O)N[C@@H](C(N1C2)=O)C(C)(C)C)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C HPAPGONEMPZXMM-CMWVUSIZSA-N 0.000 description 2
- 238000002441 X-ray diffraction Methods 0.000 description 2
- RLAHNGKRJJEIJL-RFZPGFLSSA-N [(2R,4R)-4-(2,6-diaminopurin-9-yl)-1,3-dioxolan-2-yl]methanol Chemical compound C12=NC(N)=NC(N)=C2N=CN1[C@H]1CO[C@@H](CO)O1 RLAHNGKRJJEIJL-RFZPGFLSSA-N 0.000 description 2
- FJWGYAHXMCUOOM-QHOUIDNNSA-N [(2S,3R,4S,5R,6R)-2-[(2R,3R,4S,5R,6S)-4,5-dinitrooxy-2-(nitrooxymethyl)-6-[(2R,3R,4S,5R,6S)-4,5,6-trinitrooxy-2-(nitrooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-3,5-dinitrooxy-6-(nitrooxymethyl)oxan-4-yl] nitrate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O)O[C@H]1[C@@H]([C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@@H](CO[N+]([O-])=O)O1)O[N+]([O-])=O)CO[N+](=O)[O-])[C@@H]1[C@@H](CO[N+]([O-])=O)O[C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O FJWGYAHXMCUOOM-QHOUIDNNSA-N 0.000 description 2
- FTRWNHBXCNPGCA-UHFFFAOYSA-N [5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl Chemical compound O=C1NC(=O)C(C)=CN1C1OC(COP(O)(=S)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(S)(=O)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)CO)C(O)C1 FTRWNHBXCNPGCA-UHFFFAOYSA-N 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- ZUAAPNNKRHMPKG-UHFFFAOYSA-N acetic acid;butanedioic acid;methanol;propane-1,2-diol Chemical compound OC.CC(O)=O.CC(O)CO.OC(=O)CCC(O)=O ZUAAPNNKRHMPKG-UHFFFAOYSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000000240 adjuvant Effects 0.000 description 2
- 239000003833 bile salt Substances 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 229940074360 caffeic acid Drugs 0.000 description 2
- 235000004883 caffeic acid Nutrition 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 229930016920 cichoric acid Natural products 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 239000006184 cosolvent Substances 0.000 description 2
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 2
- 239000004148 curcumin Substances 0.000 description 2
- 235000012754 curcumin Nutrition 0.000 description 2
- 229960005107 darunavir Drugs 0.000 description 2
- 239000007857 degradation product Substances 0.000 description 2
- 229940038472 dicalcium phosphate Drugs 0.000 description 2
- 235000019700 dicalcium phosphate Nutrition 0.000 description 2
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 2
- 229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000001125 extrusion Methods 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 239000007941 film coated tablet Substances 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 150000004676 glycans Polymers 0.000 description 2
- 229920001903 high density polyethylene Polymers 0.000 description 2
- 238000000265 homogenisation Methods 0.000 description 2
- 230000003301 hydrolyzing Effects 0.000 description 2
- 229920001477 hydrophilic polymer Polymers 0.000 description 2
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 2
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 2
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 2
- 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 108010045648 interferon omega 1 Proteins 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 229960004525 lopinavir Drugs 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 229920003145 methacrylic acid copolymer Polymers 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 229960001110 miglitol Drugs 0.000 description 2
- 238000003801 milling Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000006011 modification reaction Methods 0.000 description 2
- 230000000051 modifying Effects 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 238000010606 normalization Methods 0.000 description 2
- LFGREXWGYUGZLY-UHFFFAOYSA-N oxophosphanyl Chemical group [P]=O LFGREXWGYUGZLY-UHFFFAOYSA-N 0.000 description 2
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 239000008389 polyethoxylated castor oil Substances 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 150000004804 polysaccharides Polymers 0.000 description 2
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 2
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 2
- RYXIBQLRUHDYEE-UHFFFAOYSA-M potassium;5-(cyclohexen-1-yl)-3-[(4-methoxycyclohexyl)-(4-methylcyclohexanecarbonyl)amino]thiophene-2-carboxylate Chemical compound [K+].C1CC(OC)CCC1N(C1=C(SC(=C1)C=1CCCCC=1)C([O-])=O)C(=O)C1CCC(C)CC1 RYXIBQLRUHDYEE-UHFFFAOYSA-M 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 239000000612 proton pump inhibitor Substances 0.000 description 2
- 230000003482 proton pump inhibitor Effects 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 235000005875 quercetin Nutrition 0.000 description 2
- 229930002344 quercetin Natural products 0.000 description 2
- YIBOMRUWOWDFLG-ONEGZZNKSA-N rilpivirine Chemical compound CC1=CC(\C=C\C#N)=CC(C)=C1NC1=CC=NC(NC=2C=CC(=CC=2)C#N)=N1 YIBOMRUWOWDFLG-ONEGZZNKSA-N 0.000 description 2
- 229960000311 ritonavir Drugs 0.000 description 2
- 101700006972 sif1 Proteins 0.000 description 2
- 101700081395 sif2 Proteins 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 229920003109 sodium starch glycolate Polymers 0.000 description 2
- 239000008109 sodium starch glycolate Substances 0.000 description 2
- 229940079832 sodium starch glycolate Drugs 0.000 description 2
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 2
- STFSJTPVIIDAQX-LTRPLHCISA-M sodium;(E)-4-octadecoxy-4-oxobut-2-enoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCCOC(=O)\C=C\C([O-])=O STFSJTPVIIDAQX-LTRPLHCISA-M 0.000 description 2
- 229940076569 sofosbuvir 400 MG Drugs 0.000 description 2
- 238000005063 solubilization Methods 0.000 description 2
- 235000012424 soybean oil Nutrition 0.000 description 2
- 239000003549 soybean oil Substances 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 108010017101 telaprevir Proteins 0.000 description 2
- VCMJCVGFSROFHV-WZGZYPNHSA-N tenofovir disoproxil fumarate Chemical compound OC(=O)\C=C\C(O)=O.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N VCMJCVGFSROFHV-WZGZYPNHSA-N 0.000 description 2
- IYWRCNFZPNEADN-CXODAYGWSA-N tert-butyl N-[(2S)-1-[(2S,4R)-2-[[(1R,2S)-1-(cyclopropylsulfonylcarbamoyl)-2-ethenylcyclopropyl]carbamoyl]-4-(6-methoxyisoquinolin-1-yl)oxypyrrolidin-1-yl]-3,3-dimethyl-1-oxobutan-2-yl]carbamate Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC=1C2=CC=C(C=C2C=CN=1)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C IYWRCNFZPNEADN-CXODAYGWSA-N 0.000 description 2
- 231100000730 tolerability Toxicity 0.000 description 2
- 235000019731 tricalcium phosphate Nutrition 0.000 description 2
- 238000004450 types of analysis Methods 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- KRZBCHWVBQOTNZ-RDJMKVHDSA-M (-)-3,5-Dicaffeoyl quinic acid Natural products O([C@@H]1CC(O)(C[C@H](C1O)OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)C([O-])=O)C(=O)\C=C\C1=CC=C(O)C(O)=C1 KRZBCHWVBQOTNZ-RDJMKVHDSA-M 0.000 description 1
- RICZEKWVNZFTNZ-LFGITCQGSA-N (1R,2S,5S)-3-[(2S)-2-[[1-(tert-butylsulfonylmethyl)cyclohexyl]carbamoylamino]-3,3-dimethylbutanoyl]-N-[(3S)-1-(cyclopropylamino)-1,2-dioxoheptan-3-yl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide Chemical compound N([C@H](C(=O)N1C[C@H]2[C@H](C2(C)C)[C@H]1C(=O)N[C@@H](CCCC)C(=O)C(=O)NC1CC1)C(C)(C)C)C(=O)NC1(CS(=O)(=O)C(C)(C)C)CCCCC1 RICZEKWVNZFTNZ-LFGITCQGSA-N 0.000 description 1
- SLVAPEZTBDBAPI-GDLZYMKVSA-N (2R)-2-cyclopentyl-2-[2-(2,6-diethylpyridin-4-yl)ethyl]-5-[(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-3H-pyran-6-one Chemical compound CCC1=NC(CC)=CC(CC[C@]2(OC(=O)C(CC3=NN4C(C)=CC(C)=NC4=N3)=C(O)C2)C2CCCC2)=C1 SLVAPEZTBDBAPI-GDLZYMKVSA-N 0.000 description 1
- BHPRDABYBCABNU-NCNGZOBXSA-N (2R)-N-(2-aminoacetyl)-2-[[(2S)-4-[(3-aminophenyl)sulfonyl-(2-methylpropyl)amino]-3-hydroxy-1-phenylbutan-2-yl]-[(3-fluorophenyl)methyl]amino]-3,3-dimethylbutanamide Chemical compound C([C@@H](C(O)CN(CC(C)C)S(=O)(=O)C=1C=C(N)C=CC=1)N(CC=1C=C(F)C=CC=1)[C@@H](C(=O)NC(=O)CN)C(C)(C)C)C1=CC=CC=C1 BHPRDABYBCABNU-NCNGZOBXSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2R,3R,4S,5R,6S)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2S,3R,4S,5R,6R)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2R,3R,4S,5R,6R)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- IXZYCIFRVZKVRJ-RKKDRKJOSA-N (2S)-N-[(2S,3R)-4-[(4-aminophenyl)sulfonyl-(2-methylpropyl)amino]-3-hydroxy-1-phenylbutan-2-yl]-2-[[2-[(3-fluorophenyl)methylamino]acetyl]amino]-3,3-dimethylbutanamide Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)[C@@H](NC(=O)CNCC=1C=C(F)C=CC=1)C(C)(C)C)C1=CC=CC=C1 IXZYCIFRVZKVRJ-RKKDRKJOSA-N 0.000 description 1
- JLUPGSPHOGFEOB-WQLSENKSSA-N (2Z)-2-(2,2-dimethyl-5-oxo-1,3-dioxolan-4-ylidene)-N-[(4-fluorophenyl)methyl]-N-methoxyacetamide Chemical compound O\1C(C)(C)OC(=O)C/1=C/C(=O)N(OC)CC1=CC=C(F)C=C1 JLUPGSPHOGFEOB-WQLSENKSSA-N 0.000 description 1
- KRZBCHWVBQOTNZ-RDJMKVHDSA-N (3R,5R)-3,5-bis[[(E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy]-1,4-dihydroxycyclohexane-1-carboxylic acid Chemical compound O([C@@H]1CC(O)(C[C@H](C1O)OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)C(O)=O)C(=O)\C=C\C1=CC=C(O)C(O)=C1 KRZBCHWVBQOTNZ-RDJMKVHDSA-N 0.000 description 1
- QRBIFAKBTSNLCS-ZTFBILFISA-N (3S,4aS,8aS)-N-tert-butyl-2-[(2R,3S)-2-hydroxy-3-[[(2R)-3-methyl-3-methylsulfonyl-2-[(2-pyridin-3-yloxyacetyl)amino]butanoyl]amino]-4-phenylbutyl]-3,4,4a,5,6,7,8,8a-octahydro-1H-isoquinoline-3-carboxamide Chemical compound C([C@@H]([C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C)NC(=O)[C@@H](NC(=O)COC=1C=NC=CC=1)C(C)(C)S(C)(=O)=O)C1=CC=CC=C1 QRBIFAKBTSNLCS-ZTFBILFISA-N 0.000 description 1
- CWVMWSZEMZOUPC-JUAXIXHSSA-N (3S,5S,8R,9S,10S,13S,14S,16R)-16-bromo-3-hydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,14,15,16-tetradecahydrocyclopenta[a]phenanthren-17-one Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C([C@H](Br)C4)=O)[C@@H]4[C@@H]3CC[C@H]21 CWVMWSZEMZOUPC-JUAXIXHSSA-N 0.000 description 1
- AQHMBDAHQGYLIU-XNFHFXFQSA-N (3S,6S,9S,12R,15S,18S,21S,24S,27R,30S,33S)-27-[2-(dimethylamino)ethylsulfanyl]-30-ethyl-33-[(E,1R,2R)-1-hydroxy-2-methylhex-4-enyl]-24-(2-hydroxy-2-methylpropyl)-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18-tris(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10, Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)(C)O)N(C)C(=O)[C@@H](SCCN(C)C)N(C)C1=O AQHMBDAHQGYLIU-XNFHFXFQSA-N 0.000 description 1
- ZMCJFJZOSKEMOM-DNKZPPIMSA-N (4,6-dimethylpyrimidin-5-yl)-[4-[(3S)-4-[(1R,2R)-2-ethoxy-5-(trifluoromethyl)-2,3-dihydro-1H-inden-1-yl]-3-methylpiperazin-1-yl]-4-methylpiperidin-1-yl]methanone Chemical compound N([C@@H]1C2=CC=C(C=C2C[C@H]1OCC)C(F)(F)F)([C@H](C1)C)CCN1C(CC1)(C)CCN1C(=O)C1=C(C)N=CN=C1C ZMCJFJZOSKEMOM-DNKZPPIMSA-N 0.000 description 1
- KYRSNWPSSXSNEP-ZRTHHSRSSA-N (4R,5S,6S,7R)-1,3-bis[(3-aminophenyl)methyl]-4,7-dibenzyl-5,6-dihydroxy-1,3-diazepan-2-one Chemical compound NC1=CC=CC(CN2C(N(CC=3C=C(N)C=CC=3)[C@H](CC=3C=CC=CC=3)[C@H](O)[C@@H](O)[C@H]2CC=2C=CC=CC=2)=O)=C1 KYRSNWPSSXSNEP-ZRTHHSRSSA-N 0.000 description 1
- QCNJQJJFXFJVCX-ZDUSSCGKSA-N (4S)-4-(2-cyclopropylethynyl)-5,6-difluoro-4-(trifluoromethyl)-1,3-dihydroquinazolin-2-one Chemical compound C([C@@]1(NC(=O)NC2=CC=C(C(=C21)F)F)C(F)(F)F)#CC1CC1 QCNJQJJFXFJVCX-ZDUSSCGKSA-N 0.000 description 1
- JJWJSIAJLBEMEN-ZDUSSCGKSA-N (4S)-6-chloro-4-(2-cyclopropylethynyl)-4-(trifluoromethyl)-1,3-dihydroquinazolin-2-one Chemical compound C([C@]1(C2=CC(Cl)=CC=C2NC(=O)N1)C(F)(F)F)#CC1CC1 JJWJSIAJLBEMEN-ZDUSSCGKSA-N 0.000 description 1
- UXDWYQAXEGVSPS-GFUIURDCSA-N (4S)-6-chloro-4-[(E)-2-cyclopropylethenyl]-4-(trifluoromethyl)-1,3-dihydroquinazolin-2-one Chemical compound C(/[C@]1(C2=CC(Cl)=CC=C2NC(=O)N1)C(F)(F)F)=C\C1CC1 UXDWYQAXEGVSPS-GFUIURDCSA-N 0.000 description 1
- DBPMWRYLTBNCCE-UHFFFAOYSA-N 1-(4-benzoylpiperazin-1-yl)-2-(4,7-dimethoxy-1H-pyrrolo[2,3-c]pyridin-3-yl)ethane-1,2-dione Chemical compound C1=2C(OC)=CN=C(OC)C=2NC=C1C(=O)C(=O)N(CC1)CCN1C(=O)C1=CC=CC=C1 DBPMWRYLTBNCCE-UHFFFAOYSA-N 0.000 description 1
- NKPHEWJJTGPRSL-OCCSQVGLSA-N 1-(5-cyanopyridin-2-yl)-3-[(1S,2S)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea Chemical compound CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O NKPHEWJJTGPRSL-OCCSQVGLSA-N 0.000 description 1
- BEMBRAMZGVDPMH-UHFFFAOYSA-N 11-ethyl-5-methyl-8-[2-(1-oxidoquinolin-1-ium-4-yl)oxyethyl]dipyrido[2,3-d:2',3'-h][1,4]diazepin-6-one Chemical compound CN1C(=O)C2=CC(CCOC=3C4=CC=CC=C4[N+]([O-])=CC=3)=CN=C2N(CC)C2=NC=CC=C21 BEMBRAMZGVDPMH-UHFFFAOYSA-N 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- VNIWZCGZPBJWBI-UHFFFAOYSA-N 2-(1,1-dioxothiazinan-2-yl)-N-[(4-fluorophenyl)methyl]-5-hydroxy-1-methyl-6-oxopyrimidine-4-carboxamide Chemical compound OC=1C(=O)N(C)C(N2S(CCCC2)(=O)=O)=NC=1C(=O)NCC1=CC=C(F)C=C1 VNIWZCGZPBJWBI-UHFFFAOYSA-N 0.000 description 1
- XNLICIUVMPYHGG-UHFFFAOYSA-N 2-Pentanone Chemical compound CCCC(C)=O XNLICIUVMPYHGG-UHFFFAOYSA-N 0.000 description 1
- WVULKSPCQVQLCU-ZMBDPXIHSA-N 2-[(4R)-4-[(2S,5R,7R,14R,15R,16S)-5,16-dihydroxy-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadecan-14-yl]pentanamido]acetic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)C1C2C2CC[C@H]([C@@H](CCC(O)=NCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 WVULKSPCQVQLCU-ZMBDPXIHSA-N 0.000 description 1
- VUKAUDKDFVSVFT-UHFFFAOYSA-N 2-[6-[4,5-bis(2-hydroxypropoxy)-2-(2-hydroxypropoxymethyl)-6-methoxyoxan-3-yl]oxy-4,5-dimethoxy-2-(methoxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)-5-methoxyoxane-3,4-diol Chemical compound COC1C(OC)C(OC2C(C(O)C(OC)C(CO)O2)O)C(COC)OC1OC1C(COCC(C)O)OC(OC)C(OCC(C)O)C1OCC(C)O VUKAUDKDFVSVFT-UHFFFAOYSA-N 0.000 description 1
- XNDDHFZKJNTAMK-JNDBSPSASA-N 2-[[2-[2-[6-[3-[4-[2-[(2S)-1-[(2S)-2-(carboxymethylamino)-3-methylbutanoyl]pyrrolidin-2-yl]-1H-imidazol-5-yl]phenyl]thieno[3,2-b]thiophen-6-yl]-1H-benzimidazol-2-yl]pyrrolidin-1-yl]-2-oxo-1-phenylethyl]amino]acetic acid Chemical compound OC(=O)CN[C@@H](C(C)C)C(=O)N1CCC[C@H]1C1=NC=C(C=2C=CC(=CC=2)C=2C=3SC=C(C=3SC=2)C=2C=C3NC(=NC3=CC=2)C2N(CCC2)C(=O)C(NCC(O)=O)C=2C=CC=CC=2)N1 XNDDHFZKJNTAMK-JNDBSPSASA-N 0.000 description 1
- RTJUXLYUUDBAJN-KVQBGUIXSA-N 2-amino-9-[(2R,4S,5R)-4-fluoro-5-(hydroxymethyl)oxolan-2-yl]-3H-purin-6-one Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@H]1C[C@H](F)[C@@H](CO)O1 RTJUXLYUUDBAJN-KVQBGUIXSA-N 0.000 description 1
- ILAYIAGXTHKHNT-UHFFFAOYSA-N 4-[4-(2,4,6-TRIMETHYL-PHENYLAMINO)-PYRIMIDIN-2-YLAMINO]-BENZONITRILE Chemical compound CC1=CC(C)=CC(C)=C1NC1=CC=NC(NC=2C=CC(=CC=2)C#N)=N1 ILAYIAGXTHKHNT-UHFFFAOYSA-N 0.000 description 1
- GWNOTCOIYUNTQP-FQLXRVMXSA-N 4-[4-[[(3R)-1-butyl-3-[(R)-cyclohexyl(hydroxy)methyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undecan-9-yl]methyl]phenoxy]benzoic acid Chemical compound N([C@@H](C(=O)N1CCCC)[C@H](O)C2CCCCC2)C(=O)C1(CC1)CCN1CC(C=C1)=CC=C1OC1=CC=C(C(O)=O)C=C1 GWNOTCOIYUNTQP-FQLXRVMXSA-N 0.000 description 1
- HSBKFSPNDWWPSL-VDTYLAMSSA-N 4-amino-5-fluoro-1-[(2S,5R)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]pyrimidin-2-one Chemical compound C1=C(F)C(N)=NC(=O)N1[C@@H]1C=C[C@H](CO)O1 HSBKFSPNDWWPSL-VDTYLAMSSA-N 0.000 description 1
- WPMJNLCLKAKMLA-UHFFFAOYSA-N 5-(3,3-dimethylbut-1-ynyl)-3-[(4-hydroxycyclohexyl)-(4-methylcyclohexanecarbonyl)amino]thiophene-2-carboxylic acid Chemical compound C1CC(C)CCC1C(=O)N(C1=C(SC(=C1)C#CC(C)(C)C)C(O)=O)C1CCC(O)CC1 WPMJNLCLKAKMLA-UHFFFAOYSA-N 0.000 description 1
- 102100001249 ALB Human genes 0.000 description 1
- 101710027066 ALB Proteins 0.000 description 1
- XJKJWTWGDGIQRH-BFIDDRIFSA-N Alginic acid Chemical compound O1[C@@H](C(O)=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](C)[C@@H](O)[C@H]1O XJKJWTWGDGIQRH-BFIDDRIFSA-N 0.000 description 1
- UXCAQJAQSWSNPQ-XLPZGREQSA-N Alovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](F)C1 UXCAQJAQSWSNPQ-XLPZGREQSA-N 0.000 description 1
- 229950004424 Alovudine Drugs 0.000 description 1
- YMARZQAQMVYCKC-OEMFJLHTSA-N Amprenavir Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1COCC1)C1=CC=CC=C1 YMARZQAQMVYCKC-OEMFJLHTSA-N 0.000 description 1
- 230000036551 Apparent volume of distribution Effects 0.000 description 1
- RYMCFYKJDVMSIR-RNFRBKRXSA-N Apricitabine Chemical compound O=C1N=C(N)C=CN1[C@@H]1S[C@H](CO)OC1 RYMCFYKJDVMSIR-RNFRBKRXSA-N 0.000 description 1
- AXRYRYVKAWYZBR-GASGPIRDSA-N Atazanavir Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)[C@@H](O)CN(CC=1C=CC(=CC=1)C=1N=CC=CC=1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C1=CC=CC=C1 AXRYRYVKAWYZBR-GASGPIRDSA-N 0.000 description 1
- WVROWPPEIMRGAB-UHFFFAOYSA-N BIT225 Chemical compound C1=NN(C)C=C1C1=CC=CC2=CC(C(=O)NC(N)=N)=CC=C12 WVROWPPEIMRGAB-UHFFFAOYSA-N 0.000 description 1
- 229950002892 Bevirimat Drugs 0.000 description 1
- JORVRJNILJXMMG-OLNQLETPSA-N Brecanavir Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=C2OCOC2=CC=1)NC(=O)O[C@@H]1[C@@H]2CCO[C@@H]2OC1)C(C=C1)=CC=C1OCC1=CSC(C)=N1 JORVRJNILJXMMG-OLNQLETPSA-N 0.000 description 1
- 229950009079 Brecanavir Drugs 0.000 description 1
- MBNNRMVOTYNNIX-HBEKLPNASA-N C(\C=C\C1=CC(O)=C(O)C=C1)(=O)[C@]1(CC(C[C@](C1O)(O)C(\C=C\C1=CC(O)=C(O)C=C1)=O)(C(=O)O)O)O Chemical compound C(\C=C\C1=CC(O)=C(O)C=C1)(=O)[C@]1(CC(C[C@](C1O)(O)C(\C=C\C1=CC(O)=C(O)C=C1)=O)(C(=O)O)O)O MBNNRMVOTYNNIX-HBEKLPNASA-N 0.000 description 1
- 230000036030 CHANGE IN AUC Effects 0.000 description 1
- NIDRYBLTWYFCFV-FMTVUPSXSA-N Calanolide A Chemical compound C1=CC(C)(C)OC2=C1C(O[C@H](C)[C@@H](C)[C@@H]1O)=C1C1=C2C(CCC)=CC(=O)O1 NIDRYBLTWYFCFV-FMTVUPSXSA-N 0.000 description 1
- 229960003563 Calcium Carbonate Drugs 0.000 description 1
- YQXCVAGCMNFUMQ-UHFFFAOYSA-N Capravirine Chemical compound C=1C(Cl)=CC(Cl)=CC=1SC1=C(C(C)C)N=C(COC(N)=O)N1CC1=CC=NC=C1 YQXCVAGCMNFUMQ-UHFFFAOYSA-N 0.000 description 1
- 229950008230 Capravirine Drugs 0.000 description 1
- PJZPDFUUXKKDNB-KNINVFKUSA-N Ciluprevir Chemical compound N([C@@H]1C(=O)N2[C@H](C(N[C@@]3(C[C@H]3\C=C/CCCCC1)C(O)=O)=O)C[C@H](C2)OC=1C2=CC=C(C=C2N=C(C=1)C=1N=C(NC(C)C)SC=1)OC)C(=O)OC1CCCC1 PJZPDFUUXKKDNB-KNINVFKUSA-N 0.000 description 1
- 230000037250 Clearance Effects 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229950002891 DANOPREVIR Drugs 0.000 description 1
- DEZRYPDIMOWBDS-UHFFFAOYSA-N DCM Dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
- 229960005449 Daclatasvir Drugs 0.000 description 1
- FKRSSPOQAMALKA-CUPIEXAXSA-N Daclatasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C1=NC(C=2C=CC(=CC=2)C=2C=CC(=CC=2)C=2N=C(NC=2)[C@H]2N(CCC2)C(=O)[C@@H](NC(=O)OC)C(C)C)=CN1 FKRSSPOQAMALKA-CUPIEXAXSA-N 0.000 description 1
- UDMJANYPQWEDFT-ZAWFUYGJSA-N Deldeprevir Chemical compound C([C@@H]1C(=O)N2[C@H](C(N[C@@]3(C[C@H]3\C=C/CCCCC1)C(=O)NS(=O)(=O)C1CC1)=O)C[C@H](C2)OC=1C2=CC=C(C(=C2N=C(C=1)C=1SC=C(N=1)C(C)C)C)OC)C(=O)N1CCCC(F)(F)C1 UDMJANYPQWEDFT-ZAWFUYGJSA-N 0.000 description 1
- 235000004418 Durio kutejensis Nutrition 0.000 description 1
- BVAZQCUMNICBAQ-PZHYSIFUSA-N Elbasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C1=NC(C=2C=C3O[C@H](N4C5=CC=C(C=C5C=C4C3=CC=2)C=2N=C(NC=2)[C@H]2N(CCC2)C(=O)[C@@H](NC(=O)OC)C(C)C)C=2C=CC=CC=2)=CN1 BVAZQCUMNICBAQ-PZHYSIFUSA-N 0.000 description 1
- 229950006528 Elvucitabine Drugs 0.000 description 1
- MLILORUFDVLTSP-UHFFFAOYSA-N Emivirine Chemical compound O=C1NC(=O)N(COCC)C(CC=2C=CC=CC=2)=C1C(C)C MLILORUFDVLTSP-UHFFFAOYSA-N 0.000 description 1
- 229950002002 Emivirine Drugs 0.000 description 1
- 108010032976 Enfuvirtide Proteins 0.000 description 1
- 229950000206 Estolate Drugs 0.000 description 1
- PYGWGZALEOIKDF-UHFFFAOYSA-N Etravirine Chemical compound CC1=CC(C#N)=CC(C)=C1OC1=NC(NC=2C=CC(=CC=2)C#N)=NC(N)=C1Br PYGWGZALEOIKDF-UHFFFAOYSA-N 0.000 description 1
- 101700045064 FADS2 Proteins 0.000 description 1
- 102100015029 FADS2 Human genes 0.000 description 1
- 101700024954 FGD1 Proteins 0.000 description 1
- 229910016860 FaSSIF Inorganic materials 0.000 description 1
- 229960003777 Faldaprevir Drugs 0.000 description 1
- LLGDPTDZOVKFDU-XUHJSTDZSA-N Faldaprevir Chemical compound N([C@H](C(=O)N1[C@@H](C[C@H](C1)OC=1C2=CC=C(C(=C2N=C(C=1)C=1N=C(NC(=O)C(C)C)SC=1)Br)OC)C(=O)N[C@]1([C@@H](C1)C=C)C(O)=O)C(C)(C)C)C(=O)OC1CCCC1 LLGDPTDZOVKFDU-XUHJSTDZSA-N 0.000 description 1
- 229950011045 Filibuvir Drugs 0.000 description 1
- 229950003232 Fosalvudine tidoxil Drugs 0.000 description 1
- 101700068650 G6PD Proteins 0.000 description 1
- 102100005993 G6PD Human genes 0.000 description 1
- 101710027353 G6pdx Proteins 0.000 description 1
- 210000001035 Gastrointestinal Tract Anatomy 0.000 description 1
- 206010019233 Headache Diseases 0.000 description 1
- 206010019641 Hepatic cirrhosis Diseases 0.000 description 1
- 102100005076 IFNL3 Human genes 0.000 description 1
- 101700043924 IFNL3 Proteins 0.000 description 1
- DOUYETYNHWVLEO-UHFFFAOYSA-N Imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 description 1
- CBVCZFGXHXORBI-PXQQMZJSSA-N Indinavir Chemical compound C([C@H](N(CC1)C[C@@H](O)C[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H]2C3=CC=CC=C3C[C@H]2O)C(=O)NC(C)(C)C)N1CC1=CC=CN=C1 CBVCZFGXHXORBI-PXQQMZJSSA-N 0.000 description 1
- 229940029329 Intrinsic factor Drugs 0.000 description 1
- 238000003109 Karl Fischer titration Methods 0.000 description 1
- NJBBLOIWMSYVCQ-VZTVMPNDSA-N Kynostatin 272 Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)COC=1C2=CC=NC=C2C=CC=1)CSC)[C@H](O)C(=O)N1[C@@H](CSC1)C(=O)NC(C)(C)C)C1=CC=CC=C1 NJBBLOIWMSYVCQ-VZTVMPNDSA-N 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 230000036917 MEAN CMAX Effects 0.000 description 1
- 102100008175 MGAM Human genes 0.000 description 1
- 101700019282 MRL7 Proteins 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N Maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- GSNHKUDZZFZSJB-QYOOZWMWSA-N Maraviroc Chemical compound CC(C)C1=NN=C(C)N1[C@@H]1C[C@H](N2CC[C@H](NC(=O)C3CCC(F)(F)CC3)C=3C=CC=CC=3)CC[C@H]2C1 GSNHKUDZZFZSJB-QYOOZWMWSA-N 0.000 description 1
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 1
- 229950003168 Merimepodib Drugs 0.000 description 1
- 235000009421 Myristica fragrans Nutrition 0.000 description 1
- WVLHHLRVNDMIAR-IBGZPJMESA-N N'-(1H-benzimidazol-2-ylmethyl)-N'-[(8S)-5,6,7,8-tetrahydroquinolin-8-yl]butane-1,4-diamine Chemical compound C1CCC2=CC=CN=C2[C@H]1N(CCCCN)CC1=NC2=CC=CC=C2N1 WVLHHLRVNDMIAR-IBGZPJMESA-N 0.000 description 1
- 108010007843 NADH oxidase Proteins 0.000 description 1
- 229950003504 Narlaprevir Drugs 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- UDMJANYPQWEDFT-XDMHQIHASA-N Neceprevir Chemical compound C([C@@H]1C(=O)N2[C@H](C(N[C@@]3(C[C@H]3\C=C/CCCCC1)C(=O)NS(=O)(=O)C1CC1)=O)C[C@@H](C2)OC=1C2=CC=C(C(=C2N=C(C=1)C=1SC=C(N=1)C(C)C)C)OC)C(=O)N1CCCC(F)(F)C1 UDMJANYPQWEDFT-XDMHQIHASA-N 0.000 description 1
- QAGYKUNXZHXKMR-HKWSIXNMSA-N Nelfinavir Chemical compound CC1=C(O)C=CC=C1C(=O)N[C@H]([C@H](O)CN1[C@@H](C[C@@H]2CCCC[C@@H]2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-HKWSIXNMSA-N 0.000 description 1
- 229960000689 Nevirapine Drugs 0.000 description 1
- NQDJXKOVJZTUJA-UHFFFAOYSA-N Nevirapine Chemical compound C12=NC=CC=C2C(=O)NC=2C(C)=CC=NC=2N1C1CC1 NQDJXKOVJZTUJA-UHFFFAOYSA-N 0.000 description 1
- 229920001850 Nucleic acid sequence Polymers 0.000 description 1
- 101710039222 PF14_0511 Proteins 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 229940044519 Poloxamer 188 Drugs 0.000 description 1
- 238000001237 Raman spectrum Methods 0.000 description 1
- KNUXHTWUIVMBBY-JRJYXWDASA-N Rintatolimod Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(O)=O)O1.O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(=O)NC(=O)C=C1.O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(NC=NC2=O)=C2N=C1 KNUXHTWUIVMBBY-JRJYXWDASA-N 0.000 description 1
- FGHMGRXAHIXTBM-TWFJNEQDSA-N S-[2-[[(2R,3R,4R,5R)-5-(2-amino-6-oxo-3H-purin-9-yl)-3,4-dihydroxy-4-methyloxolan-2-yl]methoxy-(benzylamino)phosphoryl]oxyethyl] 3-hydroxy-2,2-dimethylpropanethioate Chemical compound C([C@@H]1[C@H]([C@@](C)(O)[C@H](N2C3=C(C(NC(N)=N3)=O)N=C2)O1)O)OP(=O)(OCCSC(=O)C(C)(CO)C)NCC1=CC=CC=C1 FGHMGRXAHIXTBM-TWFJNEQDSA-N 0.000 description 1
- 108010090287 SCY-635 Proteins 0.000 description 1
- 229950004113 SETROBUVIR Drugs 0.000 description 1
- 229950010695 SOVAPREVIR Drugs 0.000 description 1
- 101700025758 SP01 Proteins 0.000 description 1
- 101710027357 SPAC3C7.13c Proteins 0.000 description 1
- 101710027351 SPCC794.01c Proteins 0.000 description 1
- 102100000509 SPCS3 Human genes 0.000 description 1
- 108060007808 SPCS3 Proteins 0.000 description 1
- WIOOVJJJJQAZGJ-ISHQQBGZSA-N Sifuvirtide Chemical compound C([C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](N)CO)[C@@H](C)O)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O)C1=CC=C(O)C=C1 WIOOVJJJJQAZGJ-ISHQQBGZSA-N 0.000 description 1
- 206010041541 Spinal compression fracture Diseases 0.000 description 1
- 229960001203 Stavudine Drugs 0.000 description 1
- XNKLLVCARDGLGL-JGVFFNPUSA-N Stavudine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1C=C[C@@H](CO)O1 XNKLLVCARDGLGL-JGVFFNPUSA-N 0.000 description 1
- 102000018075 Subfamily B ATP Binding Cassette Transporter Human genes 0.000 description 1
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N TFA trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- UOBYJVFBFSLCTQ-UHFFFAOYSA-N TMC647055 Chemical compound C12=CC=C(C(NS(=O)(=O)N(C)CCOCCN(C)C3=O)=O)C=C2N2CC3=CC3=CC(OC)=CC=C3C2=C1C1CCCCC1 UOBYJVFBFSLCTQ-UHFFFAOYSA-N 0.000 description 1
- 229950004886 Tegobuvir Drugs 0.000 description 1
- SGOIRFVFHAKUTI-ZCFIWIBFSA-N Tenofovir Chemical compound N1=CN=C2N(C[C@@H](C)OCP(O)(O)=O)C=NC2=C1N SGOIRFVFHAKUTI-ZCFIWIBFSA-N 0.000 description 1
- 229960004556 Tenofovir Drugs 0.000 description 1
- 108010078233 Thymalfasin Proteins 0.000 description 1
- 102400000800 Thymosin alpha-1 Human genes 0.000 description 1
- NZPXPXAGXYTROM-FYBSXPHGSA-N Tipranavir Chemical compound C([C@@]1(CCC)OC(O)=C([C@H](CC)C=2C=C(NS(=O)(=O)C=3N=CC(=CC=3)C(F)(F)F)C=CC=2)C(=O)C1)CC1=CC=CC=C1 NZPXPXAGXYTROM-FYBSXPHGSA-N 0.000 description 1
- 206010066901 Treatment failure Diseases 0.000 description 1
- HWKQNAWCHQMZHK-UHFFFAOYSA-N Trolnitrate Chemical compound [O-][N+](=O)OCCN(CCO[N+]([O-])=O)CCO[N+]([O-])=O HWKQNAWCHQMZHK-UHFFFAOYSA-N 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- KUQWGLQLLVFLSM-ONAXAZCASA-N Vaniprevir Chemical compound CC[C@@H]1C[C@@]1(C(=O)NS(=O)(=O)C1CC1)NC(=O)[C@H]1N(C(=O)[C@@H](NC(=O)OCC(C)(C)CCCCC=2C=3CN(CC=3C=CC=2)C(=O)O2)C(C)(C)C)C[C@H]2C1 KUQWGLQLLVFLSM-ONAXAZCASA-N 0.000 description 1
- CNPVJJQCETWNEU-CYFREDJKSA-N Vicriviroc Chemical compound N([C@@H](COC)C=1C=CC(=CC=1)C(F)(F)F)([C@H](C1)C)CCN1C(CC1)(C)CCN1C(=O)C1=C(C)N=CN=C1C CNPVJJQCETWNEU-CYFREDJKSA-N 0.000 description 1
- 229950009860 Vicriviroc Drugs 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 208000001756 Virus Disease Diseases 0.000 description 1
- 230000036835 Vz/F Effects 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N Xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 Xylitol Drugs 0.000 description 1
- JHXLLEDIXXOJQD-VBWFMVIDSA-N [(2R)-2-decoxy-3-dodecylsulfanylpropyl] [(2R,3S,5R)-3-fluoro-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methyl hydrogen phosphate Chemical compound C1[C@H](F)[C@@H](COP(O)(=O)OC[C@H](CSCCCCCCCCCCCC)OCCCCCCCCCC)O[C@H]1N1C(=O)NC(=O)C(C)=C1 JHXLLEDIXXOJQD-VBWFMVIDSA-N 0.000 description 1
- JBPUGFODGPKTDW-SFHVURJKSA-N [(3S)-oxolan-3-yl] N-[[3-[[3-methoxy-4-(1,3-oxazol-5-yl)phenyl]carbamoylamino]phenyl]methyl]carbamate Chemical compound C=1C=C(C=2OC=NC=2)C(OC)=CC=1NC(=O)NC(C=1)=CC=CC=1CNC(=O)O[C@H]1CCOC1 JBPUGFODGPKTDW-SFHVURJKSA-N 0.000 description 1
- BINXAIIXOUQUKC-UIPNDDLNSA-N [(3aS,4R,6aR)-2,3,3a,4,5,6a-hexahydrofuro[2,3-b]furan-4-yl] N-[(2S,3R)-3-hydroxy-4-[(4-methoxyphenyl)sulfonyl-(2-methylpropyl)amino]-1-phenylbutan-2-yl]carbamate Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(CC(C)C)C[C@@H](O)[C@@H](NC(=O)O[C@@H]1[C@@H]2CCO[C@@H]2OC1)CC1=CC=CC=C1 BINXAIIXOUQUKC-UIPNDDLNSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 229940050528 albumin Drugs 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 108010028144 alpha-Glucosidases Proteins 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229960001830 amprenavir Drugs 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 230000003466 anti-cipated Effects 0.000 description 1
- 229950006356 aplaviroc Drugs 0.000 description 1
- 229960003277 atazanavir Drugs 0.000 description 1
- 150000007514 bases Chemical class 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- YJEJKUQEXFSVCJ-WRFMNRASSA-N bevirimat Chemical compound C1C[C@H](OC(=O)CC(C)(C)C(O)=O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C YJEJKUQEXFSVCJ-WRFMNRASSA-N 0.000 description 1
- 238000011087 biopharmaceutical technology Methods 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 229920003086 cellulose ether Polymers 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001684 chronic Effects 0.000 description 1
- 230000035512 clearance Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- WREGKURFCTUGRC-POYBYMJQSA-N ddC Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)CC1 WREGKURFCTUGRC-POYBYMJQSA-N 0.000 description 1
- BXZVVICBKDXVGW-NKWVEPMBSA-N ddIno Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 description 1
- 230000005860 defense response to virus Effects 0.000 description 1
- 239000008380 degradant Substances 0.000 description 1
- 230000004059 degradation Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 101700068086 des6 Proteins 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 229960002656 didanosine Drugs 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000009506 drug dissolution testing Methods 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 229960002062 enfuvirtide Drugs 0.000 description 1
- PEASPLKKXBYDKL-FXEVSJAOSA-N enfuvirtide Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(C)=O)[C@@H](C)O)[C@@H](C)CC)C1=CN=CN1 PEASPLKKXBYDKL-FXEVSJAOSA-N 0.000 description 1
- 229960004667 ethyl cellulose Drugs 0.000 description 1
- 229960002049 etravirine Drugs 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 229910021485 fumed silica Inorganic materials 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000002496 gastric Effects 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002440 hepatic Effects 0.000 description 1
- 239000004030 hiv protease inhibitor Substances 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 229960002751 imiquimod Drugs 0.000 description 1
- 229960001936 indinavir Drugs 0.000 description 1
- 229960003358 interferon alfacon-1 Drugs 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229940011051 isopropyl acetate Drugs 0.000 description 1
- GWYFCOCPABKNJV-UHFFFAOYSA-M isovalerate Chemical compound CC(C)CC([O-])=O GWYFCOCPABKNJV-UHFFFAOYSA-M 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 239000011344 liquid material Substances 0.000 description 1
- 238000011068 load Methods 0.000 description 1
- 239000001115 mace Substances 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 229960004710 maraviroc Drugs 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- YMCAVGXTSCNFDE-BBACVFHCSA-N methyl N-[(2S)-1-[(2S)-2-[5-[4-[4-[2-[(8S)-7-[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]-1,4-dioxa-7-azaspiro[4.4]nonan-8-yl]-1H-imidazol-5-yl]phenyl]phenyl]-1H-imidazol-2-yl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C1=NC=C(C=2C=CC(=CC=2)C=2C=CC(=CC=2)C=2NC(=NC=2)[C@H]2N(CC3(C2)OCCO3)C(=O)[C@@H](NC(=O)OC)C(C)C)N1 YMCAVGXTSCNFDE-BBACVFHCSA-N 0.000 description 1
- JYLMWUZJMRNMDA-SPRBZRACSA-N methyl N-[(2S)-1-[(2S)-2-[5-[6-[2-[(2S)-1-[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]pyrrolidin-2-yl]-3H-benzimidazol-5-yl]naphthalen-2-yl]-1H-imidazol-2-yl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate;dihydrochloride Chemical compound Cl.Cl.COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C1=NC=C(C=2C=C3C=CC(=CC3=CC=2)C=2C=C3NC(=NC3=CC=2)[C@H]2N(CCC2)C(=O)[C@@H](NC(=O)OC)C(C)C)N1 JYLMWUZJMRNMDA-SPRBZRACSA-N 0.000 description 1
- LBWDUXHLFJNSJJ-ZYADHFCISA-N methyl N-[(2S)-1-[(6S)-6-[5-[4-[2-[2-[(6S)-5-[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]-5-azaspiro[2.4]heptan-6-yl]-3H-benzimidazol-5-yl]ethynyl]phenyl]-1H-imidazol-2-yl]-5-azaspiro[2.4]heptan-5-yl]-3-methyl-1-oxobutan-2-yl]carbamate Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N([C@@H](C1)C=2NC(=CN=2)C=2C=CC(=CC=2)C#CC=2C=C3NC(=NC3=CC=2)[C@H]2N(CC3(CC3)C2)C(=O)[C@@H](NC(=O)OC)C(C)C)CC21CC2 LBWDUXHLFJNSJJ-ZYADHFCISA-N 0.000 description 1
- KHASNRBNVBIREH-IZEXYCQBSA-N methyl N-[(2S)-1-[[(5S)-5-[(4-aminophenyl)sulfonyl-(2-methylpropyl)amino]-6-phosphonooxyhexyl]amino]-1-oxo-3,3-diphenylpropan-2-yl]carbamate Chemical compound C=1C=CC=CC=1C([C@H](NC(=O)OC)C(=O)NCCCC[C@@H](COP(O)(O)=O)N(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)C1=CC=CC=C1 KHASNRBNVBIREH-IZEXYCQBSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000001565 modulated differential scanning calorimetry Methods 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 108010008475 narlaprevir Proteins 0.000 description 1
- 229960000884 nelfinavir Drugs 0.000 description 1
- 230000001264 neutralization Effects 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000036961 partial Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 230000003285 pharmacodynamic Effects 0.000 description 1
- 230000036231 pharmacokinetics Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 229920000333 poly(propyleneimine) Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229940057838 polyethylene glycol 4000 Drugs 0.000 description 1
- 229920002959 polymer blend Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 231100000683 possible toxicity Toxicity 0.000 description 1
- 239000008057 potassium phosphate buffer Substances 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrugs Drugs 0.000 description 1
- 230000002035 prolonged Effects 0.000 description 1
- 230000005588 protonation Effects 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N rac-1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- 229960002814 rilpivirine Drugs 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 238000000646 scanning calorimetry Methods 0.000 description 1
- 239000012056 semi-solid material Substances 0.000 description 1
- 231100000247 serious adverse effect Toxicity 0.000 description 1
- 108010048106 sifuvirtide Proteins 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 239000001187 sodium carbonate Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 229940001593 sodium carbonate Drugs 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- OABYVIYXWMZFFJ-ZUHYDKSRSA-M sodium glycocholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 OABYVIYXWMZFFJ-ZUHYDKSRSA-M 0.000 description 1
- AAYACJGHNRIFCT-YRJJIGPTSA-M sodium;2-[[(4R)-4-[(3R,5S,7R,8R,9S,10S,13R,14S,17R)-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]acetate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC([O-])=O)C)[C@@]2(C)CC1 AAYACJGHNRIFCT-YRJJIGPTSA-M 0.000 description 1
- IYPNVUSIMGAJFC-JUWYWQLMSA-M sodium;2-[[(4R)-4-[(3R,5S,7S,8R,9S,10S,13R,14S,17R)-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]ethanesulfonate Chemical compound [Na+].C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS([O-])(=O)=O)C)[C@@]2(C)CC1 IYPNVUSIMGAJFC-JUWYWQLMSA-M 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000006104 solid solution Substances 0.000 description 1
- 230000003381 solubilizing Effects 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000003595 spectral Effects 0.000 description 1
- 238000010922 spray-dried dispersion Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing Effects 0.000 description 1
- AWDRATDZQPNJFN-VAYUFCLWSA-N taurodeoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@@H](O)C1 AWDRATDZQPNJFN-VAYUFCLWSA-N 0.000 description 1
- 239000003491 tear gas Substances 0.000 description 1
- 229920001169 thermoplastic Polymers 0.000 description 1
- 239000004416 thermosoftening plastic Substances 0.000 description 1
- 229960000838 tipranavir Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 230000001052 transient Effects 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960000523 zalcitabine Drugs 0.000 description 1
- 101710011556 zfaA Proteins 0.000 description 1
Abstract
Disclosed are pharmaceutical compositions having an effective amount of substantially amorphous ledipasvir and an effective amount of substantially crystalline sofosbuvir.
Description
COMBINATION FORMULATION OF TWO ANTIVIRAL COMPOUNDS
CROSS-REFERENCE TO RELATE!) APPLICATION [0001] This application claims the benefit under 35 U.S.C. § 119(e) to U.S. Provisional Application Number 61/759,320, filed on January 31, 2013, U.S. Provisional Application Number 61/772,292, filed on March 4, 2013, U.S. Provisional Application Number 61/828,899, filed on May 30, 2013, U.S. Provisional Application Number 61/870,729, filed on August 27, 2013, U.S. Provisional Application Number 61/897,793, filed on October 30, 2013, and U.S. Provisional Application Number 61/907,332, filed on November 21, 2013, the entirety of which are ail incorporated herein by reference.
BACKGROUND [0002] Hepatitis C is recognized as a chronic viral disease of the liver which is characterized by liver disease. Although drugs targeting the liver are in wide use and hâve shown effectiveness, toxicity and other side effects hâve limited their usefulness. Inhibitors of hepatitis C virus (HCV) are useful to limit the establishment and progression of infection by HCV as well as in diagnostic assays for HCV.
[0003] Ledipasvir is a sélective inhibitor of non-structural protein 5A (NS5A), which has been described prevîously (see, for example, WO 2010/132601). The chemical name of ledipasvir i s ( 1 - {3 -[6-(9,9-difluoro-7- [ 2-[5-(2-methoxycarbonylamino-3-methyl-butyryl)-5aza-spiro[2.4]hept-6-yl]-3H-imidazol-4-yl}-9H-fluoren-2-yl)-lH-benzoimidazol-2-yl]-2-azabicyclo[2.2.1]heptane-2-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester.
[0004] Sofosbuvir (SOF) is a sélective inhibitor of non-structural protein 5B (NS5B) (see, for example, WO 2010/132601 and U.S. Patent 7,964,580). The chemical name of sofosbuvir is (S)-isopropyl 2-(((S)-(((2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidinl(2H)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2yl)methoxy)(phenoxy)phosphoryl)amino) propanoate.
SUMMARY [0005] The présent disclosure provides, in some embodiments, a pharmaceutical composition comprising ledipasvir in a substantially amorphous form and sofosbuvir in a substantially crystalline form.
[0006] Ledipasvir has the chemical name of (l-[3-[6-(9,9-difluoro-7-{2-[5-(2methoxycarbonylamino-3-methyl-butyryl)-5-aza-spiro[2.4]hept-6-yl]-3H-iinidazol-4-yl}-9Hfluoren-2-yl)-1 H-benzoimidazol-2-yl]-2-aza-bicyclo[2.2. l]heptane-2-carbonyl}-2-methylpropyl)-carbamic acid methyl ester, and has the following chemical formula:
[0007] Sofosbuvir (SOF) has the chemical name of (S)-isopropyl 2-(((S)-(((2RJR,4R,5R)5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2“ yl)methoxy)(phenoxy)phosphoryl)amino)propanoate and has the following chemical formula:
[0008] In some embodiments, provided is a pharmaceutical composition comprising: a) an effective amount of ledipasvir, wherein ledipasvir is substantially amorphous; and b) an effective amount of sofosbuvir wherein sofosbuvir is substantially crystalline.
[0009] Further embodiments of the disclosure relate to pharmaceutical dosage forms and tablets. The disclosure also provides methods for using the combination in the treatment of hepatitis C.
BRIEF DESCRIPTION OF THE DRAWINGS [0010] FIG. 1 is a XRPD pattern of the solid dispersion formulation of ledipasvir comprising copovidone in a drug:polymer ratio of 1:1. As shown by the XRPD, the solid dispersion is in the amorphous state.
[0011] FIG. 2 is a modulated differential scanning calorimetry (DSC) curve of the solid dispersion of ledipasvir comprising copovidone in a drug:polymer ratio of 1:1. The glass transition température of the solid dispersion is about 140 °C.
[0012] FIG. 3 shows a solid state characterizatîon of the solid dispersion formulation of ledipasvir comprising copovidone in a drug:polymer ratio of 1:1 by solid state nuclear magnetic résonance (SS-NMR).
[0013] FIG. 4 is a Fourier-transformed Raman spectra of the solid dispersion of ledipasvir comprising copovidone in a drugtpolymer ratio of 1:1.
[0014] FIG. 5 shows the dissolution of sofosbuvir in the sofosbuvir ¢400 mg)/ledipasvir (90 mg) combination described în Example 7.
[0015] FIG. 6 shows the dissolution of ledipasvir in the sofosbuvir (400 mg)/ledipasvir (90 mg) combination formulation described in Example 3.
[0016] FIG. 7A-D shows the HCV RNA levels during 12 weeks of treatment and 24 weeks post-treatment for treatment naïve (FIG. 7A) or null responder (FIG. 7B) patients treated with sofosbuvir (SOF) and ribavirin (RBV) and for treatment naïve (FIG. 7C) or null responder (FIG. 7D) patients treated with sofosbuvir (SOF), ledipasvir and ribavirin (RBV). This data and experimental method are further described in Example 5.
[0017] FIG. 8A-B présent charts to show that ail three formulations had comparable dissolution performance, similar to that of the single-agent controls. This is more thoroughly described in Example 7.
[0018] FIG. 9 présents the pH-solubîlity profile of ledipasvir at room température (RT). The line is the nonlinear least-square régression fit using équation
St= So [(n-ioiPKe,'PH)+lO<pKaUpKa2’2,pH))] with an intrinsic solubility (So) of 0.04 pg/mL and a weakly basic pKal and pKa2 values of 5.0 and 4.0, respectively. This is more thoroughly described in Example 8.
[0019] FIG. 10 shows the study design for treatment naïve (non-cirrhotic) and for null responders (50% cîrrhotic) for patients treated with a fixed dose combination of sofosbuvir (SOF) and ledipasvir, with and without ribavirin (RBV) for 8 and 12 weeks. The data and experimental method are described in Example 9.
[0020] FIG. 11 shows the results for treatment naïve (non-cirrhotic) and for null responders (50% cirrhotic) for patients treated with a fixed dose combination of sofosbuvir (SOF) and ledipasvir, with and without ribavirin (RBV) for 8 and 12 weeks. This data and experimental method are further described in Example 9.
DETAILED DESCRIPTION
L Définitions (0021] As used in the présent spécification, the following words and phrases are generally intended to hâve the meanings as set forth below, except to the extent that the context in which they are used indicates otherwise.
[0022] As used herein, the term “about” used in the context of quantitative measurements means the indîcated amount ± 10%, or altematively ± 5%, or± 1%. For example, with a ± 10% range, “about 2:8” can mean 1.8-2.2:7.2-8.8.
[0023] The term “amorphous” refers to a state in which the material lacks long range order at the molecular level and, depending upon température, may exhibit the physical properties of a solid or a liquid. Typically such materials do not give distinctive X-ray diffraction patterns and, while exhîbiting the properties of a solid, are more formally described as a liquid. Upon heating, a change from solid to liquid properties occurs which is characterized by a change of state, typically second order (glass transition).
[0024] The term “crystalline” refers to a solid phase in which the material has a regular ordered internai structure at the molecular level and gives a distinctive X-ray diffraction pattern with defined peaks. Such materials when heated sufficiently will also exhibit the properties of a liquid, but the change from solid to liquid is characterized by a phase change, typically first order (melting point).
[0025] The term “substantially amorphous” as used herein is intended to mean that greater than 70%; or greater than 75%; or greater than 80%; or greater than 85%; or greater than 90%; or greater than 95%, or greater than 99% of the compound présent in a composition is in amorphous form. “Substantially amorphous” can also refer to material which has no more than about 20% crystallinity, or no more than about 10% crystallinity, or no more than about 5% crystallinity, or no more than about 2% crystallinity.
[0026] The term “substantially crystalline” as used herein is intended to mean that greater than 70%; or greater than 75%; or greater than 80%; or greater than 85%; or greater than
90%; or greater than 95%, or greater than 99% of the compound présent in a composition is in crystalline form. “Substantially crystalline” can also refer to material which has no more than about 20%, or no more than about 10%, or no more than about 5%, or no more than about 2% in the amorphous form.
[0027] The term “polymer” refers to a chemical compound or mixture of compounds consisting of repeating structural units created through a process of polymerization. Suitable polymers useful in this invention are described throughout.
[0028] The term “polymer matrix” as used herein is defined to mean compositions comprising one or more polymers in which the active agent is dispersed or included within the matrix.
[0029] The term “solid dispersion” refers to the dispersion of one or more active agents in a polymer matrix at solid state prepared by a variety of methods, including spray drying, the melting (fusion), solvent, or the melting-solvent method.
[0030] The term “amorphous solid dispersion” as used herein, refers to stable solid dispersions comprising an amorphous active agent and a polymer. By “amorphous active agent,” it is meant that the amorphous solid dispersion contains active agent in a substantially amorphous solid state form. In some aspects, as shown by the XRPD in FIG. 1, the solid dispersion is in the amorphous state, and the glass transition température of the solid dispersion is about 140 °C (see FIG. 2).
[0031] The term “pharmaceutically acceptable” indicates that the material does not hâve properties that would cause a reasonably prudent medical practitioner to avoîd administration of the material to a patient, taking into considération the disease or conditions to be treated and the respective route of administration. For example, it is commonly required that such a material be essentially stérile, e.g., for injectibles.
[0032] The term “pharmaceutically acceptable polymer” refers to a polymer that does not hâve properties that would cause a reasonably prudent medical practitioner to avoid administration of the material to a patient, taking into considération the disease or conditions to be treated and the respective route of administration.
[0033] The term “carrier” refers to a glidant, diluent, adjuvant, excipient, or vehicle etc with which the compound is administered, without limitation. Examples of carriers are described herein and also in “Remington's Pharmaceutical Sciences” by E.W. Martin.
[0034] The term “diluent” refers to chemical compounds that are used to dilute the compound of interest prior to delivery. Diluents can also serve to stabilize compounds. Nonlimiting examples of diluents include starch, saccharides, disaccharides, sucrose, lactose, polysaccharides, cellulose, cellulose ethers, hydroxypropyl cellulose, sugar alcohols, xylitol, sorbitol, maltitol, microcrystalline cellulose, calcium or sodium carbonate, lactose, lactose monohydrate, dicalcium phosphate, cellulose, compressible sugars, dibasic calcium phosphate dehydrate, mannitol, microcrystalline cellulose, and tribasic calcium phosphate.
[0035] The term “bindef” when used herein relates to any pharmaceutically acceptable film which can be used to bind together the active and inert components of the carrier together to maîntain cohesive and discrète portions. Non-limiting examples of binders include hydroxypropylcellulose, hydroxypropylmethyl cellulose, povidone, copovidone, and ethyl cellulose.
[0036] The term “disintegrant” refers to a substance which, upon addition to a solid préparation, facilitâtes its break-up or désintégration after administration and permits the release of an active ingrédient as efficiently as possible to allow for its rapid dissolution. Non-limiting examples of désintégrants include maize starch, sodium starch glycolate, croscarmellose sodium, crospovidone, microcrystalline cellulose, modified com starch, sodium carboxymethyl starch, povidone, pregelatinized starch, and alginic acid.
[0037] The term “lubricant” refers to an excipient which is added to a powder blend to prevent the compacted powder mass from sticking to the equipment during the tabletting or encapsulation process. It aids the éjection of the tablet form the dies, and can improve powder flow. Non-limiting examples of lubricants include magnésium stéarate, stearic acid, silica, fats, calcium stéarate, polyethylene glycol, sodium stearyl fumarate, or talc; and solubilizers such as fatty acids including lauric acid, oleic acid, and Cg/Cio fatty acid.
[0038] The term “film coating” refers to athin, uniform, film on the surface of a substrate (e.g. tablet). Film coatings are particularly useful for protectlng the active ingrédient from photolytic dégradation. Non-limiting examples of film coatings include polyvinylalcohol based, hydroxyethyl cellulose, hydroxypropylmethylcefiulose, sodium carboxymethylcellulose, polyethylene glycol 4000 and cellulose acetate phthalate film coatings.
[0039] The term “glidant” as used herein is intended to mean agents used in tablet and capsule formulations to improve flow-properties during tablet compression and to produce an anti-caking effect. Non-limiting examples of glidants include colloïdal silicon dioxide, talc, fumed silica, starch, starch dérivatives, and bentonite.
[0040] The term “effective amount” refers to an amount that îs sufïïcient to effect treatment, as defined below, when administered to a mammal in need of such treatment. The therapeutically effective amount will vary depending upon the patient being treated, the weight and âge of the patient, the severity of the disease condition, the manner of administration and the like, which can readily be determined by one of ordinary skill in the art.
[0041] The term “treatment” or “treating,” to the extent it relates to a disease or condition includes preventing the disease or condition from occurring, inhibiting the disease or condition, eliminating the disease or condition, and/or relieving one or more symptoms of the disease or condition.
[0042] The term “sustained virologie response” refers to the absence of détectable RNA (or wherein the RNA is below the limit of détection) of a virus (i.e. HCV) în a patient sample (i.e. blood sample) for a specifc period of time after discontinuation of a treatment. For example, a SVR at 4 weeks indicates that RNA was not detected or was below the limit of dectection in the patient at 4 weeks after discontînuîng HCV therapy.
[0043] The term “% w/w” as used herein refers to the weight of a component based on the total weight of a composition comprising the component. For example, if component A is présent in an amount of 50% w/w in a 100 mg composition, component A is présent in an amount of 50 mg.
2. Pharmaceutical Compositions [0044] The pharmaceutical compositions comprise a combination of an effective amount of ledipasvir, wherein ledipasvir is substantially amorphous, and an effective amount of sofosbuvir, wherein sofosbuvir is substantially crystalline.
[0045] Such a combination composition, as the experimental examples demonstrate, exhibit unexpected properties. Both sofosbuvir and ledipasvir hâve previously been demonstrated to act as effective anti-HCV agents. Ledipasvir, when administered alone in a conventional formulation, however, exhibited a négative food effect as evidenced by a roughly 2-fold decrease in exposure when given with a high-fat meal relative to dosing in the fasted state (see, e.g,, Tables 10 and 11, Example 3). When ledipasvir is administered in a solid dispersion formulation and in the combination with sofosbuvir, no such négative food effect occurs (Table 12, Example 3).
[0046] In the combination composition, ledipasvir is présent in a substantially amorphous form. Compared to crystalline agents, amorphous agents are expected to be unstable and hâve nonlînear solubîlity and exposure profiles. The data presented herein, however, show that ledipasvir in the combination composition is stable under various conditions, both short-term and long-term, and maintains high and consistent solubîlity and exposure profiles (Example
6).
[0047] Further, according the conventional wisdom, it is not advisable to co-formulate an amorphous agent with a crystalline agent, because the crystals can serve as seeds to induce crystallization of the amorphous agent, leading to instability of the amorphous agent. The current data show that, however, whether co-granulated or co-blended with sofosbuvir in the same layer or integrated as separate layers, ledipasvir stays stable and does not form crystals in the composition (Example 6).
[0048] It is also been discovered that, in tablet formations of the combination composition where sofosbuvir and ledipasvir are either co-granulated or co-blended, drug-drug interaction does not occur (Example 7).
A. Ledipasvir [0049] Ledipasvir has previously been described (see, for example, WO 2010/132601) and can be prepared by methods described therein. In one embodiment, the pharmaceutical composition comprises ledipasvir formulated as a solid dispersion dispersed within a polymer matrix formed by a pharmaceutically acceptable polymer. The starting material of the solid dispersion can be a variety of forms of ledipasvir including crystalline forms, amorphous form, salts thereof, solvatés thereof and the free base. For example, the acetone solvaté, Dtartrate sait, anhydrous crystalline free base, amorphous free base, solvatés or desolvates of ledipasvir can be used. Solvatés of ledipasvir include, for example, those described in U.S. Publication No. 2013/0324740 (incorporated herein by reference) such as, for example, the monoacetone solvaté, diacetone solvaté, ethyl acetone solvaté, isopropyl acetate solvaté, methyl acetate solvaté, ethyl formate solvaté, acetonitrile solvaté, tetrahydrofuran solvaté, methyl ethyl ketone solvaté, tetrahydrofuran solvaté, methyl ethyl ketone solvaté, and methyl /erZ-butyl ether solvaté. Particuiar starting materials contemplated to be useful are the monoacetone solvaté, diacetone solvaté, anhydrous crystalline free base, D-tartrate sait, anhydrous crystalline free base, and amorphous free base. These forms are characterized and described in U.S. Publication No. 2013/0324496.
[0050] After dispersion with the polymer, the solid dispersion is in the amorphous form. FIGs. 1-4 characterize the amorphous solid dispersion comprising ledipasvir. As shown by the XRPD in FIG. 1, the solid dispersion is in the amorphous state, and the glass transition température of the solid dispersion is about 140 °C.
[0051] Various techniques are well known in the art for preparing solid dispersions including, but not limited to melt-extrusion, spray-drying, lyophilization, and solutionévaporation.
[0052) Melt-extrusion is the process of embedding a compound in a thermoplastic carrier. The mixture is processed at elevated températures and pressures, which disperses the compound în the matrix at a molecular level to form a solid solution. Extruded material can be further processed into a variety of dosage forms, including capsules, tablets and transmucosal Systems.
[0053] For the solution-évaporation method, the solid dispersion can be prepared by dissolving the compound în a suitable liquid solvent and then incorporating the solution directly into the melt of a polymer, which is then evaporated until a clear, solvent free film is left. The film is further dried to constant weight.
[0054] For the lyophilization technique, the compound and carrier can be co-dissolved in a common solvent, ffozen and sublîmed to obtain a lyophilized molecular dispersion.
[0055] For spray dried solid dispersions, the solid dispersion can be made by a) mixing the compound and polymer in a solvent to provide a feed solution; and b) spray drying the feed solution to provide the solid dispersion.
[0056] Spray dried solid dispersions of ledipasvir provide improved in vivo and in vitro performance and manufacturability/scal ability relative to the other formulation approaches, such as wet and dry granulation formulations. Ledipasvir can be provided either as the free base, D-tartrate sait, crystalline acetone solvaté, or other solvaté as described herein.
[0057] The sélection of the polymer for the solid dispersion is based on the stability and physical characteristics of the ledipasvir in the solution. Hypromellose and copovidone solid dispersions both showed adéquate stability and physical characteristics. Accordingly, in one embodiment, the polymer used in the solid dispersion is selected from hypromellose and copovidone. Furthermore, the copovidone-based dispersion increased in bioavailability more than the équivalent hypromellose-based formulation (F = 30% and 22%, respectively) when prepared at 2:1 APLpolymer ratio. Bioavailability of the copovidone-based formulation was further enhanced by increasing the fraction of polymer to a 1:1 ratio, resulting in a bioavailability of 35% in famotidine pretreated dogs.
[0058] In one embodiment, the polymer used in the solid dispersion of ledipasvir is hydrophilîc. Non-limiting examples of hydrophilic polymers include polysaccharides, polypeptides, cellulose dérivatives such as methyl cellulose, sodium carboxymethylcelluiose, hydroxyethylcellulose, ethylcellulose, hydroxypropyl methylcellulose acetate-succinate, hydroxypropyl methylcellulose phthalate, cellulose acetate phthalate, hydroxypropylcellulose, povidone, copovidone, hypromellose, pyroxylin, polyethylene oxide, polyvinyl alcohol, and methacrylic acid copolymers.
[0059] In a further embodiment, the polymer is non-ionic. Non-ionic polymers showed benefits in screening solubility experiments. Non-limiting examples of non-ionic polymers include hypromellose, copovidone, povidone, methyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, ethylcellulose, pyroxylin, polyethylene oxide, polyvinyl alcohol, polyethylene glycol, and polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol.
[0060] In another embodiment, the polymer is ionic. Examples of ionic polymers include hydroxypropyl methylcellulose acetate-succinate, hydroxypropyl methylcellulose phthalate, cellulose acetate phthalate, and methacrylic acid copolymers.
|0061] In a further embodiment, the polymer is selected from the group consisting of hypromellose, copovidone, and povidone. Hypromellose and copovidone solid dispersions both showed adéquate stability and physical characteristics. A copovidone-based dispersion increased bioavailability more than the équivalent hypromellose-based formulation (F = 30% and 22%, respectively) when spray dried at 2:1 ledipasviripolymer ratio (data not shown).
Accordingly, in a spécifie embodiment, the polymer is copovidone.
(0062] In certain embodiments, the weight ratio of ledipasvir to polymer is from about 5:1 to about 1:5. In further embodiments, the weight ratio of ledipasvir to polymer is about 5:1 to about 1:4, or from about 5:1 to about 1:3, or from about 5:1 to about 1:2, or from about 2:1 to about 1:2, or from about 2:1 to about 1:1. In a spécifie embodiment, the weight ratio of ledipasvir to polymer is about 1:1. In another embodiment, the weight ratio of ledipasvir to polymer is about 2:1. In further embodiments, the weight ratio of ledipasvir to polymer is about 5:1, 1:4, 1:3, or 1:2. Increasing the fraction of polymer to a 1:1 ratio may, in some instances, resuit in an increased bioavailability. For example, a 1:1 ratio of ledipasvir:copovidone resulted in increased bioavailability (F = 35%) in famotidine pretreated dogs.
[0063] The solid dispersion comprising ledipasvir may be présent in the pharmaceutical composition in a therapeutically effective amount. In some embodiments, the pharmaceutical compositions comprises from about 1% to about 50% w/w of the solid dispersion of ledipasvir. In further embodiments, the composition comprises from about 5% to about 40% w/w, or from about 5% to about 35% w/w, or from about 5% to about 30% w/w, or from about 10% to about 30% w/w, or from about 10% to about 25% w/w, or from about 15% to about 20% w/w of the solid dispersion of ledipasvir. In further embodiments, the pharmaceutical composition comprises about 1% w/w, about 5% w/w, about 10% w/w, about 20% w/w, about 25% w/w, about 30% w/w, about 35% w/w, or about 40% w/w of the solid dispersion of ledipasvir In a spécifie embodiment, the pharmaceutical composition comprises about 18% w/w of the solid dispersion of ledipasvir.
[0064] Ledipasvir may be présent in the pharmaceutical composition in a therapeutically effective amount. In some embodiments, the pharmaceutical compositions comprises from about 1% to about 50% w/w of ledipasvir. In further embodiments, the composition comprises from about 1% to about 40% w/w, or from about 1% to about 30% w/w, or from about 1% to about 20% w/w, or from about 5% to about 15% w/w, or from about 7% to about 12% w/w of ledipasvir. In further embodiments, the pharmaceutical composition comprises about 1% w/w, about 3% w/w, about 5% w/w, about 7% w/w, about 11% w/w, about 13% w/w, about 15% w/w, about 17% w/w, about 20% w/w, about 23% w/w, about 25% w/w, or about 28% w/w, or about 30% w/w of ledipasvir. In a spécifie embodiment, the pharmaceutical composition comprises about 9% w/w of ledipasvir.
[0065] As noted above, after the ledipasvir is mixed with the polymer, the mixture can then be solubilized in a solvent. It is within the skill of those in the art to select an appropriate solvent based on the drug and/or polymer properties such as solubility, glass transition température, viscosity, and molecular weight. Acceptable solvents include but are not limited to, water, acetone, methyl acetate, ethyl acetate, chlorinated solvents, éthanol, dichloromethane, and methanol. In one embodiment, the solvent is selected from the group consisting of éthanol, dichloromethane, and methanol. In a iùrther embodiment, the solvent is éthanol or methanol. In a spécifie embodiment, the solvent is éthanol.
[0066] Upon solubilization of the compound and polymer mixture with the solvent, the mixture may then be spray dried. Spray drying is a well known process wherein a liquid feedstock is dispersed into droplets into a drying chamber along with a heated process gas stream to aid in solvent removal and to produce a powder product. Suitable spray drying parameters are known in the art, and it is within the knowledge of a skilled artisan în the field to select appropriate parameters for spray drying. The target feed concentration is generally about 10 to about 50% wîth a target of about 20% and a viscosity of about 15 to about 300 cP. The inlet température of the spray dry apparatus is typically about 50-190° C, while the outlet température is about 30-90° C. The two fluid nozzle and hydrolic pressure nozzle can be used to spray dry ledipasvir. The two fluid nozzle gas flow can be about 1-10 kg/hr, the hydrolic pressure nozzle flow can be about 15-300 kg/hr, and the chamber gas flow may be about 25-2500 kg/hr The spray-dried material typically has particle size (D<xi) under 80 pm. In some instances, a milling step may be used, if desired to further reduce the particle size. Further descriptions of spray drying methods and other techniques for forming amorphous dispersions are provided in U.S. Pat. No. 6,763,607 and U.S. Pat. Pub. No. 2006-0189633, the entirety of each of which is incorporated herein by reference.
[0067] Spray drying out of éthanol resulted in high yields (88, 90, 92, 95, 97, 98, 99%) across a wide range of spray-drying outlet températures (30-90 °C) with no material accumulation on the spray dry chamber, and the yields obtained from spray drying out of
DCM were 60%, 78%, and 44%. Furthermore, ledipasvir demonstrated good chemical stability in the ethanolic feed solution.
B. Sofosbuvir [0068] Sofosbuvir has previously been described in U.S. Patent 7,964,580 and U.S.
Publication Nos: 2010/0016251, 2010/0298257, 2011/0251152 and 2012/0107278.
Sofosbuvir is provided as substantially crystalline in the pharmaceutical compositions described herein. Examples of preparing crystalline forms of sofosbuvir are disclosed in U.S. Publication Nos: 2010/0298257 and 2011/0251152, both of which are incorporated by reference. Crystalline forms, Forms 1-6, of sofosbuvir are described in U.S. Publication Nos.: 2010/0298257 and 2011/0251152, both of which are incorporated by reference. Forms 1 -6 of sofosbuvir hâve the following characteristic X-ray powder diffraction (XRPD) pattern 20-values measured according to the XRPD methods disclosed therein:
(1) 20-reflections (° ± 0.2Θ) at about: 7.5, 9.6, and 18.3 (Form 1);
(2) 26-reflections (° ± 0.20) at about: 5.0, 7.3, and 18.1 (Form 1);
(3) 29-reflections (° ± 0.20) at about: 6.9, 24.7, and 25.1 (Form 2);
(4) 20-reflections (Q ± 0.2Θ) at about: 19.7, 20.6, and 24.6 (Form 3), (5) 20-reflections (° ± 0.2Θ) at about: 5.0, 6.8, and 24.9 (Form 4);
(6) 20-reflections (° ± 0.20) at about: 5.2, 6.6, and 19.1 (Form 5); and (7) 20-reflections (° ± 0.20) at about: 6.1, 20.1, and 20.8 (Form 6).
[0069] Form 6, as described in the patent publications above, may be referred to as Form 2, such for example, by the Food and Drug Administration. Forms 1 and 6 are altematively characterized by the following characteristic XRPD pattern 20-values as measured according to the methods disclosed in U.S. Pat. Pub. Nos.: 2010/0298257 and 2011/0251152:
(1) 20-reflections (°) at about: 5.0 and 7.3 (Form 1); and (2) 20-reflectîons (°) at about: 6.1 and 12.7 (Form 6).
[0070] In one embodiment, the crystalline sofosbuvir has XRPD 20-reflections (° ± 0.2Θ) at about:
(1) 7.5, 9.6, and 18.3; (Form IA) (2) 5.0,7 3, and 18.1; (Form IB) (3) 6.9, 24.7, and 25.1; (Form 2) i
(4) 19.7, 20.6, and 24.6; (Form 3) (5) 5.0, 6.8, and 24.9; (Form 4) (6) 5.2, 6.6, and 19.1, (Form 5) or (7) 6,1,20.1, and 20.8; (Form 6).
[0071] In certain embodiments, the crystalline sofosbuvir has XRPD 20-reflections (° ±
0.2Θ) at about:
(1) 5.2, 7.5, 9.6, 16.7, 18.3, and 22.2 (Form 1);
(2) 5.0, 7.3, 9.4, and 18.1 (Form 1);
(3) 4.9, 6.9, 9.8, 19.8, 20.6, 24.7, 25.1, and 26.1 (Form 2);
(4) 6.9, 9.8, 19.7, 20.6, and 24.6 (Form 3);
(5) 5.0, 6.8, 19.9, 20.6, 20.9, and 24.9 (Form 4);
¢6)5.2,6.6, 7.1, 15.7, 19.1, and 25.0 (Form 5); or (7)6.1,8.2, 10.4, 12.7, 17.2, 17.7, 18.0, 18.8, 19.4, 19.8,20.1,20.8,21.8, and
23.3 (Form 6).
[0072] In a further embodiment, crystalline sofosbuvir has XRPD 29-reflections (° ± 0.29) at about: 6.1, 8.2, 10.4, 12.7, 17.2, 17.7, 18.0, 18.8, 19.4, 19.8, 20.1, 20.8,21.8, and 23.3. In yet a further embodiment, crystalline sofosbuvir has XRPD 29-reflections (° ± 0.29) at about: 6.1 and 12.7.
[0073] Sofosbuvir may be présent in the pharmaceutical composition in a therapeutically effective amount. In some embodiments, the pharmaceutical compositions comprises from about 10% to about 70% w/w of sofosbuvir. In further embodiments, the composition comprises from about 15% to about 65% w/w, or from about 20% to about 60% w/w, or from about 25% to about 55% w/w, or from about 30% to about 50% w/w, or from about 35% to about 45% w/w of sofosbuvir. In further embodiments, the pharmaceutical composition comprises about 10% w/w, about 15% w/w, about 20% w/w, about 25% w/w, about 30% w/w, about 35% w/w, about 45% w/w, about 50% w/w, about 55% w/w, about 60% w/w, about 65% w/w, or about 70% w/w, or about 75% w/w. In a spécifie embodiment, the pharmaceutical composition comprises about 40% w/w of sofosbuvir.
C. Excipients [0074] The pharmaceutical compositions provided in accordance with the présent disclosure are usually administered orally. This disclosure therefore provides pharmaceutical compositions that comprise a solid dispersion comprising ledipasvir as described herein and one or more pharmaceutically acceptable excipients or carriers including but not limited to, inert solid diluents and fillers, diluents, including stérile aqueous solution and various organic solvents, perméation enhancers, solubilizers, disintegrants, lubricants, binders, glidants, adjuvants, and combinations thereof. Such compositions are prepared in a manner well known in the pharmaceutical art (see, e.g., Remington’s Pharmaceutical Sciences, Mace Pubiishing Co., Philadelphia, PA 17th Ed. (1985); and Modem Pharmaceutics, Marcel Dekker, Inc. 3rd Ed. (G.S. Banker& C.T. Rhodes, Eds).
[0075] The pharmaceutical compositions may be administered in either single or multiple doses by oral administration. Administration may be via capsule, tablet, or the like. In one embodiment, the ledipasvir is in the form of a tablet. In a further embodiment, the tablet is a compressed tablet. In making the pharmaceutical compositions that include the solid described herein, the active ingrédient is usually diluted by an excipient and/or enclosed within such a carrier that can be in the form of a capsule, tablet, sachet, paper or other container. When the excipient serves as a diluent, it can be in the form of a solid, semi-solid or liquid material (as above), which acts as a vehicle, carrier or medium for the active ingrédient.
]0076] The pharmaceutical composition may be formulated for immédiate release or sustained release. A “sustained release formulation” is a formulation which is designed to slowly release a therapeutic agent in the body over an extended period of time, whereas an “immédiate release formulation” is an formulation which îs designed to quickly release a therapeutic agent in the body over a shortened period of time. In some cases the immédiate release formulation may be coated such that the therapeutic agent is only released once it reached the desired target in the body (e.g. the stomach). In a spécifie embodiment, the pharmaceutical composition îs formulated for immédiate release.
[0077] The pharmaceutical composition may further comprise pharmaceutical excipients such as diluents, binders, fillers, glidants, disintegrants, lubricants, solubilizers, and combinations thereof. Some examples of suitable excipients are described herein. When the pharmaceutical composition is formulated into a tablet, the tablet may be uncoated or may be coated by known techniques including microencapsulation to delay disintegration and adsorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl dîstearate alone or with a wax may be employed.
[0078] In one embodiment, the pharmaceutical composition comprises a diluent selected from the group consisting of dicalcium phosphate, cellulose, compressible sugars, dibasic calcium phosphate dehydrate, lactose, lactose monohydrate, mannitol, microcrystalline cellulose, starch, tribasic calcium phosphate, and combinations thereof.
[0079] In further embodiments, the pharmaceutical composition comprises lactose monohydrate in an amount from about 1 to about 50% w/w, or from about 1 to about 45% w/w, or from about 5 to about 40% w/w, or from about 5 to about 35% w/w, or from about 5 to about 25% w/w, or from about 10 to about 20% w/w. In spécifie embodiments, the lactose monohydrate is présent at about 5% w/w, at about 10% w/w, at about 15% w/w, at about 20% w/w, at about 25% w/w, at about 30% w/w, at about 35% w/w, at about 40% w/w, at about 45% w/w, or at about 50% w/w. In a further spécifie embodiment, the lactose monohydrate is in an amount of about 16.5% w/w.
[0080] In yet further embodiments, the pharmaceutical composition comprises microcrystalline cellulose in an amount from about 1 to about 40% w/w, or from about 1 to about 35% w/w, or from about 1% to about 25% w/w, or from about 5 to about 25% w/w, or from about 10 to about 25% w/w, or from about 15 to about 20% w/w. In spécifie embodiments, the microcrystalline cellulose is présent in an amount of about 5%, or about 10%, or about 15%, or about 20%, or about 25%, or about 30%, or about 35%, or about 40%w/w. In a further spécifie embodiment, the microcrystalline cellulose is in an amount of about 18% w/w.
[0081] In other embodiments, the pharmaceutical composition comprises a disintegrant selected from the group consisting of croscarmellose sodium, crospovidone, microcrystalline cellulose, modîfied corn starch, povidone, pregelatinized starch, sodium starch glycolate, and combinations thereof.
(0082] In certain embodiments, the pharmaceutical composition comprises croscarmellose sodium in an amount from about 1 to about 20% w/w, or from about 1 to about 15% w/w, or from about 1 to about 10% w/w, or from about 1 to about 8% w/w, or from about 2 to about
8% w/w. In spécifie embodîments, the croscarmellose sodium is présent in an amount of about 1%, or about 3%, or about 6%, or about 8%, or about 10%, or about 13%, or about
15% w/w. In a further spécifie embodiment, the croscarmellose sodium is in an amount of about 5% w/w.
]0083] In other embodîments, the pharmaceutical composition comprises a glidant selected from the group consîsting of colloïdal silicon dioxide, talc, starch, starch dérivatives, and combinations thereof.
[0084] In further embodîments, the pharmaceutical composition comprises colloïdal silicon dioxide in an amount from about 0.1 to about 5% w/w, or from about 0.1 to about 4.5% w/w, or from about 0.1 to about 4% w/w, or from about 0.5 to about 5.0% w/w, or from about 0.5 to about 3% w/w, or from about 0,5 to about 2% w/w, or from about 0.5 to about 1,5% w/w. In spécifie embodîments, the colloïdal silicon dioxide is présent in an amount of about 0.1% w/w, 0.5% w/w, 0.75% w/w, 1.25% w/w, 1.5% w/w, or 2% w/w. In a further spécifie embodiment, the colloïdal silicon dioxide is présent in an amount of about 1% w/w.
[0085] In other embodîments, the pharmaceutical composition comprises a lubricant selected from the group consîsting of calcium stéarate, magnésium stéarate, polyethylene glycol, sodium stearyl fumarate, stearic acid, talc, and combinations thereof.
(0086] In further embodîments, the pharmaceutical composition comprises magnésium stéarate in an amount from about 0.1 to about 3% w/w, or from about 0.1 to about 2.5% w/w, or from about 0.5 to about 3% w/w, or from about 0.5 to about 2.5% w/w, or from about 0.5 to about 2% w/w, or from about 1 to about 3% w/w, or from about 1 to about 2% w/w. In spécifie embodîments, the magnésium stéarate is présent in an amount of about 0.1%, or about 0.5, or about 1%, or about 2%, or about 2.5%, or about 3% w/w. In a fùrther spécifie embodiment, the magnésium stéarate is in an amount of about 1.5% w/w.
[0087] In one embodiment, the pharmaceutical composition comprises a) about 30 to about
50% w/w of sofosbuvir and b) about 5 to about 35 %w/w of the solid dispersion comprising ledipasvir. In a related embodiment, the composition comprises a) about 40% w/w of sofosbuvir and b) about 18% w/w of the solid dispersion comprising ledipasvir. In yet a further related embodiment, the composition further comprises a) about 5 to about 25% w/w lactose monohydrate, b) about 5 to about 25% w/w microcrystalline cellulose, c) about 1 to about 10% w/w croscarmellose sodium, d) about 0.5 to about 3% w/w colloïdal silicon dioxide, and e) about 0.1 to about 3% w/w magnésium stéarate. In a further embodiment, the pharmaceutical composition comprises a) about 40% w/w of sofosbuvir, b) about 18 %w/w of the solid dispersion comprising ledipasvir, c) about 16.5% w/w lactose monohydrate, d) about 18% w/w microcrystalline cellulose, e) about 5% w/w croscarmellose sodium, f) about
1% w/w colloïdal silicon dioxide, and g) about 1.5% w/w magnésium stéarate.
3. Pharmaceutical Dosage Forms [0088] The disclosure provides for tablets, pills, and the like, comprising the pharmaceutical compositions or dosage forms described herein. The tablets or pills of the présent disclosure may be coated to provide a dosage form affording the advantage of prolonged action or to protect from the acid conditions of the stomach. The tablets may also be formulated for immédiate release as previously described. In certain embodiments, the tablet comprises a film coating. A film coating is useful for limiting photolytic dégradation. Suitable film coatings are selected by routine screening of commercially available préparations. In one embodiment, the film coating is a polyvinylalcohol-based coating.
[0089] The tablets may be formulated into a monolayer or bilayer tablet. Typically, monolayer tablet comprise the active ingrédients (i.e., ledipasvir and sofosbuvir) co-mixed in a single uniform layer. For making monolayer tablets, exemplary methods include, but are not limited to coblend (or bi-granulation) and codry granulation. Coblend granulation is a multi-step process consisting of separate dry granulations for each active ingrédient with excipients followed by the blending of the two granulations together. Codry granulation consisted of dry granulating both active ingrédients and excipients together.
[0090] Bilayer tablets comprise the active ingrédients (i.e., ledipasvir and sofosbuvir) in separate layers and can be made by making a blend comprising excipients and one active ingrédient (i.e., ledipasvir), and making a separate blend comprising the second active ingrédient (i.e., sofosbuvir) and excipients. One blend may then be precompressed, and the second blend may then be added on top of the first precompressed blends. The resulting tablet comprises two separate layers, each layer comprising a different active ingrédient.
[0091] In one embodiment, the tablet comprises a) about 30 to about 50% w/w of sofosbuvir and b) about 10 to about 40 %w/w of the solid dispersion comprising ledipasvir.
In a related embodiment, the tablet comprises a) about 40% w/w of sofosbuvir and b) about
18% w/w of the solid dispersion comprising ledipasvir. In a further embodiment, the tablet comprises a) about 300 to about 500 mg of sofosbuvir and b) about 50 to about 130 mg of ledipasvir. In a yet further embodiment, the tablet comprises a) about 400 mg of sofosbuvir and b) about 90 mg of ledipasvir. In related embodiment, the tablet further comprises a) about 5 to about 25% w/w lactose monohydrate, b) about 5 to about 25% w/w microcrystalline cellulose, c) about 1 to about 10% w/w croscarmellose sodium, d) about 0.5 to about 3% w/w colloïdal silicon dioxide, and e) about 0.1 to about 3% w/w magnésium stéarate.
[0092] In some embodiments, the pharmaceutical compositions as described herein are formulated in a unit dosage or pharmaceutical dosage form. The term “unît dosage forms” or “pharmaceutical dosage forms” refers to physically discrète units suitable as unitary dosages for human patients and other mammals, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect, in association with a suitable pharmaceutical excipient (e.g., a tablet or capsule). The compounds are generally administered in a pharmaceutically effective amount. In some embodiments, each dosage unit contains from 3 mg to 2 g of ledipasvir. In other embodiments, the pharmaceutical dosage form comprises from about 3 to about 360 mg, or about 10 to about 200 mg, or about 10 to about 50 mg, or about 20 to about 40 mg, or about 25 to about 35 mg, or about 40 to about 140 mg, or about 50 to about 130 mg, or about 60 to about 120 mg, or about 70 to about 110 mg, or about 80 to about 100 mg. In spécifie embodiments, the pharmaceutical dosage form comprises about 40, or about 45, or about 50, or about 55, or about 60, or about 70, or about 80, or about 100, or about 120, or about 140, or about 160, or about 180, or about 200, or about 220 mg of ledipasvir. In a further spécifie embodiment, the pharmaceutical dosage form comprises about 90 mg of ledipasvir. In yet a further spécifie embodiment, the pharmaceutical dosage form comprises about 30 mg of ledipasvir.
[0093] In other embodiments, the pharmaceutical dosage form comprises from about 1 mg to about 3g of sofosbuvir. In other embodiments, the pharmaceutical dosage form comprises from about 1 to about 800 mg, or about 100 to about 700 mg, or about 200 to about 600 mg, or about 300 to about 500 mg, or about 350 to about 450 mg, of sofosbuvir. In spécifie embodiments, the pharmaceutical dosage form comprises about 50, or about 100, or about 150, or about 200, or about 250, or about 300, or about 350, or about 450, or about 500, or about 550, or about 600, or about 650, or about 700, or about 750, or about 800 mg of sofosbuvir. In a further spécifie embodiment, the pharmaceutical dosage form comprises about 400 mg of sofosbuvir. It will be understood, however, that the amount of ledipasvir and/or sofosbuvir actually admînistered usually will be determined by a physician, in the light of the relevant circumstances, including the condition to be treated, the chosen route of administration, the actual compound admînistered and its relative activity, the âge, weight and response of the indîvidual patient, the severity of the patient’s symptoms, and the like.
[0094] In a spécifie embodiment, the pharmaceutical dosage form comprises about 400 mg of sofosbuvir and about 90 mg of ledipasvir.
[0095] In one embodiment, the pharmaceutical composition, or altematively, the pharmaceutical dosage form or tablet comprises about 90 mg of amorphous ledipasvir formulated in a solid dispersion comprising a polymer:ledipasvir ratio of 1:1, about 400 mg crystalline sofosbuvir, lactose monohydrate in an amount from about 5 to about 25% w/w, microcrystalline cellulose in an amount from about 5 to about 25% w/w, croscarmellose sodium in an amount from about 1 to about 10% w/w, colloïdal silicon dioxoide ïn an amount from about 0.5 to about 3% w/w, and magnésium stéarate in an amount from about 0.1 to about 3% w/w. In one embodiment, the polymer is copovidone.
[0096] In further embodiments, the pharmaceutical composition, pharmaceutical dosage form, or tablet as described herein is free of négative drug-drug interactions. In a related embodiment, the pharmaceutical composition, pharmaceutical dosage form, or tablet is free of négative drug-drug interactions with acid suppressive thérapies. In a further embodiment, the pharmaceutical composition, pharmaceutical dosage form, or tablet as described herein is administrable without regard to food and with or without regard to the patient being on an aeîd-suppressive therapy.
4. Methods of Use |0097] The solid dispersions, pharmaceutical compositions, pharmaceutical dosage forms, and tablets of ledipasvir and sofosbuvir as described herein are admînistered to a patient suffering from hepatitis C virus (HCV) in a daily dose by oral administration. In one embodiment, the patient is human.
[0098] Previously, ledipasvir had been demonstrated to hâve a négative food effect when admînistered alone. Unexpectedly, the combination treatment of ledipasvir and sofosbuvir does not exhibit a négative food effect. Accordingly, the administration of the pharmaceutical composition comprising sofosbuvir and ledipasvir can be taken without regard to food.
[0099] In some embodiments, the combination composition achieved a reduced food effect. In some aspects, the composition achieves a first exposure, when administered to a patient following a meal, that is no more than 25%, or aitematively not more than 20%, 15% or 10%, lower than a second exposure when administered to the patient not following a meal. The exposures can be measured as Cmax, AUCiast or AUCinf. In some aspects, the administration is carried out within four, three, two or one hours following the meal.
[0100] In one embodiment, the solid dispersions, pharmaceutical compositions, pharmaceutical dosage forms, and tablets of ledipasvir and sofosbuvir as described herein are effective in treating one or more of génotype 1 HCV infected patients, génotype 2 HCV infected patients, génotype 3 HCV infected patients, génotype 4 HCV infected patients, génotype 5 HCV infected patients, and/or génotype 6 HCV infected patients. In one embodiment, the solid dispersions, pharmaceutical compositions, pharmaceutical dosage forms, and tablets of ledipasvir and sofosbuvir as described herein are effective in treating génotype 1 HCV infected patients, including génotype la and/or génotype lb. In another embodiment, the solid dispersions, pharmaceutical compositions, pharmaceutical dosage forms, and tablets of ledipasvir and sofosbuvir as described herein are effective in treating génotype 2 HCV infected patients, including génotype 2a, génotype 2b, génotype 2c and/or génotype 2d. In another embodiment, the solid dispersions, pharmaceutical compositions, pharmaceutical dosage forms, and tablets of ledipasvir and sofosbuvir as described herein are effective in treating génotype 3 HCV infected patients, including génotype 3a, génotype 3b, génotype 3c, génotype 3d, génotype 3e and/or génotype 3f In another embodiment, the solid dispersions, pharmaceutical compositions, pharmaceutical dosage forms, and tablets of ledipasvir and sofosbuvir as described herein are effective in treating génotype 4 HCV infected patients, including génotype 4a, génotype 4b, génotype 4c, génotype 4d, génotype 4e, génotype 4f, génotype 4g, génotype 4h, génotype 4i and/or génotype 4j. In another embodiment, the solid dispersions, pharmaceutical compositions, pharmaceutical dosage forms, and tablets of ledipasvir and sofosbuvir as described herein are effective in treating génotype 5 HCV infected patients, including génotype 5a. In another embodiment, the solid dispersions, pharmaceutical compositions, pharmaceutical dosage forms, and tablets of ledipasvir and sofosbuvir as described herein are effective in treating génotype 6 HCV infected patients, including génotype 6a. In one embodiment, the compositions are pangenotypic, meaning they are useful across ail génotypes and drug résistant mutants thereof.
[0101] In some embodiments, the pharmaceutical composition, pharmaceutical dosage form, or tablet of ledipasvir and sofosbuvir as described herein is administered, either alone or in combination with one or more therapeutic agent(s) for treating HCV (such as a HCV NS3 protease inhibitor or an inhibitor of HCV NS5B polymerase), for about 24 weeks, for about 16 weeks, or for about 12 weeks, or less. In further embodiments, the pharmaceutical composition, pharmaceutical dosage form, or tablet of ledipasvir and sofosbuvir is administered, either alone or in combination with one or more therapeutic agent(s) for treating HCV (such as a HCV NS3 protease inhibitor or an inhibitor of HCV NS5B polymerase), for about 24 weeks or less, about 22 weeks or less, about 20 weeks or less, about 18 weeks or less, about 16 weeks or less, about 12 weeks or less, about 10 weeks or less, about 8 weeks or less, or about 6 weeks or less or about 4 weeks or less. The pharmaceutical composition, pharmaceutical dosage form, or tablet may be administered once daily, twice daily, once every other day, two times a week, three times a week, four tîmes a week, or five times a week.
[0102] In further embodiments, a sustained virologie response is achieved at about 4 weeks, 6 weeks, 8 weeks, 12 weeks, or 16 weeks, or at about 20 weeks, or at about 24 weeks, or at about 4 months, or at about 5 months, or at about 6 months, or at about 1 year, or at about 2 years.
[0103] In one embodiment, the daily dose is 90 mg of ledipasvir and 400 mg of sofosbuvir administered in the form of a tablet. In a further embodiment, the daily dose is a tablet comprising a) about 30 to about 50% w/w of sofosbuvir, b) about 10 to about 40 %w/w of the solid dispersion comprising ledipasvir, c) about 5 to about 25% w/w lactose monohydrate, d) about 5 to about 25% w/w microcrystalline cellulose, e) about 1 to about 10% w/w croscarmellose sodium, f) about 0.5 to about 3% w/w colloïdal silicon dioxide, and g) about 0.1 to about 3% w/w magnésium stéarate.
[0104] In further embodiments, the patient is also suffering from cirrhosis. In yet a fùrther embodiment, the patient is not suffereing from cirrhosis.
5. Combination Therapy [0105] In the methods described herein, the method can further comprise the administration of another therapeutic agent for treating HCV and other conditions such as HIV infections. In one embodiment, non-limiting examples of suitable additional therapeutic agents include one or more interferons, ribavirin or its analogs, HCV NS3 protease inhibitors, alpha-glucosidase 1 inhibitors, hepatoprotectants, nucleoside or nucléotide inhibitors of HCV NS5B polymerase, non-nucleoside inhibitors of HCV NS5B polymerase, HCV NS5A inhibitors, TLR-7 agonîsts, cyclophillin inhibitors, HCV IRES inhibitors, pharmacokinetic enhancers, and other drugs or therapeutic agents for treating HCV, [0106] More specifically, the additional therapeutic agent may be selected from the group consisting of:
1) interferons, e.g., pegylated rIFN-alpha 2b (PEG-Intron), pegylated rIFN-alpha 2a (Pegasys), rIFN-alpha 2b (Intron A), rIFN-alpha 2a (Roferon-A), interferon alpha (MOR-22, OPC-18, Alfaferone, Alfanative, Multiferon, subalin), interferon alfacon-1 (Infergen), interferon alpha-nl (Wellferon), interferon alpha-n3 (Alferon), interferon-beta (Avonex, DL8234), interferon-omega (oméga DUROS, Biomed 510), albinterferon alpha-2b (Albuferon), IFN alpha-2b XL, BLX-883 (Locteron), DA-3021, glycosylated interferon alpha-2b (AVI005), PEG-Infergen, PEGylated interferon lambda-1 (PEGylated EL-29), and belerofon;
2) ribavirin and its analogs, e.g., ribavirin (Rebetol, Copegus), and taribavirin (Vîramidine);
3) HCV NS3 protease inhibitors, e.g., boceprevir (SCH-503034, SCH-7), telaprevir (VX-950), TMC435350, BI-1335, BI-1230, MK-7009, VBY-376, VX-500, GS-9256, GS9451, BMS-605339, PHX-1766, AS-101, YH-5258, YH5530, YH5531, ABT-450, ACH1625, ITMN-191, MK5172, MK6325, and MK2748;
4) alpha-glucosidase 1 inhibitors, e.g., celgosivir (MX-3253), Miglitol, and UT-231B;
5) hepatoprotectants, e.g., emerîcasan (IDN-6556), ME-3738, GS-9450 (LB-84451), silibilin, and MitoQ;
6) nucleoside or nucléotide inhibitors of HCVNS5B polymerase, e.g., R1626, R7128 (R4048), IDX184, IDX-102, BCX-4678, valopicitabine (NM-283), MK-0608, and ΓΝΧ-189 (now BMS986094);
7) non-nucleoside inhibitors of HCV NS5B polymerase, e.g., PF-868554, VCH-759, VCH-916, JTK-652, MK-3281, GS-9190, VBY-708, VCH-222, A848837, ANA-598, GL60667, GL59728, A-63890, A-48773, A-48547, BC-2329, VCH-796 (nesbuvir),
GSK625433, BILN-1941, XTL-2125, ABT-072, ABT-333, GS-9669, PSI-7792, and GS9190;
8) HCV NS5A inhibitors, e.g., AZD-2836 (A-831), BMS-790052, ACH-3102, ACH2928, MK8325, MK4882, MK8742, PSI-461, IDX719, ABT-267, and A-689;
9) TLR-7 agonists, e.g., imiquimod, 852A, GS-9524, ANA-773, ANA-975, AZD8848 (DSP-3025), and SM-360320,
10) cyclophillin inhibitors, e.g., DEBIO-025, SCY-635, and NIM811;
) HCV IRES inhibitors, e.g., MCI-067;
12) pharmacokinetic enhancers, e.g., BAS-100, SPI-452, PF-4194477, TMC-41629, GS-9350, GS-9585, and roxythromycin; and
13) other drugs for treating HCV, e.g., thymosin alpha 1 (Zadaxin), nitazoxanide (Alinea, NTZ), BIVN-401 (virostat), PYN-17 (altirex), KPE02003002, actilon (CPG-10101), GS-9525, KRN-7000, civacir, GI-5005, XTL-6865, BIT225, PTX-111, ITX2865, TT-0331, ANA971, NOV-205, tarvacin, EHC-18, VGX-410C, EMZ-702, AVI 4065, BMS-650032, BMS-791325, Bavituximab, MDX-1106 (ONO-4538), Oglufanide, and VX-497 (merimepodib).
|0107] More specifically, the additional therapeutic agent may be combined with one or more compounds selected from the group consisting of non-nucleoside inhibitors of HCV NS5B polymerase (ABT-072 and ABT-333), HCV NS5A inhibitors (ACH-3102 and ACH2928) and HCV NS3 protease inhibitors(ABT-450 and ACH-125).
[0108] In another embodiment, the therapeutic agent used in combination with the pharmaceutical compositions as described herein can be any agent having a therapeutic effect when used in combination with the pharmaceutical compositions as described herein. For example, the therapeutic agent used in combination with the pharmaceutical compositions as described herein can be interferons, ribavirin analogs, NS3 protease inhibitors, NS5B polymerase inhibitors, alpha-glucosidase 1 inhibitors, hepatoprotectants, non-nucleoside inhibitors of HCV, and other drugs for treating HCV.
|0109] In another embodiment, the additional therapeutic agent used in combination with the pharmaceutical compositions as described herein is a cyclophillin inhibitor, including for example, a cyclophilîn inhibitor dîsclosed in WO2013/185093. Non-limiting examples include one or more compounds selected from the group consisiting of:
[0110| In another embodiment, the additional therapeutic agent used in combination with the pharmaceutical compositions as described herein is a non-nucleoside inhibitor of HCV NS5B polymerase. A non-limiting example includes Compound E (as described below).
[0111] Examples of additional anti-HCV agents which can be combined with the compositions provided herein include, without limitation, the following:
A. interferons, for example, pegylated rIFN-alpha 2b (PEG-Intron), pegylated rIFN-alpha 2a (Pegasys), rIFN-alpha 2b (Intron A), rIFN-alpha 2a (Roferon-A), interferon alpha (MOR-22, OPC-18, Alfaferone, Alfanative, Multiferon, subalin), interferon alfacon-I (Infergen), interferon alpha-nl (Wellferon), interferon alpha-n3 (Alferon), interferon-beta (Avonex, DL-8234), interferon-omega (oméga DUROS, Biomed 510), albinterferon alpha-2b (Albuferon), IFN alpha XL, BLX-883 (Locteron), DA-3021, glycosylated interferon alpha-2b (AVI-005), PEG-Infergen, PEGylated interferon lambda (PEGylated IL-29), or belerofon, EFN alpha-2b XL, rIFN-alpha 2a, consensus IFN alpha, infergen, rebif, pegylated IFN-beta, oral interferon alpha, feron, reaferon, intermax alpha, r-IFN-beta, and infergen + actimmuneribavirin and ribavirin analogs, e.g., rebetol, copegus, VX-497, and viramidine (taribavirin),
B. NS5A inhibitors, for example, Compound B (described below), Compound C (described below), ABT-267, Compound D (described below), JNJ-47910382, daclatasvir (BMS-790052), ABT-267, MK-8742, EDP-239, IDX-719, PPI-668, GSK-2336805, ACH3102, A-831, A-689, AZD-2836 (A-831), AZD-7295 (A-689), and BMS-790052;
C. NS5B polymerase inhibitors, for example, Compound E (described below), Compound F (described below), ABT-333, Compound G (described below), ABT-072, Compound H (described below), tegobuvir (GS-9190), GS-9669, TMC647055, setrobuvir (ANA-598), filibuvir (PF-868554), VX-222, IDX-375, IDX-184, IDX-102, BI-207127, valopicitabine (NM-283), PSI-6130 (R1656), PSI-7851, BCX-4678, nesbuvir (HCV-796), BILB 1941, MK-0608, NM-107, R7128, VCH-759, GSK625433, XTL-2125, VCH-916, JTK-652, MK-3281, VBY-708, A848837, GL59728, A-63890, A-48773, A-48547, BC-2329, BMS-791325, and BILB-1941;
D. NS3 protease inhibitors, for example, Compound I, Compound J, Compound K, ABT-450, Compound L (described below), simeprevir (TMC-435), boceprevir (SCH503034), narlaprevir (SCH-900518), vaniprevir (MK-7009), MK-5172, danoprevir (ITMN191), sovaprevir (ACH-1625), neceprevir (ACH-2684), Telaprevir (VX-950), VX-813, VX500, faldaprevir (BI-201335), asunaprevir (BMS-650032), BMS-605339, VBY-376, PHX1766, YH5531, BILN-2065, and BILN-2061;
E. alpha-glucosidase 1 inhibitors, for example, celgosivîr (MX-3253), Miglitol, and UT-231B;
F. hepatoprotectants, e.g., IDN-6556, ME 3738, MitoQ, and LB-84451;
G. non-nucleoside inhibitors ofHCV, e.g., benzîmidazole dérivatives, benzo1,2,4-thiadiazme dérivatives, and phenylalanine dérivatives; and
H. other anti-HCV agents, e.g., zadaxin, nitazoxanide (alinea), BIVN-401 (virostat), DEBIO-025, VGX-410C, EMZ-702, AVI4065, bavituximab, oglufanide, PYN-I7, KPE02003002, actilon (CPG-10101), KRN-7000, civacir, GI-5005, ANA-975, XTL-6865, ANA 971, NOV-205, tarvacin, EHC-18, and NIM811.
[0112] Compound B is an NS5A inhibitor and is represented by the following chemical structure:
[0113] Compound C is an NS5A inhibitor and is represented by the following chemical structure:
[0114] Compound D is an NS5A inhibitor and is represented by the following chemical structure:
[0115] See U.S. Publication No. 2013/0102525 and references cited thereîn.
[0116] Compound E is an NS5B Thumb II polymerase inhibitor and is represented by the following chemical structure:
[0117] Compound F is a nucléotide inhibitor prodrug designed to inhibit réplication of viral RNA by the HCV NS5B polymerase, and is represented by the following chemical structure:
[0118] Compound G is an HCV polymerase inhibitor and is represented by the following structure:
[0119] See U.S. Publication No. 2013/0102525 and references therein.
[0120] Compound H is an HCV polymerase inhibitor and is represented by the following structure:
[0121] See U.S. Publication No. 2013/0102525 and references therein.
[0122] Compound I is an HCV protease inhibitor and is represented by the following chemical structure:
[0123] See U.S. Publication No. 2014/0017198 and references therein.
[0124] Compound J is an HCV protease inhibitor and is represented by the following chemical structure:
[0125] See U.S. Patent No. 8,178,491 and references therein.
[0126] Compound K is an HCV protease inhibitor and îs represented by the following chemical structure:
[0127] Compound L is an HCV protease inhibitor and is represented by the following chemical structure:
[0128] See U.S. Publication No. 2013/0102525 and référencés therein.
[0129] In one embodiment, the additional therapeutic agent used in combination with the pharmaceutical compositions as described herein is a HCV NS3 protease inhibitor. Nonlimiting examples include one or more compounds selected from the group consisiting of:
[0130] In another embodiment, the présent application is provided a method of treating hepatitis C in a human patient in need thereof comprising administering to the patient a therapeutically effective amount of a pharmaceutical composition as described herein and an additional therapeutic selected from the group consisting of pegylated rIFN-alpha 2b, pegylated rIFN-alpha 2a, rIFN-alpha 2b, IFN alpha-2b XL, rIFN-alpha 2a, consensus IFN alpha, infergen, rebif, locteron, AVI-005, PEG-infergen, pegylated IFN-beÎa, oral interferon alpha, feron, reaferon, intermax alpha, r-IFN-beta, infergen + actimmune, IFN-omega with DUROS, albuferon, rebetol, copegus, levovirin, VX-497, viramidine (taribavirin), A-831, A689, NM-283, valopicitabine, R1626, PSI-6130 (R1656), HCV-796, BILB 1941, MK-0608, NM-107, R7128, VCH-759, PF-868554, GSK625433, XTL-2125, SCH-503034 (SCH-7), VX-950 (Telaprevir), ITMN-191, and BILN-2065, MX-3253 (celgosivir), UT-23 IB, IDN6556, ME 3738, MitoQ, and LB-84451, benzimidazole dérivatives, benzo-l,2,4-thiadiazine dérivatives, and phenylalanine dérivatives, zadaxin, nitazoxanide (alinea), BIVN-401 (virostat), DEBIO-025, VGX-410C, EMZ-702, AVI 4065, bavituximab, oglufanide, PYN-17, KPE02003002, actilon (CPG-10101), KRN-7000, civacir, GI-5005, ANA-975 (isatoribine), XTL-6865, ANA 971, NOV-205, tarvacin, EHC-18, and NIM811 and a pharmaceutically acceptable carrier or excipient.
[0131] In yet another embodiment, the présent application provides a combination pharmaceutical agent comprising:
a) a first pharmaceutical composition comprising an effective amount of wherein ledipasvir is substantially amorphous; and an effective amount of sofosbuvir wherein sofosbuvir is substantially crystalline as described herein and
b) a second pharmaceutical composition comprising at least one additional therapeutic agent selected from the group consisting of HIV protease inhîbiting compounds, HIV non-nucleoside inhibitors of reverse transcriptase, HIV nucleoside inhibitors of reverse transcriptase, HIV nucléotide inhibitors of reverse transcriptase, HIV integrase inhibitors, gp41 inhibitors, CXCR4 inhibitors, gpl20 inhibitors, CCR5 inhibitors, interferons, ribavirin analogs, NS3 protease inhibitors, alpha-glucosidase 1 inhibitors, hepatoprotectants, nonnucleoside inhibitors of HCV, and other drugs for treating HCV, and combinations thereof.
[0132] The additional therapeutic agent may be one that treats other conditions such as
HIV infections. Accordingly, the additional therapeutic agent may be a compound useful in treating HIV, for example HIV protease inhîbiting compounds, non-nucleoside inhibitors of
HIV reverse transcriptase, HIV nucleoside inhibitors of reverse transcriptase, HIV nucléotide inhibitors of reverse transcriptase, HIV integrase inhibitors, gp41 inhibitors, CXCR4 inhibitors, gp!20 inhibitors, CCR5 inhibitors, interferons, ribavirin analogs, NS3 protease inhibitors, NS5b polymerase inhibitors, alpha-glucosidase l inhibitors, hepatoprotectants, non-nucleoside inhibitors of HCV, and other drugs for treating HCV.
[0133] More specifically, the additional therapeutic agent may be selected from the group consisting of
1) HIV protease inhibitors, e.g., amprenavir, atazanavir, fosamprenavîr, indinavir, lopinavir, ritonavir, lopinavir + ritonavir, nelfinavir, saqumavîr, tipranavir, brecanavir, darunavir, TMC-126, TMC-114, mozenavîr (DMP-450), JE-2147 (AGI 776), AG1859, DG35, L-756423, RO0334649, KNI-272, DPC-681, DPC-684, and GW640385X, DG17, PPL-100,
2) a HIV non-nucleoside inhibitor of reverse transcriptase, e.g., capravirine, emivirine, delàviridîne, efavirenz, nevirapine, (+) calanolide A, etravirine, GW5634, DPC083, DPC-961, DPC-963, MIV-150, and TMC-120, TMC-278 (rilpivirine), efavirenz, BILR 355 BS, VRX 840773, UK-453,061, RDEA806,
3) a HIV nucleoside inhibitor of reverse transcriptase, e.g., zidovudine, emtricitabine, didanosine, stavudine, zalcitabine, lamivudine, abacavîr, amdoxovir, elvucitabine, alovudine, MIV-210, racivir (+-FTC), D-d4FC, emtricitabine, phosphazide, fozîvudine tidoxil, fosalvudine tidoxil, apricitibine (AVX754), amdoxovir, KP-1461, abacavîr + lamivudine, abacavîr + lamivudine + zidovudine, zidovudine + lamivudine,
4) a HIV nucléotide inhibitor of reverse transcriptase, e.g., tenofovir, tenofovir disoproxil fumarate + emtricitabine, tenofovir disoproxil fumarate + emtricitabine + efavirenz, and adefovîr,
5) a HIV integrase inhibitor, e.g., curcumin, dérivatives of curcumin, chicoric acid, dérivatives of chicoric acid, 3,5-dicaffeoylquinic acid, dérivatives of 3,5-dîcaffeoylquinic acid, aurintricarboxylic acid, dérivatives of aurintricarboxylic acid, caffeic acid phenethyl ester, dérivatives of caffeic acid phenethyl ester, tyrphostin, dérivatives of tyrphostin, quercetin, dérivatives of quercetin, S-1360, zintevir (AR-177), L-870812, and L-870810, MK-0518 (raltegravir), BMS-707035, MK-2048, BA-011, BMS-538158, GSK364735C,
6) a gp41 inhibitor, e.g., enfuvirtide, sifuvirtide, FB006M, TRI-1144, SPC3, DES6, Locus gp41, CovX, and REP 9,
7) a CXCR4 inhibitor, e.g., AMD-070,
8) an entry inhibitor, e.g., SP01 A, TNX-355,
9) a gpl20 inhibitor, e.g., BMS-488043 and BlockAide/CR,
10) a G6PD and NADH-oxidase inhibitor, e.g., immunitin, 10) a CCR5 inhibitor, e.g., aplaviroc, vicriviroc, INCB9471, PRO-140, INCB15O5O, PF-232798, CCR5mAb004, and maraviroc,
11) an interferon, e.g., pegylated rIFN-alpha 2b, pegylated rIFN-alpha 2a, rIFN-alpha 2b, IFN alpha-2b XL, rIFN-alpha 2a, consensus IFN alpha, infergen, rebif, locteron, AVI005, PEG-infergen, pegylated IFN-beta, oral interferon alpha, feron, reaferon, intermax alpha, r-IFN-beta, infergen + actimmune, IFN-omega with DUROS, and albuferon,
12) ribavirin analogs, e.g., rebetol, copegus, levovirin, VX-497, and viramidine (taribavirin)
13) NS5a inhibitors, e.g., A-831, A-689, and BMS-790052,
14) NS5b polymerase inhibitors, e.g., NM-283, valopicitabine, R1626, PSI-6130 (R1656), HCV-796, BILB 1941, MK-0608, NM-107, R7128, VCH-759, PF-868554, GSK625433, and XTL-2125,
15) NS3 protease inhibitors, e.g., SCH-503034 (SCH-7), VX-950 (Telaprevir), ITMN-191, and BILN-2065,
16) alpha-glucosidase 1 inhibitors, e.g., MX-3253 (celgosivir) and UT-231B,
17) hepatoprotectants, e.g., IDN-6556, ME 3738, MitoQ, and LB-84451,
18) non-nucleoside inhibitors of HCV, e.g., benzimidazole dérivatives, benzo-1,2,4thîadiazine dérivatives, and phenylalanine dérivatives,
19) other drugs for treating Hepatitis C, e.g., zadaxin, nitazoxanide (alinea), BIVN401 (virostat), DEBIO-025, VGX-410C, EMZ-702, AVI 4065, bavituximab, oglufanide, PYN-17, KPE02003002, actilon (CPG-10101), KRN-7000, civacir, GI-5005, ANA-975 (isatoribine), XTL-6865, ANA 971, NOV-205, tarvacin, EHC-18, and NTM811,
20) pharmacokinetic enhancers, e.g., BAS-100 and SPI452, 20) RNAse H inhibitors, e.g., ODN-93 and ODN-112, and
21) other antî-HIV agents, e.g., VGV-1, PA-457 (bevirimat), ampligen, HRG214, cytolin, polymun, VGX-410, KD247, AMZ 0026, CYT 99007, A-221 HIV, BAY 50-4798, MDX010 (iplimumab), PBS119, ALG889, and PA-1050040.
[0134] In one embodiment, the additional therapeutic agent is ribavirin. Accordingly, methods described herein include a method of treating hepatitis C in a human patient in need thereof comprising administering to the patient a therapeutically effective amount of ribavirin and a therapeutically effective amount of a pharmaceutical composition, pharmaceutical dosage form, or tablet as described herein. In a further embodîment, the ribavirin and pharmaceutical composition, pharmaceutical dosage form, or tablet comprising sofosbuvir and ledipasvir is administered for about 12 weeks or less. In further embodiments, the ribavirin and pharmaceutical composition, pharmaceutical dosage form, or tablet comprising sofosbuvir and ledipasvir is administered for about 8 weeks or less, for about 6 weeks or less, or for about 4 weeks or less.
[0135] It is contemplated that the additional therapeutic agent will be administered in a manner that is known in the art and the dosage may be selected by someone of skill in the art. For example, the additional agent may be administered in a dose from about 0.01 milligrams to about 2 grams per day.
EXAMPLES [0136] In the following examples and throughout this disclosure, abbreviations as used herein hâve respective meanings as follows:
ACN | Acetonitrile |
AE | Adverse Event |
API | Active Pharmaceutical Ingrédient |
AUC | Area Under the Curve |
AUCinf | Area under the concentration versus time curve extrapolated to infinité time, calculated as AUC0~last + (Clast/λζ) |
AUC last | Area under the concentration versus time curve from time zéro to the last quantifiable concentration |
BMI | Body Mass Indec |
BT | Breakthrough Rate |
CI | Confidence Interval |
CL/F | Apparent oral clearance after administration of the drug: CL/F = Dose/AUC |
Clast | Last observed quantifiable concentration of the drug |
cm | Centimeter |
Cmax | Maximum Concentration |
cP | Centipoise |
cP | Centipoise |
CV | Coefficient of Variation |
Dgo | Particle Size |
DCF | Drug Content Factor |
DCF | Drug Content Factor |
DCM | Dichloromethane |
dL | Deciliter |
DRM | Drug Related Material |
DSC | Differential Scanning Calorimetry |
Emax | Maximum Effect |
F% | Percent Bioavailability |
FaSSIF | Fasted State Simulated Intestinal Fluids |
FB | Free Base |
FDC | Fixed-Dose Combination |
FeSSIF | Fed State Simulated Intestinal Fluid |
FT | Fourier Transform |
g | Gram |
GLSM | Géométrie Least Squares Mean |
GMR | Géométrie Mean Ratio |
GT | Génotype |
h or hr | Hour |
HCV | Hepatitis C virus |
HDPE | High Density Polyethylene |
HPC | Hydroxypropylcellulose |
HPLC | High-performance Liquid Chromatography |
HPMC | Hydroxymethylcellulose |
ICH | International Conférence on Harmonisation; Impurities guidelines |
IFN | Interferon |
IU | International Unit |
KF | Karl Fischer |
kg | Kilogram |
L | Liter |
LCT | Long Chain Triglycérides |
LDV | Compound I, GS-5885, Ledipasvir |
LLOD | Lower limit of détection |
LLOQ | Lower Limit of Quantification |
LOD | Limit of Détection |
M | Molar |
mg | Mîlligram |
min | Minute |
mL | Mil li liter |
mm | Millimeter |
mM | Millimolar |
N | Population Size |
n | Number of Patients |
ng | Nanogram |
nM | Nanomolar |
nm | Nanometer |
°C | Degrees Celsius |
PD | Pharmacodynamic(s) |
PEG or PG | Polyethylene Glycol |
P-gp or Pgp | P-glycoprotein |
PI | Protease-Inhibitor |
PK | Pharmacokînetic |
PLS | Partial Least Squares |
PPI | Proton-Pump Inhibitors |
PS | Particle Size |
PVP | Povidone |
PVP/VA | Copovidone |
QS | Quantum Satis |
RAV | Résistance Associated Variants |
RBV | Ribavirin |
RH | Relative Humidity |
RNA | Rîbonucleic Acid |
RSD | Relative Standard Déviation |
RT | Room Température |
So | Intrinsic Solubility |
SAE | Serious Adverse Event |
SCT | Short Chain Triglycérides |
SIBLM | Simulated Intestinal Bile Sait and Lecithin Mixture |
SIF | Simulated Intestinal Fluids |
SLS | Sodium Lauryl Sulfate |
SOF | Sofosbuvir (GS-7977, formerly PSI-7977) |
SS-NMR | Solid State Nuclear Magnetic Résonance |
SVR | Sustained Virologie Response |
t | Time |
tl/2 | Half-life (h) |
TFA | Trifluoroacetic acid |
T imax | Time (observed time point) of Cmax |
UPLC | Ultra Performance Uiquid Chromatography |
Upper Resp Tract Infx | Upper Respiratory Tract Infection |
USP | Uni form Standards and Procedures |
UV | Ultraviolet |
VL | Viral Load |
vRVR | Very Rapid Viral Response |
Vz/F | Apparent volume of distribution |
wt or w | Weight |
XRPD | Xray Powder Diffraction |
Pg | Microgram |
pL | Microliter |
pm | Micrometer |
Example 1: Synthesis of Amorphous Ledipasvir [0137] Methods for making various forms of ledipasvir may be found in U.S. Publication Nos. 2013/0324740, and 2013/0324496. Both of these applications are incorporated herein by reference. Following is a method for isolating amorphous free base of ledipasvir.
[0138] Combine ledipasvir acetone solvaté (191.4 g) and acetonitrile (1356 g) in a réaction vessel and mix contents until a solution is achieved. Add this ledipasvir in acetonitrile solution slowly to another reaction vessel containing vigorously agitated water (7870 g). Agitate contents at about 23 °C for about 30 minutes. Filter the contents and dry at about 4045 °C until constant weight is achieved to afford ledipasvir amorphous solid (146.4 g, 82% yield).
Example 2: Tablet Préparation and Formulation
A. Dose Sélection of Tablets
i. Sofosbuvir [0139] The sofosbuvir dose selected for the tablet formulation is 400 mg once daily. Support for the 400 mg sofosbuvir dose can be derived from Emax PK/PD modeling with early virological and human exposure data which also supports the sélection of a 400 mg sofosbuvir dose over others tested.
[0140] The mean sofosbuvir major métabolite AUCtau for the 400 mg sofosbuvir dose is associated with approximately 77% of the maximal HCV RNA change from baseline achîevable as determined by this model, a value which is on the cusp of the plateau of the exposure-response sigmoidal curve. In a sigmoidal Ema.x model, there is a relatively linear exposure-response relationship in the 20 to 80% maximal effect range. Therefore, given that sofosbuvir exposure with 200 mg tablets appears dose-proportional with single doses up to 1200 mg, doses below 400 mg are expected to yield considérable réductions in the magnitude of HCV RNA change from baseline. Simîlarly, in order to împrove upon an efïicacy prédiction of 77% in the plateau of the exposure-response curve, substantial increases in exposure (and hence dose) would be needed for an appréciable increase in antiviral effect.
[0141] The sofosbuvir dose of 400 mg once daily was associated with higher SVR rates in génotype 1 HCV infected patients as compared to the 200 mg once daily dose when given in conjunction with additional HCV therapeutics for 24 weeks. Safety and tolerability appeared similar across both dose levels. In addition, when sofosbuvir 400 mg once daily plus other HCV therapeutics were given to génotype 2 or 3 HCV infected patients, 100% SVR24 was observed.
ii. Ledipasvir |0142] The maximum médian HCV RNA loglO réduction was 3 or greater for ail cohorts dosed with > 3 mg of ledipasvir. An Emax PK/PD model indicates that the exposures achieved following administration of the 30 mg dose provides > 95% of maximal antiviral response in génotype 1 a HCV infected patients. It was also observed that 30 mg or greater of ledipasvir likely provided coverage of some drug related mutations that doses less than 30 mg did not, based on an analysis of NS5A mutants that arase in response to exposure to ledipasvir.
Therefore, 30 mg and 90 mg of ledipasvir were selected as the dose for the formulations described herein.
[0143] Further studies suggest that, when ledipasvir is administered in combination with other therapeutic agents, the breakthrough (BT) rate (number of patients with HCV RNA > lower limit of quantification (LLOQ) after having achieved vRVR/total number of patients who achieved vRVR), is higher with doses of 30 mg (BT = 33%, 11/33; 30 mg ledipasvir), than with doses of 90 mg (BT = 12%, 9/74; 90 mg ledipasvir). Therefore, the 90 mg dose of ledipasvir may confer a greater antiviral coverage that prevents viral breakthrough.
B, Solid Dispersion Comprising Ledipasvir [0144] To make the tablets comprising the combination of sofosbuvir and ledipasvir as described herein, a solid dispersion comprising ledipasvir was co-formulated with crystalline sofosbuvir. The starting material of the solid dispersion can be a variety of forms of ledipasvir including crystalline forms, amorphous form, salts thereof, solvatés and free base, as described herein. Because of the high solubility in organic solvents and excipients and the ability to isolate the ledipasvir free base crystalline acetone solvaté, this form was used in the amorphous solid dispersion of ledipasvir.
[0145] The spray dried solid dispersion approach achieved the most désirable characteristics relative to the other formulation approaches, which included improved in vivo and in vitro performance and manufacturability/scalability.
[0146] The spray dry feed solution was prepared by solubilizing ledipasvir acetone solvaté and polymer in the feed solvent. Aggressive mixing or homogenization was used to avoid dumping of the composition.
[0147] Different polymers were tested for preferred characteristics in the solid dispersions. Non-ionic polymers such as hypromellose and copovidone solid dispersions both showed adéquate stability and physical characteristics.
[0148] The feed solution was initially evaluated for appropriate solvent with regard to solubility, stability, and viscosity. Ethanol, methanol, and dichloromethane (DCM) ail demonstrated excellent solubility (ledipasvir solubility >500 mg/mL). Ethanolic and
DCM-based feed stocks were assessed for préparation ease and spray dried at a range of inlet and outlet températures to assess the robustness of the spray dry process. Both solvents gave rapid dissolution of ledipasvir and copovidone.
[0149] Spray drying out of éthanol resulted in high yields (88, 90, 92, 94, 95, 97, 98, 99%) across a wide range of spray-drying outlet températures (49-70 °C) with no material accumulation on the spray dry chamber. Spray drying out of DCM resulted in yields of 60%, 78%, and 44%. Overall, the ledipasvir Solid Dispersion (50% w/w) in a ledipasvir to copovidone ratio of 1:1 demonstrated good chemical stability in the ethanolic feed solution.
[0150] An ethanolic solution of 10% ledipasvir acetone solvaté and 10% copovidone was prepared using homogenization. Viscosity of ethanolic solutions of ledipasvir: copovidone were low, measured through 30% solids content (-65 cP).
[0151] Spray drying was conducted using two fluid nozzle or a hydrolytic pressure nozzle. Table 1 présents the spray dry process parameters evaluated at 100 g-4000 g of total feed solution using the Anhydre MS35 spray dryer and Table 2 shows the spray dry process parameters using the hydrolytic pressure nozzle. Particle size data suggested sufficiently large particle size (10-14 gm mean PS) and was minimally affected by using higher spray rates or a larger diameter spray nozzle. Nozzle gas flow was not modulated to increase particle size.
Table 1. Ledipasvir Spray Dry Parameters on Anhydro MS35 Spray Dryer Using a Two Fluid Nozzle
Parameter | Trial 1 | Trial 2 | Trial 3 | Trial 4 |
Batch Size (g) | 100 | 250 | 250 | 4000 |
Solids % | 20 | 20 | 20 | 20 |
Feed Rate (mL/min) | 30 | 40 | 40 | 40 |
Spray Nozzle (mm) | 1.0 | 1.0 | 1.2 | 1.2 |
Nozzle Gas Flow (kg/hr) | 6.0 | 6.0 | 6.0 | 6.0 |
Chamber Gas Flow (kg/hr) | 35.0 | 35.0 | 35.0 | 35.0 |
Inlet Temp (°C) | 125 | 165 | 165 | 165 |
Outlet Temp (°C) | 70 | 73 | 72 | 76 |
PS dio/dîo/dgo/mean (gm) | 4/9/18/10 | 5/10/20/12 | 5/10/19/11 | 6/12/22/14 |
Post Spray LOD (%) | 5.56 | 4.86 | 4.29 | 3.42 |
Table 2. Example of Ledipasvir Spray Dry Parameters Using a Hydrolyic Pressure
Nozzle
Parameter | Trial 1 |
Batch Size (kg) | 200 |
Solids % | 20 |
Feed Rate (kg/hr) | 178 |
Pressure Feed (bar) | 52 |
Inlet Temp (°C) | 158 |
Outlet Temp (°C) | 65 |
PS dio/dio/dWmean (pm) | 3/14/34 |
Post Spray LOD (%) | 0.6 |
[0152] Organic volatile impurities, including the spray dry solvent éthanol and residual acetone from ledipasvir acetone solvaté are rapidly removed during secondary drying at 60 °C. Smaller scale production can be tray dried. On larger scale batches, a double cône dryer or an agitated dryer can be used. Loss on drying (LOD) was proportionately slower and is attributable to water, which was later confirmed by Karl Fischer titration.
[0153] Residual éthanol was reduced below ICH guidelines of 0.5% w/w by 6 hours of drying (or 8 hours for larger scale). Ethanol content upon completion of drying was 0.08% w/w, and residual acetone was 0.002%, indicating that the secondary drying process is adéquate for removal of residual solvent.
C. Tablet Préparation
i. Monolayer Tablet [0154] Ledipasvir copovidone solid dispersion (1:1) was made by dissolving ledipasvir and copovidone into éthanol, and then spray drying the mixture. The spray dried ledipasvir: copovidone solid dispersion is further dried in a secondary dryer. The amorphous solid dispersion comprising ledipasvir was blended with sofosbuvir and excipients and milled to facilîtate mixing and blend uniformity. Either a coblend or codry granulation process can be used. Coblend granulation is a multi-step process consisting of separate dry granulations for each active ingrédient with excipients followed by the blending of the two granulations together. Codry granulation consisted of dry granulating both active ingrédients and excipients together. The coblend and codry processes demonstrated comparable physical and chemical tablet properties. Exemplary coblend and codry formulations are provided in Table and Table 4 shown below.
Table 3. Représentative Example Composition of Sofosbuvir/Ledipasvir Codry (Cogranulated) Tablets at Varions Fill Weîghts
Intra-granular | % w/w Tablet | |||
Sofosbuvir | 50,00 | 40.00 | 36.36 | 33.33 |
Ledipasvir. Copovidone Solid Dispersion (kl) | 22.50 | 18.00 | 16.36 | 15.00 |
Lactose Monohydrate | 6.67 | 16.33 | 23.19 | 26.11 |
Microcrystalline cellulose | 3.33 | 8.17 | 11.60 | 13.05 |
Croscarmellose Sodium | 2.50 | 2.50 | 2.50 | 2.50 |
Silicon Dioxide | 1.00 | 1.00 | 1.00 | 1.00 |
Magnésium stéarate | 0.75 | 0.75 | 0.75 | 0.75 |
Extra-granular | ||||
Microcrystalline cellulose | 10.00 | 10.00 | 5.00 | 5.00 |
Croscarmellose Sodium | 2.50 | 2.50 | 2.50 | 2.50 |
Magnésium stéarate | 0.75 | 0,75 | 0.75 | 0.75 |
Fill wt (mg) | 800 | 1000 | 1100 | 1200 |
Table 4. Représentative Example Composition of Sofosbuvir/Ledipasvir Coblend (Bigranulated) Tablets
Composition | % w/w Intragranular Blend | % w/w Tablet | mg/Tablet | |
Sofosbuvir Intra-granular Blend | Sofosbuvir | 80 | 40 | 400 |
Microcrystalline cellulose | 6 | 3 | 30 | |
Lactose Monohydrate | 6 | 3 | 30 | |
Croscarmellose Sodium | 4 | 2 | 20 | |
Silicon Dioxide | 3 | 1.5 | 15 | |
Magnésium stéarate | 1 | 0.5 | 5 | |
Intra-granular Subtotal | 100 | 50 | 500 |
Ledipasvir Intra-granular Blend | Ledipasvir: Copovidone Solid Dispersion | 42.4 | 18 | 180 |
Microcrystalline cellulose | 43,5 | 18.5 | 185 | |
Croscarmellose Sodium | 9.4 | 4 | 40 | |
Silicon Dioxide | 3.5 | 1.5 | 15 | |
Magnésium stéarate | 1.2 | 0.5 | 5 | |
Intra-granular Subtotal | 100 | 42.5 | 425 | |
Extra-granular | Microcrystalline cellulose | 5 | 50 | |
Croscarmellose Sodium | __ | 2 | 20 | |
Magnésium stéarate | — | 0.5 | 5 | |
Total | — | 100 | 1000 | |
Coating | Film Coat | — | 3 | 30 |
Purified water | — | — | — |
[0155] The granules were then mixed with a lubricant prior to tablet compression. The total resulting core tablet weight was 1000 mg.
[0156] Film-coating of the tablets is provided to reduce photolytic dégradation. Tablets were coated to a target 3% weight gain. The film-coating material was a polyvinylalcohol-based coating. Exemplary tablet formulation is provided in Table 5.
Table 5. Représentative Example of the Composition of Tablets Comprising the Solid Dispersion of Ledipasvir and Sofosbuvir
Ingrédient | % w/w | Component Weight (mg/tablet) |
Sofosbuvir | 40.00 | 400 |
Ledipasvir Solid Dispersion | 18.00 | 180.0 |
Lactose Monohydrate | 16.50 | 165.0 |
Microcrystalline Cellulose | 18.00 | 180.0 |
Croscarmellose Sodium | 5.00 | 50.0 |
Colloïdal Silicon Dioxide | 1.00 | 10.0 |
Magnésium Stéarate | 1.50 | 15 |
Total Tablet Core Weight | 100.0 | 1000.0 |
Film coating | 3.00 | 30.0 |
Purified Water | — | -- |
Total Coated Tablet Weight | 1030.0 |
ii. Bilayer Tablet [0157] Tablets comprising the co-formulation of a solid dispersion comprising ledipasvir and crystalline sofosbuvir can also be made as a bilayer tablet wherein each active ingrédient is in a separate layer. To make the bilayer tablet, a ledipasvir: copovidone (1:1) solid dispersion is made by dîssolving ledipasvir and copovidone into éthanol, and then spray drying the mixture. The spray dried ledipasvir:copovidone solid dispersion is further dried in a secondary dryer. Next, the spray dried ledipasvir:copovidone solid dispersion is then blended with excipients. The mixture is milled and then blended with lubricant prior to dry granulation. The ledipasvir granules are blended with extragranular lubricant. Separately, the sofosbuvir drug substance is blended with excipients, and then the mixture is milled and then blended with lubricant prior to dry granulation. The sofosbuvir granules are then blended with extragranular lubricant. Finally, the sofosbuvir powder blend and ledipasvir powder blend are compressed into bilayer tablet cores. The bilayer tablet cores are then filmcoated prior to packaging. A représentative example composition of a bilayer tablet comprising the solid dispersion of ledipasvir and sofosbuvir is shown in Table 6. In this table, the solid dispersion comprises ledipasvir:copovidone in a 1:1 ratio.
Table 6. Représentative Example of Composition of Bilayer Tablets Comprising the Solid Dispersion of Ledipasvir and Sofosbuvir
Ingrédient | % w/w | Component Weïght (mg/tablet) |
Layer 1 | ||
Sofosbuvir | 33.34 | 400.0 |
Lactose Monohydrate | 5.66 | 68.0 |
Microcrystalline Cellulose | 7.50 | 90.0 |
Croscarmellose Sodium | 2.00 | 24.0 |
Colloïdal Silicon Dioxide | 0.50 | 50.0 |
Magnésium Stéarate | 1.00 | 12.0 |
Layer 2 | ||
Ledipasvir Solid Dispersion | 15.00 | 180.0 |
Lactose Monohydrate | 15.00 | 180.0 |
Microcrystalline Cellulose | 17.00 | 204.0 |
Croscarmellose Sodium | 2.50 | 30.0 |
Magnésium Stéarate | 0.50 | 6.0 |
Total Tablet Core | 100.00 | 1200 |
Example 3: PK, Stability and Dissolution Properties of Ledipasvir Single-Agent Tablets and Ledipasvir/Sofosbuvir Tablets and Réduction of Food-Effect and Effects of Gastric Acid Suppressants
A. Ledipasvir Single-Agent Tablets Bioavailability [0158] A sériés of in vivo experiments were conducted to evaluate the potential benefit of the solid dispersion approach relative to conventîonal formulations, as well as to optimize the solid dispersion by identifying the most bénéficiai polymer type and relative polymer concentration within the dispersion.
[0159] Equivalent bioavailability was achieved between formulations comprising the free base amorphous form (4% w/w, 10 mg amorphous free base tablet) and formulations comprising the D-tartrate sait of ledipasvir (5.85% w/w, 10 mg D-tartrate sait tablet), both using conventîonal formulations, in the pentagastrin pretreated dog model, as shown in Table 7. Pentagastrin is a synthetic polypeptide that stimulâtes the sécrétion of gastric acid, pepsin, and intrinsic factor.
Table 7. Mean (RSD) Pharmacokinetic Parameters of Ledipasvir Following Oral Administration of Tablets, 25 mg, in Beagle Dogs (n 6)
Drug Substance Form | Pretreatmen t | Cniax (nM) | AUCo-24 (nM*hr) | F (%) |
Amorphous Free base | Pentagastrin | 743 (17) | 8028(22) | 71 |
Crystalline D-tartrate | Pentagastrin | 665 (38) | 7623 (44) | 67 |
|0160] Because these formulations displayed similar PK properties and the isolation properties of the D-tartrate sait were préférable to the free base amorphous form, the crystalline D-tartrate sait formulation was chosen to compare to the amorphous solid dispersion compositions. For these studies, 30 mg tablets comprising the crystalline Dtartrate sait of ledipasvir and 30 mg or 90 mg tablets comprising the amorphous solid dispersion of ledipasvir were used. Dog pharmacokinetic results for select immédiate release ledipasvir tablets comprising ledipasvir solid dispersions are shown in Table 8.
Table 8. Mean (RSD) Pharmacokinetic Parameters of Ledipasvir after Oral Administration of Ledipasvir Tablets, Fasted Beagle Dogs (n=6)
Polymer | Ledipasvir: polymer Ratio | Dose (mg) | Pretreatment | Cmax (nM) | AUCo-24 (nM*hr) | F (%) |
Crystalline Dtartrate Ledipasvir Tablets | N/A | 30 | Pentagastrin | 665 (38) | 7623 (44) | 67 |
Famotidine | 154 (44) | 1038 (41) | 9 | |||
90 | Pentagastrin | 1831 (28) | 18086 (36) | 54 | ||
Famotidine | 349 (37) | 3322(40) | 10 | |||
Amorphous Solid Dispersion Ledipasvir Tablet: HPMC | 2:1 | 30 | Famotidine | 251 (51) | 2553 (54) | 22 |
Amorphous Solid Dispersion Ledipasvir Tablet: Copovidone | 2:1 | 30 | Famotidine | 369 (26) | 3383 (36) | 30 |
1:1 | Pentagastrin | 983 (22) | 10541 (24) | 93 | ||
1:1 | Famotidine | 393 (30) | 3930 (20) | 35 | ||
1:1 | 90 | Pentagastrin | 1644 (38) | 20908 (41) | 62 | |
1:1 | Famotidine | 740 (24) | 7722 (28) | 23 |
[0161 ] Compared to the crystalline D-tartrate ledipasvir formulations, the amorphous solid dispersion tablets displayed higher bioavailability with lower variability. In pentagastrin pretreated animais, an approximate 40% increase in exposure and a 2-fold decrease in variability were noted. More importantly in famotidine pretreated animais, up to a 3.5-fold increase in bioavailability was observed compared to the D-tartrate sait tablet formulations.
[0162] A copovidone-based dispersion increased bioavailability more than the équivalent hypromellose-based formulation (F = 30% and 22%, respectively) when spray dried at 2:1
API:polymer ratio. Bioavailability of the copovidone-based formulation was further enhanced by increasing the fraction of polymer to a 1:1 ratio, resulting in a bioavailability of
35% in famotidine pretreated dogs.
[0163] Because of the improved in vivo performance and acceptable stability and physical properties, a 1 ; 1 mixture of ledipasvir:copovidone was chosen as the spray-dried material.
[0164] Formulations comprising the amorphous solid dispersions proved to be advantageous over formulations comprising either the amorphous free base or the D-tartrate sait. It was observed that the bioavailability of amorphous free base formulations was similar to D-tartrate sait formulations. Additional data showed a decrease in bioavailability when ledipasvir was dosed with gastric acid suppressing agents (famotidine), indicating an unfavorable drug-drug interaction in free base amorphous and D-tartrate sait formulations of ledipasvir. A solid dispersion using spray drying with a hydrophilic polymer was identified to hâve acceptable stability, physical characteristics, and in vivo performance. A rapidly disintegrating tablet was developed using a dry granulation process and commonly used excipients. A bioavailability study comparing formulations comprising the D-tartrate sait with formulations comprising the amorphous solid dispersion showed improved biopharmaceutical performance and overcame much of the négative drug-drug interactions with acid suppressîve thérapies seen in the D-tartrate sait formulations.
B. Ledipasvir+Sofosbuvir Tablets Bioavailability [0165] PK results for the combination of sofosbuvir with ledipasvir (wherein the ledipasvir is in solid dispersion with copovidone in a 1:1) are shown in Table 9, and demonstrate lack of a significant interaction between sofosbuvir and ledipasvir.
Table 9: Pharmacokinetic Data for Sofosbuvir and Ledipasvir on Administration of Sofosbuvir and Ledipasvir Alone or in Combination
Sofosbuvir (n=17) | |||
Mean (%CV) | Sofosbuvir alone | Sofosbuvir + Ledipasvir | %GMR (90%CI) |
AUCinf (ng.hr/mL) | 794 (36.4) | 1750 (27.8) | 229 (191, 276) |
AUC last (ng.hr/mL) | 788 (36.6) | 1740 (27.8) | 230(191,277) |
Cmax (ng/mL) | 929 (52,3) | 1870 (27.9) | 221 (176, 278) |
Métabolite I (n=17) | |||
Mean (%CV) | Sofosbuvir alone | Sofosbuvir + Ledipasvir | %GMR (90%CI) |
AUCinf (ng.hr/mL) | 1110(31.6) | 1950 (22.8) | 182(157, 210) |
AUClasi (ng.hr/mL) | 1060 (32.7) | 1890 (22.8) | 179(155, 207) |
Cmax (ng/mL) | 312(38.7) | 553 (26.6) | 182(154,216) |
Métabolite II (n=17) | |||
Mean (%CV) | Sofosbuvir alone | Sofosbuvir + Ledipasvir | %GMR (90%CI) |
AUCinf (ng.hr/mL) | 10900(17.5) | 13000(16.7) | 119(113, 125) |
AUClast (ng.hr/mL) | 10200(17.9) | 12100(15.5) | 119 (113, 126) |
Cmax (ng/mL) | 1060(17.3) | 864 (20.1) | 81.2(76.9, 85.8) |
Ledipasvir (n=17) | |||
Mean (%CV) | Ledipasvir alone | Sofosbuvir + Ledipasvir | %GMR (90%CI) |
AUCinf (ng.hr/mL) | 11900 (26.2) | 11400 (27.0) | 95.7(92.1,99.5) |
AUClast (ng.hr/mL) | 755 (24.7) | 734 (27.0) | 96.5 (89.9, 104) |
Cmax (ng/mL) | 375 (28.8) | 360 (31.2) | 95.5 (91.9, 99.1) |
[0166] Sofosbuvir plasma exposure was increased by ~ 2.3-fold by ledipasvir. The effect of ledipasvir on sofosbuvir is likely due to inhibition of P-gp, of which Sofosbuvir is a known substrate. The increase in sofosbuvir was not considered significant due to its very low and transient exposure relative to total drug related material (DRM) exposure (DRM, calculated as the sum of the AUCs for each of the analytes, corrected for molecular weight). Based on this calculation, the AUC of sofosbuvir with ledipasvir is only ~ 5.7% of DRM AUC. The exposure of métabolite II, the major circulating sofosbuvir métabolite, was not impacted by the administration of ledipasvir, and demonstrates the lack of significant interaction between sofosbuvir and ledipasvir.
C. Réduction of Food Effect în Solid Dispersions of Ledipasvir and Ledipasvir/Sofosbuvir Tablets [0167] Ledipasvir alone in a conventional formulation (not the solid dispersion) has been demonstrated to hâve a négative food effect. Table 10 summarizes PK parameters of ledipasvir following a single dose of ledipasvir, 30 mg, under fasted and fed conditions. The ledipasvir PK profile was altered in the presence of food. Specifically, the high-fat meal appeared to delay ledipasvir absorption, prolong Tmax (médian Tmax of 8 hours), and decreased ledipasvir plasma exposure (approximately 45% decrease each in mean Cmax,
AUCiast, and AUCinf, respectively).
Table 10: Plasma Ledipasvir PK Parameters Following Single-dose Administration of Ledipasvir by Concomitant Food Intake Status
Mean (%CV) | ||
PK Parameter | Ledipasvir 30 mg (N=8) | Ledipasvir 30 mg Fed (N=8) |
Cmax (ng/mL) | 73.1 (50.8) | 36.5 (22.6) |
Tmax (h) | 6.00 (5.00, 6,00) | 8.00 (7.00, 8.00) |
AUC last (ngh/mL) | 1988.2 (58.2) | 996.5 (21.6) |
AUCinf (ngh/mL) | 2415.9(60.3) | 1175.0(25.3) |
1½ (h) | 39.82 (33.15,41.65) | 36,83 (22.19, 49,08) |
CL/F (mL/h) | 17,034.5(58.6) | 26,917.9(23.6) |
Vï/F (mL) | 876,546.3 (44.2) | 1,386,469 (24.9) |
Ciast (ng/mL) | 6.8 (68.0) | 3.1 (42.2) |
[0168] Table 11 présents the ratio of the GLSMs (ledipasvir 30 mg under fasted conditions/ledipasvir 30 mg under fed conditions) for each of the primary PK parameters.
Table 11: Statistical Evaluations of Ledipasvir PK Parameters for Food Effect
Géométrie Least Squares Mean (GLSM) | GLSM Ratio (Fed/Fasted) % | 90% Confidence Interval | ||
Ledipasvir 30 mg Fed (N=8) | Ledipasvir 30 mg Fasted (N 8) | |||
Cmax (ng/mL) | 35.87 | 65.33 | 54.90 | 39.10, 77.08 |
AU C]asl (ng hr/mL) | 977.76 | 1724.28 | 56.71 | 38.87, 82.73 |
AUCinf (ng-hr/mL) | 1143.64 | 2058.78 | 55.55 | 36.88,83.67 |
[0169] Similar médian half-lives of ledipasvir were observed independent of administration under fasted or fed conditions (ti/2of 39.82 hours under fasted conditions vs 36.83 hours under fed conditions) indicating that food decreased the bioavailability of ledipasvir by reducing its solubîlity and/or absorption.
[0170] Because ledipasvir has been demonstrated to hâve a négative food effect, the composition comprising both sofosbuvir and ledipasvir (as solid dispersion in copovidone (kl)) was tested for a food effect. These results are shown in Table 12. Food slowed the rate of absorption of sofosbuvir (médian Tmax: 1,00 vs 2.00 hours) with only modest alteration in the bîoavailability, as evidenced by increases of 2-fold or less in sofosbuvir and sofosbuvir métabolite I plasma exposure. For sofosbuvir métabolite II, an approximately 20-30% lower Cmax was observed upon sofosbuvir administration with food with no change in AUC. The %GMR and associated 90% CI (fed/fasted treatments) for AUC of sofosbuvir métabolite II were within the équivalence bounds of 70% to 143%. Since the decrease in sofosbuvir métabolite II Cmix was modest and the AUC parameters met the équivalence criteria, the effect of food on sofosbuvir métabolite II was not considered significant.
10171 ] Similar ledipasvir plasma exposures (AUC and Cmax) were achieved upon administration of ledipasvir under fasted or fed conditions. The %GMR and associated 90% CIs (fed/fasted treatments) were within the équivalence bounds of 70-143%. While a “négative” food effect was previously observed on ledipasvir when administered alone (as the amorphous free base, not solid dispersion), the pharmacokinetics of ledipasvir (amorphous solid dispersion; copovidone (kl)) administered in combination with sofosbuvir does not appear to be altered by food. As such, the combination of sofosbuvir and ledipasvir may be administered without regard to food.
Table 12: Pharmacokinetic Data for Sofosbuvir, Sofosbuvir Métabolites 1 and II, and Ledipasvir on Administration of Sofosbuvir/Ledipasvir Tablets Fasted or with a Moderate-Fat Meal or with a High-Calorie/High Fat Meal
Sofosbuvir (n=29) | |||
Mean (%CV) | Sofosbuvir/Ledipasvir Tablet Fasted | Sofosbuvir/Ledipasvir Tablet Moderate-Fat Meal | % GMR (90% CI) [ModerateFat/Fasted | |
AUCinf (ng.hr/mL) | 1520 (39.5) | 2860 (33 .4) | 195 (176, 216) |
AUCiast (ng.hr/mL) | 1520 (39.7) | 2850(33.5) | 195(176,216) |
Cmax (ng/mL) | 1240 (49.6) | 1520 (39.8) | 126(109, 147) |
Sofosbuvir/Ledipasvir Tablet Fasted | Sofosbuvir/Ledipasvir Tablet High-Calorie/High-Fat Meal | GMR (90% CI) [High-Fat/F asted] | |
AUCinf (ng hr/mL) | 1520 (39.5) | 2570 (34.0) | 179(162, 198) |
AUCiast (ng.hr/mL) | 1520 (39.7) | 2550(34.6) | 178 (161, 198) |
Cmax (ng/mL) | 1240 (49.6) | 1350(42.5) | 115 (99.0, 134) |
Sofosbuvir Métabolite I (n=29) | |||
Mean (%CV) | Sofosbuvir/Ledïpasvir Tablet Fasted | Sofosbuvir/Ledïpasvir Tablet Moderate-Fat Meal | % GMR (90% Cl) [ModerateFat/Fasted] |
AUCinf (ng.hr/mL) | 1520 (42.0) | 2520(21.4) | 177 (163, 192) |
AUCiast (ng.hr/mL) | 1470 (43.3) | 2460 (21.8) | 180(164, 196) |
Cmax (ng/mL) | 352 (42.7) | 495 (22.2) | 151 (136, 167) |
Sofosbuvir/Ledïpasvir Tablet Fasted | Sofosbuvir/Ledipasvir Tablet High-Calorie/High-Fat Meal | GMR (90% CI) [High-Fat/Fasted] | |
AUCinf (ng.hr/mL) | 1520 (42.0) | 2550 (22.2) | 181 (166, 196) |
AUCiasi (ng.hr/mL) | 1470 (43.3) | 2500 (22.5) | 184(168, 201) |
Cmax (ng/mL) | 352 (42.7) | 501 (26.8) | 154(139, 171) |
Sofosbuvir Métabolite 11 (n=29) | |||
Mean (%CV) | Sofosbuvir/Ledïpasvir Tablet Fasted | Sofosbuvir/Ledipasvir Tablet Moderate-Fat Meal | % GMR (90% CI) [ModerateFat/Fasted] |
AUCinf (ng.hr/mL) | 11800 (23.0) | 13800(17.7) | 117(112, 123) |
AUCiast (ng.hr/mL) | 11300 (23.4) | 12900(18.2) | 114(108, 121) |
Cmax (ng/mL) | 865 (26.6) | 700 (19.5) | 81,5 (75.6, 87.9) |
Sofosbuvir/Led i pasvî r Tablet Fasted | Sofosbuvir/Ledipasvir Tablet High-Calorie/High-Fat Meal | GMR (90% CI) [High-Fat/Fasted] | |
AUCmf (ng.hr/mL) | 11800 (23.0) | 12900 (18 .5) | 112(107,118) |
AUC^t (ng.hr/mL) | 11300 (23.4) | 12100 (20.1) | 110(103, 116) |
Cmax (ng/mL) | 865 (26.6) | 600 (22.9) | 70.2 (65.0, 75.8) |
Ledipasvir (n=29) | |||
Mean (%CV) | Sofosbuvir/Ledipasvir Tablet Fasted | Sofosbuvir/Ledipasvir Tablet Moderate-Fat Meal | % GMR (90% CI) [ModerateFat/Fasted| |
AUCmf (ng.hr/mL) | 10600 (57.2) | 10600 (35.6) | 115 (99.4, 134) |
AUCiaat (ng.hr/mL) | 8600 (53.8) | 8650(32.1) | 114 (98.0, 133) |
Cmax (ng/mL) | 324 (44.8) | 319(24.8) | 109 (93.5, 126) |
Sofosbuvir/Ledipasvîr Tablet Fasted | Sofosbuvir/Ledipasvîr Tablet High-Calorie/High-Fat Meal | GMR (90% CI) [High-Fat/Fasted] | |
AUC.,., (ng.hr/mL) | 10600 (57.2) | 9220 (36.1) | 103 (88.5, 119) |
AUCjast (ng.hr/mL) | 8600 (53.8) | 7550 (33.9) | 104 (88.8, 121) |
Cmax (ng/mL) | 324 (44.8) | 255 (25.9) | 88.2 (75.8, 103) |
D. Réduction of Effects of Gastric Acid Suppressants in Ledipasvir/Sofosbuvir Tablets [0172] Ledipasvir, 30 mg, alone in both a conventional formulation (as the D-tartrate sait) and as the solid dispersion has been demonstrated to hâve a decrease in bioavailability when administered with some gastric acid suppressants; most significantly, proton-pump inhibitors (PPI’s, e.g., omeprazole), but also including histamine-2 antagonsists (H2RA’s, e.g., famotidine, data not included). Table 12A summarizcs PK parameters of ledipasvir following administration of ledipasvir conventional single agent tablets, 30 mg, ledipasvir tablets as solid dispersion (ledipasvir:copovidone 1:1), 30 mg, and sofosbuvir/ledipasvir FDC tablets (90 mg of ledipasvir solid dispersion comprising copovidone 1:1) with and without omeprazole. The bioavailability of ledipasvir as single agent tablets was reduced approximately 2-fold when administered with omeprazole; however, administration of ledipasvir as part of the sofosbuvir/ledipasvir FDC tablet with omeprazole resulted in no significant decrease in ledipasvir exposure (AUC and Cmax) compared to sofosbuvir/ledipasvir FDC tablet administration in absence of omeprazole.
Table 12A. Pharmacokinetic Data for Ledipasvir on Administration of Ledipasvir Single Agent Tablets or Sofosbuvir/Ledipasvîr Tablets with and without Omeprazole
Ledipasvir, Conventional Formulation (N = 10) | |||
Mean (%CV) | Ledipasvir alone | Ledipasvir + Omeprazole | %GMR (90%CI) |
AUCtau (ng.hr/mL) | 1640(18.5) | 865 (37.7) | 50.7(43.4, 59.3) |
Cmax (ng/mL) | 99.0 (20.1) | 51.2(39.2) | 49.7(41.7, 59.1) |
Ctau (ng/mL) | 52.2(22.1) | 28.3 (36.0) | 52.4(44.3,61.9) |
Ledipasvir* Solid Dispersion (N = 17) | |||
Mean (%CV) | Ledipasvir alone | Ledipasvir + Omeprazole | %GMR (90%CI) |
AUCinf (ng.hr/mL) | 2140 (38.8) | 1300 (50.7) | 58.5 (48.3, 70.8) |
AUClasl (ng.hr/mL) | 1850(33.5) | 1070 (45.5) | 56.3 (46.4, 68.3) |
Cmax (ng/mL) | 64.8 (32.9) | 36.2(55.9) | 52.2(41.4, 65.9) |
Ledipasvir, SOF/LDV FDC (N = 16) | |||
Mean (%CV) | SOF/LDV FDC Alone | SOF/LDV FDC + Omeprazole | %GMR (90%CI) |
AUCinf (ng.hr/mL) | 7990 (66.2) | 6660 (51.8) | 96.0(66.5, 139) |
AUCjasl (ng.hr/mL) | 7160 (65.8) | 5700 (51.8) | 92.5 (64.8, 132) |
Cmax (ng/mL) | 242 (68.6) | 176 (51.1) | 89.1 (60.9, 130) |
E. Dissolution of Ledipasvir/Sofosbuvir Tablets [0173] Dissolution studies were conducted comparing the sofosbuvir 400 mg/ledipasvir 90 mg tablets (ledipasvir:copovidone (1:1). The sofosbuvîr/ledipasvîr tablets (LOT 1-5) display greater than 85% sofosbuvir (FIG. 5) and ledipasvir (FIG. 6) dissolved in 30 minutes for both tablet formulations. These results are shown in FIGs. 5 and 6.
Exampic 4: Stability of Sofosbuvir/Ledipasvir Co-formulation [0174] The compatîbilîty of sofosbuvir anhydrous crystalline drug substance was evaluated with the ledipasvir:copovidone solid dispersion. A blend ofthe sofosbuvir and ledipasvir: copovidone (1:1) solid dispersion was prepared at a ratio représentative ofthe final 400 mg sofosbuvir/90 mg ledipasvir tablets. The blend was compressed into pellets and placed in stability chambers at 40 °C/75% RH and 60 °C/ambient humîdity and tested after two and four weeks of storage in open glass vials. The results summarized in Table 13 show that no dégradation was observed for either sofosbuvir or ledipasvir, demonstrating the chemical compatibility of sofosbuvir and the ledipasvir:copovidone solid dispersion with each other.
Table 13: Strength and Impurity Content of Sofosbuvir and Ledipasvir:Copovidone
Solid Dispersion Blend Stored at 40 °C/75% RH and 60 °C
Ledi | pasvir | Sofosbuvir | |||
Condition | Time (weeks) | Strength (%) | Total Impurity Content (%) | Strength (%) | Total Impurity Content (%) |
45 °C/75 % RH | 0 | 98.8 | 0.0 | 102,9 | 0.4 |
2 | 96.9 | 0.0 | 101.6 | 0.3 | |
4 | 97.1 | 0.0 | 100.5 | 0.2 | |
60 °C | 0 | 98.8 | 0.0 | 102.9 | 0.4 |
1 | 99.2 | 0.0 | 102.4 | 0.3 | |
2 | 99.6 | 0.0 | 103.2 | 0.3 | |
4 | 98.9 | 0.0 | 102.8 | 0.2 |
Exarnple 5: Efïicacy of Sofosbuvir/Ledipasvir/Ribavirin Treatment in Patients with HCV Infections [0175] Patients with HCV infections were treated with either the combination of sofosbuvir, ledipasvir, and ribavirin or the combination of sofosbuvir and ribavirin. Patients used in the study included those that were treatment naïve, i.e. had not prevtously been treated for HCV and those that were null responders, i.e. had previously been treated for HCV but faiied to respond to the treatment. Standard doses (90 mg of ledipasvir, 400 mg of sofosbuvir, and 1000 mg of ribavirin, for example) were given of each drug to the patients for a duration of 12 weeks. Throughout treatment, HCV RNA was measured, and the Sustained Virologie Response (SVR) was measured after treatment was discontinued. By four weeks of treatment, almost ail patients had achieved an HCV RNA measurement below the limit of détection (LOD of 15 IU/mL), and by the end of treatment, 100% of patients achieved an HCV RNA level below the LOD (Table 14).
Table 14: Patients with HCV RNA below the limit of détection over time.
Sofosbuvir + Ribavirin | Sofosbuvir + Ribavirin + Ledipasvir | |||
T reatment-naïve (n = 25) | Null responder (n-'O) | Treatment-naïve (n = 25) | Null responder in = 9) | |
Week 1 | 32% | 10% | 44% | 0% |
Week 2 | 68% | 70% | 88% | 44% |
Week 4 | 100% | 100% | 100% | 89% |
End of Treatment | 100% | 100% | 100% | 100% |
[0176] Surprisingiy, 100% of patients receiving the combination of sofosbuvir, ledipasvir, and ribavirin achieved a sustained virologie response at four and twelve weeks post treatment. In contrast, only 88% of treatment naïve and 10% of null responder patients treated with the combination of sofosbuvir and ribavirin achieved a SVR at four weekes post treatment, and only 84% of treatment naïve and 10% of null responder patients treated with the combination of sofosbuvir and ribavirin achieved SVR at twelve weekes post treatment (Table 15).
Table 15: Sustained Virologie Response
Sofosbuvir + Ribavirin | Sofosbuvir + Ribavirin + Ledipasvir | |||
Treatment-naïve (n = 25) | Null responder (n= 10) | Treatment-naïve (n = 25) | Null responder (n = 9) | |
SVR4 | 88% | 10% | 100% | 100% |
SVR12 | 84% | 10% | 100% | 100% |
[0177] These results are graphically depicted as FIG. 7A-D and demonstrate that the addition of ledipasvir in the treatment regimen gave 100% SVR at weeks 4 and 12. Example 9, below, shows similar results are obtained with treatment regimens of less than twelve weeks (i.e. treatment regimens of about 8 or 6 weeks), and that similar results are obtained with treatment regimens of sofosbuvir and ledipasvir without the addition of ribavirin.
Example 6. Stability of SOF 400 mg/ Ledipasvir 90 mg Fixed-Dose Combination Tablets [0178] This example summarizes the physicochemical stability of packaged Sofosbuvir (SOF) 400 mg/ ledipasvir 90 mg blue film-coated fixed-dose combination (FDC) tablets at 25 °C/60% relative humidity (RH) and 40 °C/75% RH as a function of desiccant. The ledipasvir portion of the table comprised ledipasvir:copovidone in a 1:1 ratio. In addition the chemical and physical stability of SOF/ledipasvîr FDC tablets were evaluated at 40°C/75% RH under open condition for up to 4 weeks.
[0179] The physico-chemical properties that were evaluated included appearance, potency, dégradant formation, dissolution rate and water content. Physical stability ofthe tablets in the absence of desiccant was evaluated after 24 weeks using FT-Raman spectroscopy and modulated differentîal scanning calorimetry (mDSC).
[0180] SOF 400 mg/ledipasvir 90 mg blue film-coated FDC tablets exhibited satisfactory stability at 25°C/60% RH and 40°C/75%RH for up to 24 weeks in the presence of 0, 1, and 3 g of desiccant. No significant changes were observed in potency, impurity content or dissolution rate. However, a ledipasvir photodegradant was présent at 0.1% for ail conditions.
FT-Raman analysis for the tablets stored in the absence of desiccant showed no détectable crystallization after 24-weeks.
Methods and Materials
Materials [0181] Table 16 lists the physicochemical properties for SOF drug substance and ledipasvir solid dispersion used to produce tablets. The quantities of SOF drug substance and ledipasvir solid dispersion were adjusted based on their respective drug content factor (DCF) with concomitant adjustment in the quantity of lactose monohydrate. The DCF used for SOF and ledipasvir solid dispersion powder, 50% w/w were 0.997 and 0.497 (0.994 when adjusted for the amount of copovidone), respectively.
Table 16. Physicochemical Properties of SOF Drug Substance and Ledipasvir Solid Dispersion, 50% w/w, Bulk Powder Used to Produce SOF 400 mg/Ledipasvir 90 mg Film-Coated FDC Tablets
Active Ingrédient | Crystal Form | Assay by HPLC (%) | Impurities (%) | Drug Content Factor | Water Content by Karl Fischer (%) | Particle Size (μιη) | ||
dlO | d50 | d90 | ||||||
SOF | Anhydrous Form II | 99.8 | 0.1 | 0.996 | 0.1 | 3 | 10 | 29 |
Ledipasvir Solid Dispersion, 50% w/w, Bulk Powder | Amorphous | 49.7 | 0.2 | 0.497 | 1.09 | 5 | 22 | 44 |
Equipment [0182] The primary equipment used to manufacture SOF 400 mg/Ledipasvir 90 mg film-coated FDC tablets included an 12 qt. V- Blender, a screening mill (Comil 197S, Quadro, Waterloo, Canada) equipped with a 0.094 in grated screen, a roller compactor/granulator (MiniPactor, Gerteis, Jona, Switzeriand) equipped equipped with a
1.0 mm milling screen and a smooth/smooth roller configuration, a 12-station instrumented rotary tablet press (XM-12, Korsch, Berlin, Germany), and a tablet coater (LabCoat, O'Hara Technologies Inc., Ontario, Canada). The diamond-shaped tablet tooling (Elizabeth Carbide Die Co., Inc., McKeesport, PA, USA) consisted of diamond, standard concave Dtype punches with dimensions of 0.7650 in x 0.4014 in (19.43 mm x 10.20 mm). A 15 inch perforated pan film coater was used to coat the tablet cores.
Container Closure [0183] Sofosbuvir/Ledipasvir FDC tablets are packaged in 100 mL white, high density polyethylene (HDPE) bottles. Each bottle contained 30 tablets and 0, 1 or 3 g silica gel desiccant canister or sachet and polyester packing materiai. Each bottle was enclosed with a white, continuons thread, child-resistant screw cap with an induction-sealed, aluminumfaced liner.
[0184] A selected number of bottles were left open and packaged without desiccant to evaluate the physical and chemical stability at 40°C/75% RH under accelerated heat and humidity conditions.
General Study Design [0185] The solid state and chemical stability of the packaged lot were evaluated in the following configurations:
1) At 25 °C/60% RH and 40 °C/75% RH as a function of desiccant. The samples were stored under closed condition for a minimum of 24 weeks.
2) At 40°C/75% RH under open condition for up to 4 weeks.
[0186] Samples were pulled at predetermined time points. Chemical stability testing for appearance, potency, dégradant formation, dissolution rate and water content was conducted. Additional physical stability assays to monitor potential crystallization and phase séparation were conducted.
Physical Stability Evaluation [0187] Physical stability tests included appearance and FT-Raman. The visual inspection was performed on stressed film-coated tablets to identify changes in tablet color and coating integrity. FT-Raman spectroscopy was used to detect potential crystalline ledipasvir (Form
III) in the film-coated tablets.
[0188] Tablets were visually inspected for changes in appearance at ail time points and storage conditions. In contrast, FT-Raman was only performed on tablets with 0 g desiccant at 24 weeks (25°C/60% RH and 40°C/75% RH).
Appearance [0189] At ali time points tablets were examined for physical integrity (i.e. color, shape, coating integrity and debossing).
FT-Raman [0190] FT-Raman experiments were conducted. The 24-week SOF/ledipasvir film-coated FDC tablets stored in closed containers at 25°C/60% RH and 40°C/75% RH were analyzed using FT-Raman spectroscopy to detect the formation of crystalline ledipasvir (Form III). Briefly, the coating from the tablets was carefully removed using an Xacto™ knife followed by grinding of the tablet in a mortar and pestle. Tablet powder was then packed into cups and spectra were collected using a backscattering geometry.
Chemical Stability Evaluation [0191] Chemical stability assays încluded measuring water content by Karl Fischer (KF), potency, formation of impurity/degradation products and dissolution rate were conduced.
KF Water Content [0192] The water content was reported for SOF 400 mg/iedipasvir 90 mg film-coated FDC tablets following USP <921>.
Potency and Impurity/Degradant Formation by UPLC [0193] The potency and dégradation product formation of SOF/ledipasvir film-coated FDC tablets were evaluated by analysis of composite sample solution of 10 tablets according to STM-2542 [5], The reference standard concentration for SOF and ledipasvir is 2.0 mg/mL and 0.45 mg/mL, respectively. The strength and dégradation product content of SOF and ledipasvir was determined by UPLC using extemal reference standard and area normalization at wavelengths of 262 nm and 325 nm, respectively.
Dissolution Methodology [0194] Dissolution testing was performed on SOF/ledipasvir film-coated FDC tablets. A
USP type 2 dissolution apparatus with 900 mL of dissolution medium and a paddle speed of rpm was used. The medium was 1.5% polysorbate 80 in 10 mM potassium phosphate buffer at pH 6.0 and the température was maintained at 37 °C for the duration of the assay.
The extent of SOF and ledipasvir released as a function of time was monitored by UPLC using area normalization and an extemal reference standard at a wavelength of 250 nm.
RESULTS
A. Physical Stability
Al. Appearance [0195] Samples at ail stability conditions and desiccant levels were visually inspected for ail time points and found to resemble blue, diamond-shaped fïlm-coated tablets.
A2. FT-Raman [0196] The FT-Raman analysis was performed on powder extracted from tablets stored in the absence of desiccant after 24 weeks. Calculations of % crystallinity using the PLS model did not show signs of crystalline ledipasvir (Form III) above the LOD of 3% at either storage condition.This was consistent with the original sample (t = 0) in which ledipasvir (Form III) was also below the LOD. Spectra from selected samples were included in a chart, from 1577 cm'1 to 1514 cm'1 with the baselines artificially adjusted for clarity. This région is in one of the four spectral régions used to estimate the % ledipasvir (Form III) in tablets by PLS model.
[0197] The top two spectra (used as standards in the PLS model), in the chart, were from tablets spiked with 10% w/w and 3% w/w, of crystalline ledipasvir (Form III). The next two spectra represent stressed tablets stored for 24 weeks at 40 °C/75% RH and 25 °C/60% RH. The last spectrum represents the initial time point (t = 0). Ledipasvir (Form ΙΠ) has a distinct peak at 1552 cm'1, which can clearly be seen in the spiked tablets with increasing intensity from 3% to 10%. The intensity in this région for the stressed samples stored for 24 weeks does not increase from the t = 0 sample, indicating no change in crystallinity. Ledipasvir (Form III) in the t = 0 sample and the 24 week samples is below that présent in the tablets spiked with 3% Form III ledipasvir, the current limit of détection for this analytical technique.
B. Chemical Stability
B. 1 KF Water Content [0198] The water content of stressed samples stored for 4 weeks under open condition increased from 2.28% to 5.23%. The amount of water content of stressed samples stored at 25 °C/60%RH decreased to 1.91%, 1.58%, and 1.65% for tablets with no desiccant, with lg desiccant, and 3g desiccant, respectively. At 40 °C/75%RH, the amount of water content decreased to 2.03%, 1.79%, and 1.46% for tablets without desiccant, with lg desiccant, and
3g desiccant, respectively.
B. 2 Potency and Impurity/Degradation Product Formation [0199] The potency and impurity/degradation content for SOF 400 mg/ledipasvir 90 mg film-coated FDC tablets were determined at 25 °C/60%RH and 40 °C/75%RH.
Représentative chromatograms of stability samples stored at 40 °C/75%RH were obtained. The data showed that SOF and ledipasvîr remained chemically stable in SOF 400 mg/ledipasvir 90 mg film-coated FDC tablets stored for 24 weeks at 25 °C/60%RH and 40 °C/75%RH. The label strength for SOF and ledipasvîr remains unchanged at 25°C/60%RH and 40°C/75%RH.
Dissolution [0200] The dissolution profiles of SOF and ledipasvîr in SOF 400 mg/ledipasvir 90 mg film-coated FDC tablets were obtained. At the 24 week time point, the tablets ranged between 99% and 100% dissolution at 45 minutes for SOF, and between 99% and 98% for ledipasvîr at both 25°C/60%RH and 40°C/75% RH for ail desiccant levels tested.
[0201] From the foregoing, this example shows that SOF 400 mg/ledipasvir 90 mg FilmCoated FDC tablets exhibited satisfactory stability at 25°C/60% RH and 40 °C/75%RH for up to 24 weeks in the presence of 0, 1, and 3 g of desiccant.In addition, crystalline ledipasvîr (Form HI) was not detected by FT-Raman analysis after 24 weeks of storage.
Example 7. Formulation Development of a Fixed Dose Combination (FDC) Tablet SOF 400 mg/Ledipasvir 90 mg [0202] This example shows the development of a SOF 400 mg/ledipasvir 90 mg fixed dose combination (FDC) tablet comprising ledipasvîr: copovidone (1:1). There were expected difficulties with such a development, one of which was the expected poor powder flow and the other relates to non-homogenous blend, given the existing formulations of each individual agent.
[0203] Three tablet formulations were tested, including (1) a monolayer co-granulated tablet formulation, (2) a monolayer co-blended tablet formulation and (3) a bilayer tablet formulation. In ail of these formulations, SOF was in anhydrous crystalline form II and ledipasvîr was in amorphous solid dispersion (ledipasvîr:copovidone (1:1)).
[0204] Formulation (1) is typically associated with the highest risk of drug-drug interaction but is the most cost-effective during manufacturing. The bîlayer formuation of (3), by constrast, is perceîved to hâve the lowest drug-drug interaction risk.
[0205] The dissolution performance ofthe formulations were tested in a dissolution media that included 10 mM phosphate buffer at pH 6.0 (1.5% Tween® 80). As shown in FIG. 8AB, ail three formulations had comparable dissolution performance, similar to that ofthe single-agent controls.
[0206J The pharmacokinetic (PK) performance of each formulation was also tested. Plasma Concentration of SOF/ledipasvir after oral administration of SOF/ledipasvîr FDC and control tablets in fasted dogs (100 mg/22.5 mg fixed/dog). Table 17 below shows the PK results.
Table 17. Phamacokinetic performance of the forumations in famotidine pretreated dogs
Total Tablet weight /Formulation | Treatment | SOF | Ledipasvir | ||
AUCo-t (ng*hr/inL) | Cmai (ng/mL) | AUCo-last (itg*hr/mL) | Cmax (ng/mL) | ||
Control SOF tablet + Ledipasvir SD tablet | Famotidine | 314 ± 207 | 503 ±363 | 3260± 1312 | 345±132 |
Monolayer, Cogranulated | Famotidine | 501± 249 | 729 ± 434 | 3236 ±730 | 333 ± 56 |
Monolayer, Coblended | Famotidine | 483 ±406 | 652 ± 527 | 4208 ±2216 | 444 ±215 |
Bilayer | Famotidine | 283 ±193 | 288 ±201 | 4,712 ±2,270 | 421.7 ±203.7 |
[0207J Based on these results, the monolayer co-granulated tablet was selected for further analysis. The composition of this formulation is provided in Table 18.
Table 18. Composition of SOF 400 mg/Ledipasvir 90 mg FDC Tablets
Composition | % w/w |
Intra-granular | |
SOF | 40.00% |
Ledipasvir SD | 18.00% |
Lactose Fast Flow 316 | 16.50% |
MCC 101 | 8.00% |
Croscarmellose | 2.50% |
Silicon Dioxide | 1.00% |
Magnésium Stéarate | 0.75% |
Extragranular | |
MCC 101 | 10.00% |
Croscarmellose | 2.50% |
Magnésium stéarate | 0.75% |
Total Fill weight Core Tablet (mg) | 1000 |
Coating | |
Opadry II Orange 85F13912 | 3.0% |
Water | QS |
]0208| A bioavaîlability clinical study was carried out with this formulation, with single agent tablets as control, in 24 healthy patients under fasted conditions. The results are shown in Table 19
Table 19. Bioavailability of SOF/Ledipasvir fixed dose combination and single agent tablets
Total Tablet weight /Formulation | Dose (mg) | SOF | Ledipasvir | ||
AUCinf (ng*hr/mL) | Cmax (ng/mL) | AUCinf (ng*hr/mL) | Cmax (ng/mL) | ||
Signle Agent Control SOF tablet + Ledipasvir SD tablet | SOF 400 mg Ledipasvir 90 mg | 11900 (23.5) | 764 (27.3) | 9620 (45.6) | 314(40.5) |
SOF/Ledipasvir FDC Tablet | 12500 (23.1) | 784 (36.2) | 9570 (46.6) | 314 (45.2) |
[0209] These results, therefore, show that SOF/ledipasvir fixed dose combination (cogranulated) and single agent tablets are bioequîvalent.
Example 8. Solubility Studies for Amorphous Ledipasvir [0210] This example examines the physicochemical properties different ledipasvir forms, including amorphous and crystalline free base, solvatés, and salts, with respect to solubility.
A. Materials and Methods pH-Solubility Profile [0211] The aqueous solubility of ledipasvir amorphous free base was determined across the pH range of 1 to 10. Excess solid ledipasvir was added to a range of pH-adjusted aqueous solutions (titrated with HCl or NaOH) and stirred for 48 hours at room température. The suspensions were then fîltered through regenerated cellulose syringe filters. The pH value of the supematant was measured, and the supernatant was diluted as appropriate with 50:50 H2Û+0.1% TFA:ACN and assayed for ledipasvir content by the HPLC-UV method.
Solubility in Simulated Intestinal Media [0212] Solubility of ledipasvir amorphous free base was assessed in three types of simulated intestinal fluids at pH 6.5 or pH 5.0; and simulated intestinal bile sait and lecithin mixture (SIBLM), pH 6.4. Excess solid ledipasvir was added to the respective SIFs and stirred for 48 hours at room température. The resulting suspensions were then filtered through regenerated cellulose syringe filters. The supernatant was diluted as appropriate with 50:50
ΗίΟ+Ο.Ιθ/ο TFA: ACN and assayed for ledipasvir content by the HPLC-UV method.
Excipient Solubility [0213] Solubility of ledipasvir amorphous free base and ledipasvir crystalline D-tartrate was measured in a wide range of pharmaceutically acceptable solvents, including cosolvents, surfactants, fatty acids, triglycérides, or blends thereof. Material was weighed into scintillation vials and stirred for up to 48 hours at room température. In many cases, solubility was higher than the amount of solid used in the sample, thus many results are reported as ‘greater than’ or ‘greater than or equal to’ if the concentration was not quantitatively determîned by HPLC-UV.
[0214] Additionally, aqueous solubility was measured as a function of time in the presence of 0.1% w/w surfactants and polymers in pH 2 (50 mM citrate) and pH 5 (50 mM citrate), ledipasvir crystalline forms (acetone solvaté Form II; anhydrous FB Form III; D-tartrate) and amorphous form were evaluated to identify différences in dissolution behavior. Excess solid was added to aqueous buffered solutions; samples were withdrawn at predetermined intervals (2, 5, 8, 10, 15, 20, 30, 45, 60 minutes, and 24 hours), filtered through regenerated cellulose filters, and diluted for concentration measurement by the HPLC-UV method.
B. Results
Solubility and Dissolution Rate [0215J The pH-solubility profiles of ail available ledipasvir forms were determîned at room température and are graphically shown in FIG. 9. The fiat portion of the solubility profile (pH >5) represents the intrinsic aqueous solubility of the free base. The aqueous solubility of ledipasvir significantly increases as the pH of the solution is lowered below the pKa of the ionizable groups. Ail forms lose crystallinity, reverting to the amorphous free base în aqueous solution, and thus show similar aqueous solubility properties at steady-state. However, dissolution properties are form dépendent and are described in further detail below,
Ledipasvir Amorphous Free Base [0216] The intrinsic solubility of ledipasvir amorphous free base (FB) is approximately
0.04 pg/mL. Under acidic conditions, the solubility increases to 1 mg/mL at pH 2.3, and peaks at about 7 mg/mL at pH 1.6, as shown in Table 20 and FIG. 9. Solubility of ledipasvir in simulated intestinal fluids is govemed by both the pH of the medium and the presence of bile salts and lecithin. In fasted state simulated intestinal fluids (FaSSIF) at pH 6.5 and room température, the solubility is 0.025 mg/mL, and this is increased approximately 10-fold to
0.232 mg/mL in simulated bile and lecithin mixture (SIBLM, pH 6.5) due to the increased concentration of bile salts and lecithin. A similar solubility enhancement to 0.230 mg/mL is observed in fed state simulated intestinal fluid (FeSSIF, pH 5), containîng lower bile sait and lecithin mixtures than SIBLM. The solubility increase in this mixture is predominantly attributed to the ionization sate of the molécule at pH 5.
Table 20, Solubility of Ledipasvir amorphous free base as a function of pH at room température
Aqueous Media | Solubility (mg/mL) |
Aqueous, pH 1.6 (HCl) | 6.855 |
Aqueous, pH 2.3 (HCl) | 1.096 |
Aqueous, pH 3.1 (HCl) | 0.0132 |
Aqueous, pH 4 .1 (HCl) | 0.00011 |
Aqueous, pH 5.5 (HCl) | 0.00003 |
Aqueous, pH 6.2 (unaltered) | 0,00003 |
Aqueous, pH 7.2 (NaOH) | 0.00001 |
FaSSIF1 pH = 6.5 | 0.025 |
FeSSIF2 pH = 5.0 | 0.230 |
SIBLM3 pH = 6.4 | 0.232 |
1 FaSSIF is water with 3mM sodium taurocholate and 0.75 mM lecithin, pH adjusted to 6.5 with phosphate buffer, ionic strength adjusted to 0.15M with NaCl.
2 FeSSIF is water with 15 mM sodium taurocholate and 3.75 mM lecithin, pH adjusted to 6.5 with phosphate buffer, ionic strength adjusted to 0.15M with NaCl.
3 SIBLM is water with 30 mM sodium glycocholate, 30 mM sodium glycochenodesoxycholate, 15 mM sodium glycodesoxycholate, 10 mM sodium taurocholate, 10 mM sodium taurochenodesoxycholate, 5 mMsodium taurodesoxycholate, 50 mM sodium chloride, and 11 mM lecithin, pH adjusted to 6.4 with phosphate buffer, ionic strength adjusted to 0.15M with NaCl.
[0217] The dissolution rate of ledipasvir amorphous free base at pH 3 and 6 was also tested. At pH 3, the dissolution of the amorphous free base form is faster than that of the crystalline free base and acetone solvaté forms. However, at pH 6, ail free base forms show similar dissolution rate profiles.
[0218] As shown in Table 21, ledipasvir amorphous free base is ffeely soluble (>500 mg/mL) in éthanol and other organic solvents such as propylene glycol and PEG 400. Its solubility is greater than 200 mg/mL in surfactants (e.g., polysorbate 80, Cremophor EL,
Labrasol) and lipid blends. Its solubility in oleic and octanoic acids is greater than 500 mg/mL. Solubility of ledipasvir in shorl-chain triglycérides (SCTs, tributyrin) is limited to 20 mg/mL, and decreases to less than I mg/mL in long-chain triglycérides (LCTs, soybean oil).
It has a solubility of25 mg/mL in the vehicle chosen for toxicological studies: 45% propylene glycol, 15% caprylocaproyl macrogol-8 glycerides (Solutol HS 15®), and 40% water (pH 2.5 by HCl).
Table 21. Solubility of Ledipasvir free base forms and Ledipasvir D-tartrate in organic solvents and excipients at room température
Solubility (mg/mL) | ||||
Amorphous Free Base | Crystalline Acetone Solvaté | Anhydrous Crystalline Free Base | Crystalline D-tartrate Sait | |
(Ledipasvir) | (Ledipasvir03) | (Ledipasvir Form m) | (Ledipasvir-02) | |
Acetone | 5 | 5 | -- | <1 |
Acetonitrile | >500 | — | — | 12 |
Methanol | >500 | >500 | — | 23 |
95% Methanol + 5% water | — | — | — | 19 |
Ethanol | >500 | >500 | >500 | 4 |
95% Ethanol + 5% water | — | — | — | 5 |
PEG 400 | >500 | >500 | >500 | 4 |
Propylene glycol | >500 | >500 | >500 | 6 |
Octanoic acid | >500 | >500 | — | <1 |
Oleic acid | >500 | >500 | >500 | <1 |
Polyoxyl 35 Castor Oil (Cremophor EL) | >200 | — | — | |
Polysorbate 80 (Tween 80) | >200 | >200 | >200 | 3 |
Caprylocaproyl macrogolglyceri des (Labrasol) | >300 | >300 | >300 | 3 |
Tributyrin | 9 | — | — | — |
Soybean oil | 2 | 2 | 2 | — |
RSSEDDS1 | >500 | — | 10 |
1 RSSEDDS: 10% Ethanol, 10% PG, 40% Solutol HS-15, 40% Labrasol [0219] Dîlute nonionic surfactants generally increase ledipasvir solubility at both pH 2 and 5, as presented in Table 22. Similar effects were observed with nonionic polymers, though to a lesser extent. Sodium lauryl sulfate (SLS), an anionic surfactant, improves the solubility of ledipasvir at pH 5. However, a significant decrease in solubility is noted in presence of SLS under acidic conditions (pH 2). This observation is consistent with weakly basic compounds that hâve low intrinsic aqueous solubility, presumably forming an insoluble estolate sait.
Table 22. Solubility of Ledipasvir amorphous free base in surfactant or polymeric excipients (0.1% w/w) diluted into aqueous media at pH 2 and 5 at room température
Excipient (0.1% w/w in aqueous media) | Solubility (mg/mL) | |
pH 2 | pH 5 | |
No excipient | 4.94 | 0.0001 |
Sodium lauryl sulfate | 0.05 | 0.243 |
Labrasol | 7.44 | -- |
Cremaphor EL | 9.11 | 0.0699 |
Polysorbate 80 | 9.27 | 0.0624 |
Poloxamer 188 | 7.19 | 0.0005 |
HPC (hydroxypropylcellulose) | 4.67 | 0.0001 |
HPMC (hydroxymethylcellulose) | 5.27 | 0.0003 |
PVP (povidone) | 5.47 | 0.0004 |
PVP/VA (copovidone) | 6.73 | 0.0010 |
Ledipasvir Crystalline Acetone Solvaté (Ledipasvir-03) [0220] The ledipasvir acetone solvaté (ledipasvir-03) showed similar steady-state solubility as the other forms. Ledîpasvir-03 has the siowest dissolution of ail forms tested. Its dissolution at pH 6 was indistinguishable fforn that of other forms due to poor intrinsic solubility (<0.1 pg/mL).
[0221] Ledipasvir-03 is soluble in many organic solvents and pharmaceutically acceptable solvents, and the solubilities are comparable to those listed for ledipasvir amorphous free base, as also shown in Table 21.
Ledipasvir Crystalline Free Base (Form III) [0222] Ledipasvir crystalline free base Form III showed similar steady-state solubility as the other forms (FIG. 9). This form dissolves more slowly than the amorphous free base, but faster than ledipasvir-03. Dissolution at pH 6 was indistinguishable from that ofthe other forms due to poor intrinsic solubility (<0,1 pg/mL). Solubilîty in a wider range of organic vehicles has not been explored, though is anticipated to be similar to other free base forms.
Ledipasvir Crystalline D-tartrate Sait (Ledipasvir-02) [0223] Ledipasvir crystalline D-tartrate sait (ledipasvir-02) showed similar steady-state solubility as the other forms (FIG. 9). Dissolution behavior ledipasvîr-02îs improved relative to ail free base forms. At pH 3, ledïpasvir-02shows a roughly 5- to 10-fold faster initial dissolution rate than the free base forms, and roughly doubled the amount of ledipasvir in solution through 60 minutes compared to the amorphous form. At pH 6, the increased dissolution rate was also apparent. However, rapid dissociation ofthe sait at this pH resulted in équivalent solubility values to other forms within minutes.
[0224] Ledipasvir-02 is not soluble in various organic media, as shown in Table 21. Maximal solubility of ledipasvir-02 in any organic vehicle is 20 mg/mL in methanol; this limits the use of ledipasvir-02 in solubilized formulations or processes that require solubilization in organic media.
[0225] Ledipasvir has low aqueous solubility and high permeabîlity, and is considered a BCS Class 2 compound. The data presented in this example indicate that in water, ail forms of ledipasvir: the amorphous free base, crystalline free base acetone solvaté (ledipasvir-03), crystalline anhydrous free base (Form III), and crystalline D-tartrate sait (ledipasvir-02), convert to the amorphous free base, and hâve similar aqueous solubility at steady state. The aqueous solubility of ledipasvir is less than 0.1 pg/mL in its neutral form (pH > 5), but substantially încreases under acidic conditions due to protonation of two basic moietîes. The aqueous dissolution rate of ledipasvir amorphous free base is faster than that of crystalline free base forms. However, ail free base forms hâve slower dissolution rates than the crystalline D-tartrate sait (ledipasvir-02). Ledipasvir-02 also shows improved wetting in aqueous media, ledipasvir free base forms, crystalline and amorphous, are highly soluble in a range of cosolvents and surfactants. In contrast, ledipasvir-02 is poorly soluble in organic excipients, and this property potentially limits its utility.
[0226] Ledipasvir amorphous free base was used in Phase 1 clinical studies, but drug substance manufacturing was identified as a critical limitation ofthe form. Ledipasvir crystalline D-tartrate sait (ledipasvir-02) was then identified as part of a more extensive sait and form screen and was used in Phase 2, however, poor solubility in organic excipients limits its utility in non-conventional formulations. Crystalline ledipasvir acetone solvaté (ledipasvir-03) is used to develop a spray dried dispersion formulation to support future clinical studies due to its solubility in organic solvents and excipients relative to crystalline ledipasvir D-tartrate sait and improved manufacturability over the other free base forms.
Example 9: Efficacy of a Fixed Dose Combination of Sofosbuvir and Ledipasvir With and Without Ribavirin in Patients with HCV Infections |0227] Patients with HCV infections were treated with the fixed dose combination of sofosbuvir and ledipasvir, with and without ribavirin. Patients used in the studies include those that were treatment naïve (non-cirrhotic), i.e. had not previously been treated for HCV, and those that were prior protease-inhibitor (PI) failures and null responders (with and without cirrhosis), i.e. had previously been treated for HCV but failed to respond to the treatment. The treatment naïve pateints were treated for 6, 8, and 12 weeks and the null responders were treated for 12 weeks.
Study 1 [0228| Cohort 1 of study 1 included treatment-naïve, Genotype-1 patients without cirrhosis. The patients were randomized 1:1:1 into three groupds to receive 1) SOF/Iedipasvir fixed dose combination for 8 weeks, 2) SOF/ledipasvir fixed dose combination with ribavirin for 8 weeks, or 3) SOF/ledipasvir fixed dose combination for 12 weeks (FIG. 10).
[0229] Cohort 2 of study 1 included Protease-inhibitor treatment-experienced, Génotype -1 patients (Prior Protease-inhibitor treatment failures, 50% of whom had compensated cirrhosis). The pateints were randomized to receive 12 weeks of: 1) SOF/ledipasvir fixed dose combination or 2) SOF/ledipasvir fixed dose combination with ribavirin (FIG. 10). In Cohort 2, the patients must not hâve discontinued prior therapy due to an adverse event.
[0230] In study 1, there was a broad inclusion criteria, namely, there was no upper limît to âge or BMI. Platelets were >50,000/mm3. The demographics of study 1 are shown in Table
23, below.
Table 23. Demographics
SOF/Ledipasvir fixed dose combination ± ribavirin (Cohort 1 and 2) N=100 | |
Mean âge, y (range) | 50 (21-73) |
Male, n (%) | 66 (66) |
Black, n (%) | 9(9) |
Hispanic, n (%) | 40 (40) |
2 Mean BMI, kg/m (range) | 29.9(18-48) |
IL28B CC, n (%) | 15(15) |
GT la, n (%) | 87 (87) |
Mean baseline HCV RNA, log10 IU/mL (range) | 6.1 (3.7-7.2) |
Cohort 2 (N=40) | |
Cirrhosis, n (%) | 22/40 (55) |
3 Mean Platelet Count (xlO /pL) | 107 |
Mean Albumin (g/dL) | 3.8 |
[0231] Of 100 patients enrolled în study 1, 97% achieved sustained viral response. Of the failures, two patients relapsed (one from Group 1 (i.e., SOF/Ledipasvir x 8 Weeks) and one from Group 4 (i.e., SOF/ledîpasvir x 12 Weeks), and one patient was lost to follow up from Group 3 (i.e,, SOF/ledîpasvir x 12 Weeks). However, the patient lost to follow up had achieved SVR at week 8 and declined further retum visits.
[0232] In Cohort 1 of study 1 (i.e. Treatment Naïve, Non-Cirrhotic Patients), 58 out of the 60 patients treated for 8 or 12 Weeks achieved SVR. In corhort 2 of study 1 (i.e. Treatment Experienced, PI failure Patients), 39 out of the 40 patients treated for 12 Weeks achieved SVR12. 21 out of the 21 patients with cirrhosis achieved SVR 12 (FIG. 11).
[0233] In study 1, seven out ofthe nine patients with NS5A Résistance Associated
Variants (RAVs) achieved sustained viral response. In addition, ail patients with NS3/4A
Résistance Associated Variants achieved sustained viral response. Interestingly, S282T mutation and multiple NS5A RAVs were detected at relapse in the patient who failed from the Group 1 (Table 24). The safety summary and a breakdown of the adverse effects are shown în Tables 25 and 26, respectively.
Table 24. Résistance analysis
SOF/Ledipasvir fixed dose combination ± ribavirin | |
NSSARAVs, n% | 9/100 (9) |
NS3/4A RAVs, n % | 29/40 (73)* |
*number of patients in Cohort 2 with prior exposure to a protease inhibitor
Table 25. Safety Suminary
Patients, n (%) | SOF/Ledipasvir fixed dose combination N=58 | SOF/Ledipasvir fixed dose combination + ribavirin N=42 | |
Overall safety | AEs | 24 (41%) | 24 (57%) |
Grade 3-4 AEs | 0 | 6 (14%) | |
Serious AEs | 2* (3%) | 2** (5%) | |
Treatment discontinuation due to AEs | 0 | 0 | |
Laboratory abnormalities | Grade 3-4 laboratory abnormal ity | 4 (7%) | 6 (14%) |
Hemoglobin <10 g/dL | 0 | 8 (19%) | |
Hemoglobin <8.5 g/dL | 0 | 2 (5%) |
*peptic ulcer, spinal compression fracture **delerium, suicidai idéation
Table 26. Adverse Events ( > 5% of patients overall)
Preferred term, n (%) | SOF/Ledipasvir fixed dose combination N=58 | SOF/Ledipasvir fixed dose combination + ribavirin N=42 |
Any adverse event | 24 (41%) | 24 (57%) |
Nausea | 3 (5%) | 6 (14%) |
Anémia | 0 | 8 (19%) |
Upper Resp Tract Infx | 4 (7%) | 4 (10%) |
Headache | 3 (5%) | 4(10%) |
Study 2 [0234] In study 2, the treatment-naïve patients received SOF/ledipasvir fixed dose combination with ribavirin and prior null responders, ail of whom had cirrhosis, were randomized to receive twelve weeks of: 1) SOF/ledipasvir fixed dose combination or 2)
SOF/ledipasvir fixed dose combination with ribavirin.
Results [0235] Of the 144 patients treated in both studies 1 and 2, 136 out of 144 (94%) achieved SVR at four weeks post treatment. Of the 85 treatment-naïve patients in these two studies, three of 25 patients failed to achieve SVR after 6 weeks of SOF/ledipasvir fixed dose combination with ribavirin therapy, whereas 100% (60/60) patients achieved SVR after 8 or 12 weeks of SOF/ledipasvir fixed dose combination with and without ribavirin therapy. Of the 59 treatment-experienced patients in these two studies, three cirrhotic patients relapsed after receiving 12 weeks of SOF/ledipasvir fixed dose combination without ribavirin. Conversely, no virologie failures were observed in the SOF/ledipasvir fixed dose combination with ribavirin treatment groups, but two patients in these groups were lost to follow-up. SOF/ledipasvir fixed dose combination with and without ribavirin was well tolerated, with few SAEs and minimal adverse events.
Conclusion [0236] SOF/ledipasvir fixed dose combination +/- ribavirin may be given for as lîttle as 8 weeks to treatment-naïve non-cirrhotic patients. Treatment-experienced patients, even those with cirrhosis, achieved high SVR rates with 12 weeks of the of SOF/ledipasvir fixed dose combination with and without ribavirin therapy.
Example 10: Eflïcacy of Multiple Anti-HCV Combination Therapy in Chronically Infected Hepatitis C Patients [0237] To evaluate the safety, tolerability, and eflïcacy of 4 to 12 weeks of SOF with ledipasvir, alone or in combination with Compound E and/or Compound J in patients with HCV, patients with HCV will be dosed as shown in Table 27.
Table 27. Dosing
Group | Treatment | Dosing | Patient description |
Group A | 12 weeks of SOF/ledipasvir | SOF with ledipasvir (400 mg/90 mg respectively once a day in a fixed dose combination) administered orally for 12 weeks | Patients (n=20) monoinfected with HCV génotype 1 who are HCV treatment naïve |
Group B | 6 weeks of SOF/ledipasvir/ Compound E | SOF with ledipasvir (400 mg/90 mg respectively once a day in a fixed dose combination) in combination with Compound E (500 mg once daily) for 6 weeks | Patients (n=20) monoinfected with HCV génotype 1 who are HCV treatment naïve |
Group C | 6 weeks of SOF/ledipasvir/ Compound J | SOF with ledipasvir (400 mg/90 mg respectively once a day in a fixed dose combination) in combination with Compound J (80 mg once daily) for 6 weeks. | Patients (n=20) monoinfected with HCV génotype 1 who are HCV treatment naïve |
Group D | 12 weeks of SOF/ledipasvir | SOF with ledipasvir (400 mg/90 mg respectively once a day in a fixed dose combination) administered orally for 12 weeks | Patients (n=up to 25) monoinfected with HCV génotype 1 who were previously treated in Group B, C, F, G or H of this study or a similar study |
Group E | 12 weeks of SOF/ledipasvir | SOF with ledipasvir (400 mg/90 mg respectively once a day in a fixed dose combination) administered orally for 12 weeks | Patients (n=20) monoinfected with HCV génotype 4 who are HCV treatment naïve or treatment experienced |
Group F | 6 weeks of SOF/ledipasvir/ Compound J | SOF with ledipasvir (400 mg/90 mg respectively once a day în a fixed dose combination) in combination with Compound J (80 mg once daily) for 6 weeks. | Patients (n=50) monoinfected with HCV génotype 1 with advanced liver disease who are HCV treatment naïve (n=25) or treatment experienced (n=25) |
Group G | 4 weeks of SOF/ledipasvir/ Compound J | SOF with ledipasvir (400 mg/90 mg respectively once a day in a fixed dose combination) in combination with Compound J (80 mg once daily) for 4 weeks | Patients (n=25) monoinfected with HCV génotype 1 who are HCV treatment naïve, Stage 0-2 liver disease |
Group | Treatment | Dosing | Patient description |
Group H | 4 weeks of SOF/ledipasvîr/ Compound J/Compound E | SOF with ledipasvir (400 mg/90 mg respectively once a day in a fixed dose combination) in combination with Compound J (80 mg once daily) and Compound E (250 mg once daily) for 4 weeks | Patients (n=25) monoinfected with HCV génotype 1 who are HCV treatment naïve, Stage 0-2 liver disease |
[0238] The primary analysis set for safety analyses will include patients who received at least one dose of study drug. On treatment data will be analyzed and defîned as data collected from the first dose of study drug through the date of last dose of study drug plus 30 days. Patients who receive study drug other than that to which they were assigned will be analyzed according to the study drug received.
[0239] The analysis set for antiviral activity analyses will include patients who were enrolled into the study and received at least one dose of study drug.
[0240] The pharmacokinetic analysis set will include ail patients who are enrolled and hâve received at least one dose of study médication.
[0241] The patient will be started on study treatment after confirming elîgibîlity on Day 0 and after being informed fully about the remainder of the study, and then signing the spécifie consent for the treatment group (if not done previously). Blood will be drawn for HCV viral loads, study drug levels, lipid levels for research if not already drawn during screening, immunologie studies, and for storage prior to dosing as part of the screening consent. A pregnancy test will be done for females with childbearing potential and the pregnancy test must be négative on Day 0 prior to dosing with study drugs. Patients may be asked to fill out a baseline adhérence questionnaire and an electronîc pill bottle cap, which records pill bottle openings will be placed on ail study drug bottles. Assistance will be provided filling out the questionnaire as needed. Patients on Arms B and H, will also be provided with a diary at Day 0, Week 2, Week 4 (Arm B only) on which to record gastrointestinal side effects.
[0242] On arrivai at the clinic for scheduled study visits, patients will hâve their vital signs obtained, females will undergo a pregnancy test (if appropriate per schedule and of childbearing potential), clinical laboratories drawn, and a review of the study restrictions.
[0243] At each scheduled study visit (does not include Day 1, 3, 5, 10, Week 2, Week 3, Week 6 (not applicable for arm F, G or H) or post-treatment week 2 and 8 which are for lab collection only), patients will be asked about their state of health and use of any concomitant médication since the previous study visit. They will also be questioned about adverse events and their adhérence with study restrictions. Vital signs, weight and examination will be performed as per the study flow. A complété list of study procedures and lab tests to be performed is in the Schedule of Tests, below. In addition, patients may be seen at unscheduled visits for a grade 3 or 4 adverse event or any unexpected adverse event or potential toxicity.
[0244] Patients may be asked to fill out a follow-up adhérence questionnaire and pill bottle openings may be recorded from the electronic bottle cap at Day 7 (Group A), Week 4 (Group A), Week 6 (Groups B and C), Week 8 (Group A), and Week 12 (Group A). Assistance will be provided filling out the questionnaire as needed.
[0245] Patients in Groups B and H will be asked to bring their side-effect diaries to visits on Week 2, 4, 6 (B only).
[0246] Some of the visits hâve a small amount of flexibility regarding when they need to occur. Visits occurring during the interval when the patient is receiving study drug hâve limited flexibilîty since they occur so ffequently, so a visit skipped during this period may be considered a missed visit. The window period for visit schedules is as shown in Table 28.
Table 28. Window Period for Visit Schedule
For 12 week regimen, Group A: | |||
Days 0, 1, 3 (no window) | Days 5, 7, 10, 14 (+/- 2 days) | Weeks 3, 4, 6 (+/- 3 days) | Weeks 8, 12 (+/- 5 days) Optional Week 12 Research Liver Biopsy (+/-14 days) |
For 6 week regimens, Groups B & C : | |||
Days 0, 1, 3 (no window) | Days 5, 7, 10, 14 (+/- 2 days) | Weeks 3, 4, 6 (+/- 3 days) Optional Week 6 Research Liver Biopsy (+/-14 days) | |
For 12 week regimens, Groups D and Έ: | |||
Day 0 (no window) | Week 4 (+/- 3 days) | Weeks 8, 12 (+/- 7 days) |
For 6 week regimen, Group F: | |||
Day 0 (no window) | Weeks 2, 4 (+/- 3 days | Week 6 (+/- 5 days) Optional Week 6 Research Liver Biopsy (+/-14 days) | |
For 4 week regimen, Group G or H: | |||
Day 0 (no window) | Day 7 (+/- 2 days) Group H only | Weeks 2, 4 (+/- 3 days) Optional Week 4 Research Liver Biopsy (+/-14 days) |
[0247] During the four week visit, HCV RNA may be obtained to détermine if virologicresponse based treatment stopping criteria hâve been met. Patients who fail to achieve >2 logIO HCV RNA drop at this time (unless > 2 log drop would be below LLOQ) should be discontinued from therapy unless a review by the PI/LAI/Sponsor Medical Monitor détermines otherwise (see 9.3.1).
[0248] At the end of treatment duration as determined by the study group, patients may discontinue dosing of SOF and ledipasvir, Compound E, and/or Compound J. In addition, if a patient’s participation terminâtes prior to completîon of pre-specified study drug duration, the End of Treatment assessments may be performed at any end-of-treatment visit. An optional research liver biopsy for research purposes may be performed at this time in up to 10 patients in each study group. The additional liver biopsy data will serve to explore hepatic HCV RNA sequence analysis. If patients are undergoing the optional research liver biopsy, they may hâve safety labs completed prior to the procedure and imaging as medically indicated. Patients who hâve a HCV VL< LLOQ may receive éducation about how to prevent reinfection with HCV.
[0249] Ail patients may be assessed for sustained virologie response at the 12 Weeks Post End of Treatment visit. Patients who hâve HCV VL< LLOD may be provided with éducation about how to prevent re-infection with HCV.
[0250] After discontinuation of the study drug, patients may be followed at 2, 4, 8, 12, 24,
36, and 48 weeks post-end of treatment. A sérum pregnancy test may be done with each visit, as appropriate. Week 2 and 8 Post-End of Treatment may include only collection of labs.
[0251] Subjects (n=18) received single doses of sofosbuvir (400 mg) alone or in combination with Compound E (500 mg QD) under fed conditions. Preliminary PK results for the combination of sofosbuvir with Compound E are presented in Table 29 and demonstrate lack of a clinically significant interaction between sofosbuvir and Compound E.
Table 29: Pharmacokinetic Data for SOF, Compound E, and ledipasvir alone and upon co-administration
SOF(n=18) | |||
Mean (%CV) | SOF alone | SOF + Compound E | %GMR(90%CI) |
AUCinf (ng.hr/ml) | 921(61.2) | 1150(40.2) | 135(116, 159) |
SOF + Compound E+ ledipasvir | %GMR(90%CI) | ||
2560 (42.9) | 297(253, 348) | ||
AUClast (ng.hr/ml) | 908 (62.2) | SOF + Compound E | %GMR(90%CI |
1140 (41.4) | 135(115, 159) | ||
SOF + Compound E+ ledipasvir | %GMR(90%CI) | ||
2550(43.1) | 301 (255,354) | ||
Cmax (ng/ml) | 515(78.3) | SOF + Compound E | %GMR(90%CI |
587 (51.1) | 130(97.1, 175) | ||
SOF + Compound E+ ledipasvir | %GMR(90%CI) | ||
1260 (55.1) | 283 ¢219.366) |
* * * [0252] It should be understood that although the présent invention has been specifically disclosed by preferred embodiments and optional features, modification, improvement and variation of the inventions embodîed therein herein disclosed may be resorted to by those skilled in the art, and that such modifications, improvements and variations are considered to be within the scope ofthis invention. The materials, methods, and examples provided here are représentative of preferred embodiments, are exemplary, and are not intended as limitations on the scope of the invention.
[0253] The invention has been described broadly and generically herein. Each of the narrower species and subgeneric groupings falling within the generic disclosure also form part of the invention. This includes the generic description of the invention with a proviso or négative limitation removing any subject matter from the genus, regardless of whether or not the excised material is specifically recited herein.
[0254] In addition, where features or aspects of the invention are described in terms of Markush groups, those skilled in the art will recognize that the invention is also thereby described in terms of any individual member or subgroup of members of the Markush group.
[0255] Ail publications, patent applications, patents, and other references mentioned herein are expressly incorporated by reference in their entirety, to the same extent as if each were incorporated by reference individually. In case of conflict, the présent spécification, including définitions, will control.
Claims (30)
1. A pharmaceutical composition comprising:
wherein the ledipasvir is substantially amorphous; and
b) an effective amount of sofosbuvir having the formula:
wherein the sofosbuvir is substantially crystalline, and further wherein the composition exhibits unexpected properties.
2. The pharmaceutical composition of claim 1, wherein the ledipasvir is formulated as a solid dispersion comprising ledipasvir dispersed within a polymer matrix formed by a pharmaceutically acceptable polymer.
3. The pharmaceutical composition of claim 2, wherein the polymer îs copovidone.
4. The pharmaceutical composition of claim 3, wherein the weight ratio of ledipasvir to copovidone in the solid dispersion îs about 1:1.
5. The pharmaceutical composition of claim 4, comprising
a) about 40% w/w of sofosbuvir, and
b) about 18% w/w of the solid dispersion.
6. The pharmaceutical composition of claim 5, further comprising
a) about 5 to about 25% w/w lactose monohydrate,
b) about 5 to about 25% w/w microcrystalline cellulose,
c) about 1 to about 10% w/w croscarmellose sodium,
d) about 0.5 to about 3% w/w colloïdal silicon dioxide, and
e) about 0.1 to about 3% w/w magnésium stéarate.
7. A pharmaceutical dosage form comprising the pharmaceutical composition of claim 1, comprising about 90 mg of ledipasvir and about 400 mg of sofosbuvir.
8. The pharmaceutical dosage form of claim 7, wherein the ledipasvir is formulated as a solid dispersion within a polymer matrix of copovidone.
9. The pharmaceutical dosage form of claim 8, wherein the amount of copovidone is about 90 mg.
10. The pharmaceutical dosage form of claim 9, further comprising:
(a) about 165 mg of lactose monohydrate;
(b) about 180 mg of microcrystalline cellulose;
(c) about 50 mg of croscarmellose sodium;
(d) about 10 mg of colloïdal silicon dioxide; and (e) about 15 mg of magnésium stéarate.
11. The pharmaceutical dosage form of claim 9 which is in the form of a tablet comprising a film coating.
12. A method of treating a patient infected with hepatitis C virus comprising administering to the patient a therapeutically effective amount of a pharmaceutical composition of claim 1.
13. The method of claim 12, wherein the pharmaceutical composition is administered for about 24 weeks or less.
14. The method of claim 12, wherein the pharmaceutical composition is administered for about 12 weeks or less.
15. The method of claim 12, wherein the pharmaceutical composition is administered for about 8 weeks or less.
16. The method of claim 12, wherein the pharmaceutical composition is administered for about 6 weeks or less.
17. The method of claim 12, wherein the pharmaceutical composition is administered once daily for about 12 weeks or less and wherein the hepatitis C virus is génotype 1, 2, 3,4, 5, or 6.
18. The method of claim 12, wherein the pharmaceutical composition is administered once daily for about 8 weeks or less and wherein the hepatitis C viras is génotype 1, 2, 3, 4, 5, or 6.
19. The method of claim 12, wherein the pharmaceutical composition is administered once daily for about 6 weeks or less and wherein the hepatitis C viras is génotype 1, 2, 3, 4, 5, or 6.
20. The method of claim 17, wherein the hepatitis C virus is génotype la or lb.
21. The method of claim 18, wherein the hepatitis C viras is génotype la or lb
22. The method of claim 19, wherein the hepatitis C viras is génotype la or lb.
23 The method of claim 12, wherein the pharmaceutical composition is administered once daily for about 12 weeks and wherein the hepatitis C virus is génotype la, lb, 2a, 2b, 2c, 2d, 3a, 3b, 3c, 3d, 3e, 3f, 4a, 4b, 4c, 4d, 4e, 4f, 4g, 4h» 4i, 5a, or 6a.
24. The method of claim 12, wherein the pharmaceutical composition is administered once daily for about 8 weeks and wherein the hepatitis C virus is génotype la, lb, 2a, 2b, 2c, 2d, 3a, 3b, 3c, 3d, 3e, 3f, 4a, 4b, 4c, 4d, 4e, 4f, 4g, 4h, 4i, 5a, or 6a.
25. The method of claim 12, further comprising administering ribavirin.
26. The method of claim 12, wherein the treatment does not include interferon.
27. The method of claim 12, wherein the treatment does not include ribavirin.
28. The method of claim 12, wherein the treatment does not include interferon or ribavirin,
29. The method of claim 12, further comprising administering an NS3 protease inhibitor.
30. The method of claim 12, further comprising administering simeprevir.
Publications (1)
Publication Number | Publication Date |
---|---|
OA17450A true OA17450A (en) | 2016-12-22 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2018203696B2 (en) | Combination formulation of two antiviral compounds | |
AU2019264624B2 (en) | Combination formulation of two antiviral compounds | |
OA17450A (en) | Combination formulation of two antiviral compounds. |